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ABSTRACT
REGULATION OF SYSTEM XC- BY THE NEUROPEPTIDE PACAP:
IMPLICATIONS FOR GLUTAMATE TRANSMISSION
IN DRUG ADDICTION

Linghai Kong, B.S.
Marquette University, 2017

Drug addiction is a chronic brain disorder characterized by heightened relapse
susceptibility. Drug-induced aberrant glutamate signaling in corticostriatal circuitry
contributes to behaviors in virtually every preclinical model of drug seeking and
correlates with drug craving in human. Here, we propose that glutamate signaling is a
product of integrated activity between neurons and astrocytes, such that disruptions
within astrocytes can stem from abnormal neuronal signaling (e.g., altered corticostriatal
firing) and be the source of additional disruptions in other neuronal circuits. The
astrocytic mechanism studied in these experiments is system xc- (Sxc) since drug-induced
changes to this non-vesicular glutamate release mechanism contribute to heightened
relapse vulnerability in preclinical models of addiction. My first objective was to
determine whether neurons or neuronal factors regulate Sxc activity in astrocytes
(Chapter II and III) since this would illustrate the degree to which glutamate signaling
involves integrated activity of multiple cell types. We found that neurons release a
soluble factor that potently increases Sxc activity. Moreover, we discovered that the
neuropeptide PACAP (pituitary adenylate cyclase-activating peptide) likely contributes to
this effect since it upregulates Sxc activity in astrocytes (Chapters II and III). Next, we
focused on the importance of PACAP regulation of Sxc to synaptic transmission in the
nucleus accumbens (NAc), since this structure is highly implicated in drug addiction
(Chapter IV). PACAP depressed synaptic transmission in NAc neurons projecting to the
substantia nigra, an important efferent that encodes motivated behaviors. Interestingly,
PACAP-induced control over synaptic transmission required enhanced Sxc activity.
Given this, we then determined the behavioral impact of increasing PACAP signaling in
the NAc on drug-seeking behavior (Chapter IV). Specifically, we found that
microinfusion of PACAP into the NAc attenuated cocaine-primed reinstatement of drug
seeking. Lastly, we determined that PACAP is expressed in corticostriatal projections to
the NAc, and that endogenous PACAP is an unrecognized factor influencing relapse
vulnerability (Chapter IV). Collectively, this dissertation reveals that a novel form of
neuron-astrocyte communication, namely PACAP regulation of Sxc, is a critical link
integrating the glutamate network that mediates motivated behavior.
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CHAPTER I

INTRODUCTION
General Introduction
Drug abuse and addiction have long been considered problems resulting from
moral failures such as poor life decisions or a lack of willpower. Slowly, over the past
several decades, scientific advances have progressively worked to break down this
stigma. Today, addiction is defined by most medical associations as a chronic disease of
the central nervous system (CNS). Similar to other diseases such as cancer and heart
disease that are caused by a malfunction of the underlying physiological substrates, the
disease of drug addiction is a result of drug-induced abnormal and persistent changes of
the underlying organ, the brain.
One of the hallmarks of addiction is characterized by periods of heightened
relapse susceptibility, even following protracted abstinence (Jaffe et al., 1989; Withers et
al., 1995). As such, relapse is arguably the most important problem to address when
developing treatments for addiction. Towards this, a better understanding of the
biological basis of relapse becomes a top priority. Studies suggest that relapse originates
from the persistent neuroadaptations at the molecular and cellular levels in the related
brain circuit (Baker et al., 2003; Kalivas and Volkow, 2005; Nestler, 2005; Hyman et al.,
2006; Koob and Volkow, 2010). Among these neuroadaptations, drug-induced changes in
synaptic transmission due to aberrant glutamate signaling have been linked to behavior in
virtually every preclinical model of drug seeking and have been found to correlate with
the severity of drug craving in human substance abusers (Pierce et al., 1996; Breiter et al.,
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1997; Volkow et al., 1999; Park et al., 2002; Baker et al., 2003; McFarland et al., 2003;
McFarland et al., 2004; Schmidt et al., 2005; Volkow et al., 2005; Madayag et al., 2007;
Kau et al., 2008; Ary et al., 2013).
It is becoming apparent that excitatory signaling is the product of a highly
integrated activity of a network of glutamate release mechanisms, receptors, and
transporters expressed by multiple cell types, especially neurons and astrocytes (HerreraMarschitz et al., 1996; Timmerman and Westerink, 1997; Danbolt, 2001; Schoepp, 2001;
Baker et al., 2002; Baker et al., 2003; Pirttimaki et al., 2011; Bridges et al., 2012a). As a
result of the complexity of this network, identifying approaches that can reverse cocaineinduced changes throughout the glutamate system has been challenging. This, at least in
part, is due to the emphasis in most studies of a single cell type (e.g. astrocytes or
neurons) while overlooking the fact that glutamate transmission results from the
integrated actions of neurons and astrocytes. Therefore, understanding how these cells
interact to achieve coordinated glutamate transmission is an essential goal for
understanding the biological basis of drug relapse.
The main effort of this thesis is to explore neuronal regulation of a non-canonical
glutamate transporter, system xc- (Sxc) and how this novel form of neuron-astrocyte
signaling contributes to synaptic transmission in the nucleus accumbens (NAc) efferents
that control drug seeking behaviors. As a cystine-glutamate antiporter that is mainly
located on astrocytes, Sxc plays an important role in neuronal glutamate signaling and
has been repeatedly demonstrated to be involved in cocaine addiction (Baker et al., 2003;
Madayag et al., 2007; Moussawi et al., 2009; Amen et al., 2011; Moussawi et al., 2011;
Schmaal et al., 2012). In these studies, I focus on the regulation of Sxc by a neuropeptide,
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pituitary adenylate cyclase-activating polypeptide (PACAP), which is exclusively
expressed by neurons in the CNS (Figiel and Engele, 2000; Zhang et al., 2014), yet has
been repeatedly demonstrated to regulate astrocytic functions, including glutamate
transmission (Goursaud et al., 2008; Resch et al., 2014b). Therefore, the intersection of
PACAP and Sxc on the regulation and coordination of neuronal and astrocytic glutamate
systems presents itself as a unique opportunity to better understand this important and
complex excitatory signaling network and how its disruption by drugs of abuse
contributes to relapse.

Preclinical Models of Drug Seeking
The attempts to understand the biological basis of addiction have involved two
primary approaches: brain imaging in humans and preclinical models of addiction that
permit mechanistic-type studies. In this section, I will focus on the latter, although many
key discoveries realized by preclinical studies have often been replicated in human
studies (Grant et al., 1996; Breiter et al., 1997; Childress et al., 1999; Volkow et al.,
2005).
Conditioned place preference
Addiction is a multi-faceted disorder. As such, various animal models have been
developed to study the biological underpinnings of multiple components of addiction.
For example, the conditioned place preference (CPP) can be used to study aspects of
addiction related to drug context (Bardo and Bevins, 2000). This is because the CPP
model is a form of classical conditioning, in which drug experience is associated with
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certain contextual cues, demonstrated by a longer time spent in the environment
associated with drug administration (Tzschentke, 2007). While useful in studying aspects
of drug addiction related to the formation of contextual associations, this paradigm lacks
face validity when compared to other models that enable self-administered drugs.
Moreover, given that drug-induced plasticity can be intake-dependent, the CPP paradigm
may lack construct validity since the amount of cocaine administered in this paradigm is
relatively low.
Self-administration model
Drug self-administration model is often used to study factors that govern drug
reinforcement and drug intake. In a typical self-administration paradigm as shown in
Figure 1.1A, rats are trained to press an active lever that is equipped in the selfadministration chamber, which triggers a computer interface controlling mechanical

Figure 1.1. Self-administration and reinstatement models of drug seeking. A. Illustration of a
typical self-administration chamber. B. Typical lever responses during drug self-administration
(self-ad.), extinction training (ext.) and reinstatement test (rein.).

equipment to deliver an intravenous infusion of the drug through a catheter mounted on
the back of the rats. As such, the animals self-administer drugs similarly to human
subjects. Because drug self-administration is a form of operant conditioning, it permits
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the study of factors that govern the reinforcing qualities of drugs of abuse. Further, the
self-administration paradigm can be modified to study other aspects of addiction,
including factors related to relapse, as described below.
Reinstatement model
The self-administration paradigm is often modified in order to study factors
related to increases in non-reinforced drug seeking, which is used to model human
relapse (Shaham et al., 2003; Lynch et al., 2010). Typically, the paradigm is extended
such that subjects that have completed cocaine self-administration training, often to the
point of having consumed enough cocaine to produce persistent drug-induced plasticity,
undergo a series of manipulations designed to elicit non-reinforced operant responding
(Shaham et al., 2003; Bossert et al., 2013). For example, many studies examine the
factors enabling a priming dose of cocaine, which typically involves non-contingent
administration to ensure the lack of reinforced responding, to produce significant levels
of operant behavior. To facilitate the detection of increased behavior, extinction training
can be used between the self-administration and reinstatement phases of the experiment
(Figure 1.1B). Similar designs can also be used to test the capacity of stress, discrete
drug-cues, and drug context to reinstate drug seeking (Lee et al., 2006; Crombag et al.,
2008; Anker and Carroll, 2010; Mantsch et al., 2016). This paradigm has face validity in
that the stimuli that cause relapse in humans can cause reinstatement of drug seeking in
rodents (Gerber and Stretch, 1975; de Wit and Stewart, 1981; Self et al., 1996). In
addition, the reinstatement model (incorporating self-administration) captures key
features of human addiction, such as the reinforcing effect of the drugs, transition from
recreational drug use to compulsive drug abuse, and resumption of drug intake after
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prolonged periods of abstinence. Lastly, comparable data obtained from this animal
model and human subjects supports the construct validity of this model. For example,
studies with the reinstatement model demonstrated that activation of the prefrontal cortex
(PFC) is required for the expression of drug-seeking behavior (Baker et al., 2003;
Capriles et al., 2003; McFarland et al., 2003; McLaughlin and See, 2003), consistent with
the results from clinical imaging studies (Grant et al., 1996; Breiter et al., 1997; Childress
et al., 1999; Volkow et al., 2005). This indicates that there are shared biological
substrates and mechanisms underlying relapse in both animals and human (Kalivas and
McFarland, 2003).
With the aid of many neuroscience tools, including traditional techniques such as
microdialysis (Baker et al., 2003; Madayag et al., 2010), microinjection (Blacktop et al.,
2011; Graf et al., 2013), and also fast developing modern techniques such as
chemogenetics (Scofield et al., 2015; Augur et al., 2016) and optogenetics (Stefanik and
Kalivas, 2013; Stefanik et al., 2013), the reinstatement paradigm has proven to be a
valuable preclinical model over the last few decades in elucidating the mechanisms
underlying relapse. The value of this model is further supported by the discoveries of
promising treatments for human drug addiction founded in part through the use of this
model. For example, N-acetylcysteine was found to reduce cocaine-seeking in rodents
and similarly to reduce drug craving in human subjects in clinical trials (Baker et al.,
2003; LaRowe et al., 2007; Madayag et al., 2007; Amen et al., 2011; Moussawi et al.,
2011; Reichel et al., 2011).
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The Motive Circuit
The above paradigms have been widely used over the past 30+ years to
specifically unmask the neuroanatomical and neurochemical systems underlying
addiction. One of the major findings is that the rewarding properties of drugs of abuse
and natural rewards such as food and sex share the same neural substrates that mediate
motivated adaptive behaviors. Much of this work has led to the establishment of the
motive circuit (Figure 1.2) as a key circuit involved in multiple components of drug
addiction. Of particular importance, many findings over the past 25 years have supported

Figure 1.2. The motive circuit. Illustration of the interconnected brain regions and nuclei of the
motive circuit. Adapted from (Kalivas and Volkow, 2005)
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a central hypothesis in addiction that relapse and compulsive drug seeking arise from
persistent neuroadaptations at molecular and cellular levels in the motive circuitry
(Nestler, 2001; Kalivas and Volkow, 2005; Nestler, 2005; Kalivas, 2009).
The motive circuit, which is characterized by a collective of interconnected brain
areas, including mainly the PFC, the amygdala, the hippocampus, the NAc, and the
ventral tegmental area (VTA), is a circuit of neural networks that controls goal-directed
behaviors.
The PFC, especially the medial portion (mPFC), is the executive center of the
brain that is critical for decision making (Bechara et al., 2000; Rushworth et al., 2011;
Euston et al., 2012). This function in part attributes to its anatomical position of receiving
extensive projections directly from other cortical, subcortical and limbic regions, and
therefore its capability of associating retrieved memory, sensory and emotional inputs
(Miller and Cohen, 2001). As such, inputs from these cortical structures as an important
component of the motive circuit enable executive function to contribute to the expression
of goal-directed behaviors.
The amygdala is a forebrain limbic structure that is critical for the formation of
emotional memory and thus conditioned learning (Rogan et al., 1997). In brief, it
associates the motivationally relevant experiences, either rewarding or aversive, with the
environmental stimuli, which subsequently predict the relevant events (Belova et al.,
2007). As such, the amygdala, specifically, the basolateral amygdala has been heavily
implicated in cue-induced drug-seeking behavior (See et al., 2001; Alleweireldt et al.,
2002; Crombag et al., 2002). Therefore, inputs from the amygdala should be viewed as
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enabling conditioned learning and/or emotional memory to also contribute to the
expression of goal-directed behaviors.
The hippocampus, which is also part of the limbic cortex, is located in the
temporal lobe of the brain and is a structure critical for the formation of contextual and
declarative memories (Eichenbaum, 2000, 2004). Together with amygdala, these
structures form and preserve detailed contextual memories of experiences, for example,
those associated with drug taking (Kelley, 2004; Robbins et al., 2008). Hence, inputs
from these structures enable contextual memories to contribute to the expression of goaldirected behaviors.
Midbrain nuclei, including the VTA, project throughout the motive circuit and are
thought to release neurotransmitters, which collectively encode multiple aspects of
motivated behavior (Adinoff, 2004; Alcaro et al., 2007). While these projections are
primarily studied for their dopaminergic inputs, which have been long recognized to be
strong modulators of motivated behavior (Kauer and Malenka, 2007; Gerfen and
Surmeier, 2011), additional neurotransmitters include glutamate, gamma-aminobutyric
acid (GABA), and co-neurotransmitters such as opioid peptides (Chuhma et al., 2009;
Jarjour et al., 2009; Stuber et al., 2010; Tecuapetla et al., 2010; Tritsch et al., 2012).
While much work is needed to parse out the components of motivated behavior encoded
by each of these key neurotransmitters, it is clear that these inputs to the motive circuit
enable goal-directed behavior to be a product of incentive salience, motivation, and
reward.
Among all these structures in the motive circuit, this dissertation focuses on the
NAc. The NAc is part of the ventral striatum and is located in the basal forebrain. It is a
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central structure in the expression of goal-directed behaviors, in part because it connects
the limbic subcircuit to the motor subcircuit. Specifically, it integrates inputs from the
PFC, amygdala, hippocampus, and midbrain nuclei (Morgane et al., 2005). In turn, it
then projects to the motor nuclei, ventral pallidum (VP) and the substantia nigra (SN). As
such, the NAc is anatomically positioned as a gateway to integrate limbic information
and lead to the expression of behaviors through recruitment of the motor system
(Groenewegen et al., 1996; Yin and Knowlton, 2006).
Projections from the PFC to the NAc core have been shown to be involved in
multiple forms of drug seeking (Cornish and Kalivas, 2000; Di Ciano and Everitt, 2001;
McFarland and Kalivas, 2001; Kalivas and Volkow, 2005). This glutamatergic projection
and the NAc efferents to the motor system, simplified as the corticostriatal pathway, have
been described to be the final common pathway for generating reinstatement behavior
(Kalivas and Volkow, 2005). This is supported by its obligatory involvement in the
initiation of drug seeking induced by all the three common triggers, i.e. cues, stress and
drug (Cornish and Kalivas, 2000; McFarland and Kalivas, 2001; Park et al., 2002;
Capriles et al., 2003; McFarland et al., 2003; McLaughlin and See, 2003; McFarland et
al., 2004).
As introduced above, the development of addiction involves both the limbic and
motor units of the corticostriatal pathway with the NAc serving as the gateway
connecting the two (Kalivas, 2009). While the limbic subcircuit is critical for the
development and establishment of addiction, such as the expression of drug seeking
behavior, it also retains the power for altering well-established behaviors in order to adapt
to constantly changing environment, in other words, generating new adaptive behaviors
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(Barnes et al., 2005; Doya, 2008). For example, in the model of cocaine selfadministration, when lever pressing reliably yields desired drug delivery, the influence of
the limbic unit diminishes while the motor function gradually predominates in
performing the task (Barnes et al., 2005; Yin and Knowlton, 2006). The same rules apply
to the development of other habitual behaviors. However, when lever pressing fails to
yield the expected drug delivery, such as in extinction training, the limbic subcircuit reengages to re-evaluate environmental stimuli and reassign values, while the established
motor pattern re-organizes concordantly. As such, a new adaptive behavior develops
(Barnes et al., 2005; Doya, 2008).
These concepts indicate that drug-seeking behavior arises from the
neuroadaptions that favor such established behavior, and/or that impair the capability of
controlling or changing such behavior (Kalivas, 2009; Belin et al., 2013). In other words,
drug reinstatement results from weakened limbic control and/or strengthened motor
involvement. Consistently, extended drug intake promotes the progressive reliance on the
motor systems, and at the same time the gradual disengagement of the limbic system (Ito
et al., 2000; Ito et al., 2002; Porrino et al., 2004; Vanderschuren and Everitt, 2004;
Vanderschuren et al., 2005; Pelloux et al., 2007).
As introduced above, the NAc is a gateway where limbic information gains its
access for the motor expression. As such, dysfunction of this structure induced by
repeated drug exposure might underlie the declining engagement of the limbic subcircuit.
In fact, studies from the past two decades indicate that the imbalanced corticostriatal
pathway arises at least in part from the malfunction of the glutamatergic signaling in the

12

NAc. This involves neuroadaptations in glutamate receptors, release and clearance
mechanisms, for review see (Kalivas, 2009).

Glutamate Transmission in Addiction
Glutamate is the primary excitatory neurotransmitter in the brain (Curtis and
Johnston, 1974; Choi, 1988; Harris and Kater, 1994; Meldrum, 2000; Franks et al., 2002;
Javitt et al., 2011). Its transmission underlies virtually all brain functions, as supported by
its involvement in numerous CNS disorders (Carlsson and Carlsson, 1990; Olney, 1990;
Brown and Bal-Price, 2003; Hynd et al., 2004; Maragakis and Rothstein, 2004; Foster
and Kemp, 2006; Niswender and Conn, 2010; Rondard and Pin, 2015).

Figure 1.3. A typical glutamate synapse. Pre: presynaptic terminal; Post: postsynaptic terminal;
Glu: glutamate; A: AMPA receptor; N: NMDA receptor; M: metabotropic glutamate receptor; E:
excitatory amino acid transporter; CC: cystine; Sxc: system xc- . Adapted and modified from
(Bridges et al., 2012a).
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With advances in neuroscience, it is gradually becoming apparent that glutamate
neurotransmission is achieved by a complicated network that is formed by multiple cell
types, including mainly neurons and astrocytes. Both of these cell types express
glutamate receptors, transporters and release mechanisms (Figure 1.3).
Glutamate receptors
There are two types of glutamate receptors, ionotropic (iGluR) and metabotropic
glutamate receptors (mGluR). iGluRs are ligand-gated ion channels that are formed by
tetramers and mediate fast excitatory synaptic transmission (Dingledine et al., 1999; Platt,
2007; Traynelis et al., 2010). Based on their sequence differences and pharmacological
ligand (agonist) selectivity, iGluRs are further divided into three subtypes, α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), N-Methyl-D-aspartate
receptor (NMDAR) and kainate receptor (Dingledine et al., 1999; Platt, 2007; Traynelis
et al., 2010). These different receptor subtypes are distinctly distributed in the CNS and
exhibit different channel properties determined by their subunit compositions and
location (Dingledine et al., 1999; Platt, 2007; Traynelis et al., 2010). In this dissertation, I
will focus on AMPARs and NMDARs, as they are the most studied iGluRs in addiction.
AMPA receptors
Most AMPARs are heterotetrameric, consisting of subunits GluA2 and either
GluA1, GluA3, or GluA4, with a prototype of dimers of dimers (Nakagawa et al., 2005).
Each of the four subunits harbors a binding site for glutamate. AMPARs are activated
upon the occupation of as little as two binding sites by glutamate or agonists (Platt,
2007). The channel formed by the four subunits then opens to allow the influx of sodium
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and potassium. The binding sites to glutamate are of low-affinity (EC50: 200-500 µM),
and AMPARs deactivate fast due to the transient bound time of the glutamate that is
caused by the rapid diffusion and dilution of the transmitter (Dingledine et al., 1999;
Platt, 2007; Traynelis et al., 2010). Given that AMPARs are not voltage gated, this fast
gating property renders AMPARs obligatory players in most of the fast excitatory
neurotransmission (Zhang and Trussell, 1994; Edmonds et al., 1995; Palmer et al., 2005).
Specifically, activation of AMPARs initiates depolarization that is essential for removing
the magnesium blockers residing within NMDAR ion channels (Nowak et al., 1984;
Dingledine et al., 1999). Thus, it facilitates the participation of NMDARs in generating
the excitatory postsynaptic potential (EPSPs). As such, synaptic expression of AMPARs
is critical in determining synaptic strength (Malinow and Malenka, 2002; Shepherd and
Huganir, 2007).
Functional AMPARs are primarily located on postsynaptic terminals. The
membrane expression of the receptors is a rather dynamic and highly amendable process
(Anggono and Huganir, 2012; Niciu et al., 2012). It involves the expression of the
receptors, the trafficking from the cell soma, and the lateral membrane diffusion from the
extrasynaptic to the synaptic compartment (Groc and Choquet, 2006; Kennedy and
Ehlers, 2006; Shepherd and Huganir, 2007; Newpher and Ehlers, 2008; Kapitein et al.,
2010). The whole process is highly dependent on synaptic events, and in turn plays a key
role in synaptic plasticity (Malinow and Malenka, 2002). For example, it has been well
established that the integration of AMPARs to the synaptic membrane is critical in
mediating long-term potentiation (LTP), a key mechanism that underlies learning and
memory formation (Lynch, 2004). As such, AMPARs are broadly involved in

15

experience-induced neuroadaptations; disruption of AMPAR functions often negatively
impact brain functions and has been demonstrated in various CNS disorders, including
addiction.
AMPARs are enriched in the medium spiny neurons (MSNs) in the striatum
(Martin et al., 1993; Bernard et al., 1997) where the NAc resides. Drug-induced AMPAR
plasticity has been recurrently implicated in addiction studies. For example, repeated
cocaine leads to increased surface expression of GluA1-containing AMPARs (GluA1AMPARs) in the NAc, and consequently postsynaptic potentiation (Conrad et al., 2008;
Moussawi et al., 2009). In addition, impairment of GluA1-AMPAR trafficking decreases
cocaine induced reinstatement, suggesting that increased membrane expression of
GluA1-AMPARs is critical for cocaine relapse (Anderson et al., 2008). Consistently,
activating AMPARs with AMPA in the NAc reinstates cocaine-seeking behavior, while
blocking AMPARs with receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione
(CNQX) eliminates cocaine-induced reinstatement (Cornish and Kalivas, 2000).
Membrane expression of AMPARs is, to a certain degree, dependent on the
phosphorylation of the receptor, a labile post-translational modification that is reversible
and relatively dynamic (Wang et al., 2006; Mao et al., 2011). Phosphorylation sites exist
on the C-terminals of each GluA subunit, which are intracellular domains that undergo
protein-protein interaction and phosphorylation. There are four sites identified on the
GluA1 intracellular domain, including serine 818 (S818), S831, S845 and threonine 840
(T840). Among these, T840 could be phosphorylated by p70S6 kinase and PKC (Delgado
et al., 2007; Lee et al., 2007). Dephosphorylation of GluA1-T840 by NMDAR-mediated
signaling has been implicated in long-term depression (LTD) (Delgado et al., 2007).
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S845 is a substrate for PKA. Phosphorylation of S845 by PKA in response to cellular
activity facilitates synaptic trafficking of the receptor, augments AMPAR-mediated
currents, and is critical for LTP (Roche et al., 1996; Derkach et al., 1999; Banke et al.,
2000; Esteban et al., 2003). Phosphorylation of S845 in striatal neurons has been
extensively studied in addiction. It contributes to the psychostimulant (e.g. cocaine)induced increase of synaptic AMPAR expression, and consequently the potentiation of
synaptic strength (Price et al., 1999; Snyder et al., 2000; Chao et al., 2002; Mangiavacchi
and Wolf, 2004; Swayze et al., 2004). Therefore, this mechanism is likely correlated with
the neuroadaptations that underlie drug-seeking behavior.
NMDA receptors
Similar to AMPAR, NMDARs are also heterotetrameric. The receptor is
composed of subunits from three classes, including GluN1, GluN2, and GluN3. Each
NMDAR contains two GluN1 obligatory subunits, and two GluN2 and/or GluN3 subunits
(Dingledine et al., 1999; Platt, 2007; Traynelis et al., 2010). Unlike AMPARs that are
activated by glutamate or agonists, opening of the NMDAR ion channel requires the
binding of both glycine/D-serine (co-agonists) and glutamate, with glycine to GluN1 and
glutamate to the other two subunits (Kleckner and Dingledine, 1988; Chen et al., 2005;
Wolosker, 2006). Additionally, full occupation of all four binding sites appears to be
necessary for maximum activation of the receptor. However, activation of the receptor
and the opening of the NMDAR channel does not assure the ion flux, as the channel is
constitutively blocked by magnesium, which could be removed by the rapid
depolarization of the membrane potential mediated by AMPARs (Nowak et al., 1984;
Dingledine et al., 1999). Unblocked NMDAR channels allow the influx of sodium, and
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calcium, and the outflow of potassium (Dingledine et al., 1999; Liu and Zhang, 2000;
Cull-Candy et al., 2001; Paoletti and Neyton, 2007). The intracellular surge of calcium
from NMDARs leads to activation of different calcium-dependent signaling pathways
that are differentially involved in the induction of LTP and LTD (Shouval et al., 2002;
Citri and Malenka, 2008; Luscher and Malenka, 2012).
In contrast to AMPARs, NMDARs demonstrate much higher affinity for
glutamate. The affinity varies depending on the subunit composition and splicing
variance of each receptor, yet the EC50 of NMDARs typically falls at micromolar or submicromolar level (McBain and Mayer, 1994; Meldrum, 2000). Unlike AMPARs,
NMDARs activate and deactivate much slower (Edmonds et al., 1995; Wyllie et al.,
1998), and thus mediate the slow component of the EPSP (Meldrum, 2000; VargasCaballero and Robinson, 2004). The slow kinetics of NMDARs allows a temporal
summation of depolarization which generates a persistent excitation and thus is critical
for neuronal firing (Herron et al., 1986; Daw et al., 1993; Larkum and Nevian, 2008;
Polsky et al., 2009). Given that ion flux through NMDARs requires both the binding of
glutamate that is released from the presynaptic terminal and the removal of channel
blockers by postsynaptic depolarization, the slow kinetics of the receptor render
NMDARs the capability to simultaneously detect both the pre- and post-synaptic
activities that are necessary for the induction of LTP and LTD (Malenka and Nicoll,
1993; Luscher and Malenka, 2012). As such, NMDAR-mediated synaptic plasticity has
been extensively studied in learning and memory formation (Tsien et al., 1996;
Nakazawa et al., 2004).
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NMDARs are enriched in the striatum and are predominantly GluN2A- and
GluN2B-containing in this region; they are widely expressed by MSNs projecting to both
the SN and the VP, and cholinergic interneurons (Landwehrmeyer et al., 1995; Chen et
al., 1996; Dunah and Standaert, 2003). The concentrated expression of NMDARs in the
striatum and their critical role in synaptic transmission and plasticity implicate that
NMDARs are likely involved in addiction. In support, blocking NMDARs in the NAc
induces reinstatement of drug seeking (Cornish and Kalivas, 2000; Famous et al., 2007).
While not studied as extensively as AMPARs, NMDARs also demonstrate drug-induced
plasticity. For example, cocaine self-administration alters the phosphorylation of striatal
NMDARs in rats (Edwards et al., 2007). Such plasticity may in turn contribute to drug
craving and relapse.
Metabotropic glutamate receptors
In comparison to iGluRs, which are ion channels that mediate fast synaptic
transmission, mGluRs are G-protein coupled receptors that mediate their modulatory
effects through activation of G-proteins and downstream second messenger systems (Pin
et al., 2003). There are eight subtypes of mGluRs which are divided into three groups
based on their amino acid compositions and signaling cascades (Niswender and Conn,
2010). Group I mGluRs (mGluR1 and 5) are coupled to Gαq, stimulation of which results
in the calcium release from the endoplasmic reticulum (ER), as well as the activation of
PKC, and thus related transduction cascades. Both group II (mGluR2 and 3) and group III
mGluRs (mGluR4, 6, 7 and 8) are coupled to Gαi that negatively impact the activity of
adenylate cyclase (AC). Therefore, activation of group II or group III mGluRs decreases

19

the production of cyclic adenosine monophosphate (cAMP), and consequently inhibits
downstream signaling pathways including PKA-mediated cascades.
Both neurons and astrocytes express mGluRs. Neuronal mGluRs are located on
presynaptic and extrasynaptic membranes. Activation of postsynaptic mGluRs has been
shown to modulate ion channel activity (Haak et al., 1997; Benquet et al., 2002;
Niswender and Conn, 2010), while presynaptic mGluR activation leads to reductions in
presynaptic neurotransmitter release including glutamate and GABA (Schrader and
Tasker, 1997; Mitchell and Silver, 2000; Pinheiro and Mulle, 2008). Such a mechanism is
potentially involved in addiction. Specifically, repeated cocaine exposure leads to a
persistent functional disruption of mGluR2/3 in the NAc (Xi et al., 2002). As presynaptic
mGluR2/3 reduces the release probability of glutamate (Moran et al., 2005), this results
in an augment of synaptic glutamate transmission and contributes to the reinstatement of
cocaine seeking (McFarland et al., 2003; McFarland et al., 2004; Madayag et al., 2007;
Miguens et al., 2008). Given that mGluR2/3 binds to glutamate with nanomolar high
affinity (Muguruza et al., 2016) and is potentially activated by extrasynaptic glutamate
released from Sxc (Xi et al., 2002; Losonczy et al., 2003; Moran et al., 2003; Grueter and
Winder, 2005; Moran et al., 2005), cocaine-induced attenuation of Sxc in the NAc may
exaggerate such consequences resulting from blunted mGluR2/3.
Glutamate clearance through EAATs
Extracellular glutamate needs to be maintained at a relatively low level, for at
least two reasons. First, excessive stimulation of glutamate receptors by high
concentrations of glutamate is toxic. For example, pathological surges of extracellular
glutamate over-stimulate extrasynaptic glutamate receptors, which leads to cell death
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(Hardingham et al., 2002; Ivanov et al., 2006; Leveille et al., 2008). Second, a relatively
low level of extracellular glutamate is critical in limiting tonic activation of glutamate
receptors (Danbolt, 2001). It has significant physiological meaning, because in such a
manner, activation of glutamate receptors by activity/excitation-dependent glutamate
becomes distinguishable from that induced by basal glutamate. As such, it provides
appropriate signal-to-noise ratio (Danbolt, 2001). However, unlike many other
neurotransmitters that can be enzymatically degraded, there is a lack of evidence for the
existence of such an extracellular mechanism to metabolize glutamate. Therefore, a
cellular uptake machinery is the only clearance mechanism that could rapidly eliminate
the build-up of extracellular glutamate from constant synaptic release and other release
mechanisms (Logan and Snyder, 1971; Balcar and Johnston, 1972; Danbolt, 2001). In
fact, this function is mainly carried out by a family of cell-surface expressed proteins,
excitatory amino acid transporters (EAATs).
EAATs are a family of Na+-dependent high-affinity glutamate transporters. They
are symporters; 2-3 Na+ and one proton are co-transported intracellularly with each
molecule of glutamate, while a K+ is counter-transported to complete the circle and
restore conformation of the transporter for the next circle (Rose et al., 2009). Five
subtypes of EAATs (EAAT1-5) have been identified (O'Shea, 2002). EAAT1&2 are
primarily expressed by astrocytes and EAAT 3-5 predominantly by neurons (Lehre et al.,
1995; Anderson and Swanson, 2000; Pow and Barnett, 2000; Hu et al., 2003; Holmseth et
al., 2012). Glial EAATs, EAAT1 and EAAT2 are believed to play the major role in
extracellular glutamate clearance (Danbolt, 2001). EAAT1 is predominantly distributed
in the neocortex and cerebellum and is the main transporter in the CNS during
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development. EAAT2 is abundantly expressed in the forebrain; it occurs almost
exclusively in astrocytes (Lehre et al., 1995), with particularly high densities in the
astrocytic compartments that surround the synaptic cleft (Minelli et al., 2001). EAAT2 is
the primary player in glutamate clearance, given that it accounts for as much as 90% of
glutamate uptake in adult brain tissues (Haugeto et al., 1996; Tanaka et al., 1997;
Danbolt, 2001). As such, disruption of glial glutamate transporter-1 (GLT1; rodent
homologue of EAAT2) functions leads to toxic accumulation of extracellular glutamate
(Rothstein et al., 1996; Tanaka et al., 1997).
Disruption of GLT1 has been repeatedly demonstrated in addiction studies.
(Knackstedt et al., 2010; Fischer-Smith et al., 2012; Fischer et al., 2013; Reissner et al.,
2014; Reissner et al., 2015). For example, cocaine self-administration reduces expression
of GLT1 in the NAc (Knackstedt et al., 2010; Fischer-Smith et al., 2012; TranthamDavidson et al., 2012). This down-regulation of GLT1 is likely involved in the drug
relapse. In support, a number of studies demonstrated that restoration of GLT1 in animals
with cocaine history prevented the reinstatement of drug-seeking behavior that is induced
by cues or the drug, for review see (Roberts-Wolfe and Kalivas, 2015).
To date, studies of the regulation of EAAT2/GLT1 are still scarce. EAAT2/GLT1
undergoes post-translational alterations that are induced by several factors, including the
substrate glutamate and arachidonic acid, resulting in a rapid activity change
(Gegelashvili and Schousboe, 1998). Neurochemical signals, such as epidermal growth
factor, influence EAAT2/GLT1 expression (Zelenaia et al., 2000; Su et al., 2003).
Interestingly, several studies using in vitro cell cultures reveal that the expression of
GLT1 in astrocytes is regulated by neurons or secretory neuronal factors including
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PACAP, most likely through activating PKA (Gegelashvili et al., 1997; Swanson et al.,
1997; Schlag et al., 1998; Figiel and Engele, 2000). Neuronal regulation of GLT1 is
further demonstrated in vivo, as the expression of this transporter is regulated by inputs
from presynaptic neurons (Yang et al., 2009).
Glutamate release through Sxc
System xc- (Sxc) is a sodium-independent, chloride-dependent cystine-glutamate
antiporter (Bannai and Kitamura, 1980, 1981; Sato et al., 1999). It belongs to the
heteromeric amino acid transporter family that are glycoprotein associated amino acid
exchangers (Broer and Wagner, 2002; Verrey et al., 2004; Palacin et al., 2005).
Functional Sxc, expressed on plasma membrane, is a heterodimer that consists of a heavy
chain 4F2 (corresponding gene SLC3A2) and a light chain xCT (corresponding gene
SLC7A11) (Sato et al., 1999). The two subunits are covalently linked through a disulfide
bond (Bridges et al., 2012b). While the 4F2 heavy chain is shared by multiple amino acid
transport systems and contributes to membrane expression of Sxc, the light chain xCT is
unique to Sxc and determines its substrate specificities to cystine and glutamate (Sato et
al., 1999; Sato et al., 2000; Bridges et al., 2001). By driving the release of glutamate into
the extracellular space, Sxc transports cystine molecules into the cytoplasm (Figure 1.3)
at a 1:1 ratio (Sato et al., 1999). As such, Sxc serves as a non-vesicular glutamate
releasing mechanism.
Functions of Sxc
Both cystine and glutamate play important roles in maintaining normal functions
of the CNS. Intracellular transport of cystine through Sxc is a rate limiting step for the
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synthesis of glutathione (Deneke and Fanburg, 1989; Kato et al., 1992; O'Connor et al.,
1995), a major antioxidant in the CNS. It is synthesized mostly in astrocytes (Raps et al.,
1989; Trenga et al., 1991), yet yields its protection against oxidative stress for not only
astrocytes, but also neurons (O'Connor et al., 1995; Shih et al., 2003; He et al., 2015).
Glutamate release from Sxc, on the other hand, is critical for maintaining extracellular
glutamate level/glutamate homeostasis. As introduced above, glutamate and glutamate
receptors exist both within and outside of a synapse. Glutamate that is released from
presynaptic terminals into the synaptic cleft contributes to the synaptic pool of glutamate.
In contrast, extrasynaptic glutamate originates from mainly astrocytes through multiple
mechanisms, including calcium-dependent vesicular release (Araque et al., 2000; Bezzi et
al., 2004; Montana et al., 2004; Malarkey and Parpura, 2008), hemi-channels (Ye et al.,
2003), and Sxc (Murphy et al., 1990; Warr et al., 1999; Baker et al., 2002). Among these,
non-vesicular release from Sxc has been implicated to be the major source of basal
glutamate in brain regions including the NAc (Baker et al., 2002; De Bundel et al., 2011;
Massie et al., 2011).
Extrasynaptic glutamate is important in shaping synaptic transmission and
plasticity by activating extrasynaptic receptors. For example, activation of presynaptic
autoreceptor mGluR2/3 negatively regulates synaptic glutamate release. Such an
inhibitory effect is facilitated by Sxc function, which provides extracellular glutamate for
the activation of mGluR2/3 (Manzoni et al., 1997; Moran et al., 2005; Moussawi and
Kalivas, 2010). Extrasynaptic NMDARs facilitate the induction of LTD (Liu et al., 2013),
while excessive activation of extrasynaptic NMDARs is involved in the inhibition of LTP
(Katagiri et al., 2001; Izumi et al., 2008; Li et al., 2011). Interestingly, extrasynaptic
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NMDARs cluster at the perisynaptic domain and dendritic shaft (Petralia et al., 2010),
where they are in close proximity to processes from neighboring cells including
astrocytes (Tao-Cheng et al., 2007), and thus are likely to be activated by astrocytereleased glutamate (Angulo et al., 2004; Fellin et al., 2004; Le Meur et al., 2007;
Shigetomi et al., 2008; Nie et al., 2010). In support, it has been shown that activation of
extrasynaptic NMDARs requires glutamate release from glia (Bezzi et al., 2004; Fellin et
al., 2004; Bergersen and Gundersen, 2009; Hamilton and Attwell, 2010; Bergersen et al.,
2012). However, the direct link between Sxc and extrasynaptic NMDAR activation
remains unclear. Sxc originated glutamate has been shown to attenuate postsynaptic
clustering of glutamate receptors (Augustin et al., 2007). It also facilitates postsynaptic
removal of AMPAR, resulting in the attenuation of synaptic strength (Williams and
Featherstone, 2014). Consistently, loss of functional Sxc in mice leads to decreased levels
of basal glutamate, and disruption of LTP, working memory and long-term memory (De
Bundel et al., 2011; Li et al., 2012).
Therefore, dysregulation/dysfunction of Sxc has been shown to cause disrupted
glutamate homeostasis and inability in coping with oxidative stress, and is implicated in
various neuropsychiatric and neurodegenerative diseases, including addiction,
schizophrenia, amyotrophic lateral sclerosis and Parkinson’s disease, for review see
(Bridges et al., 2012a; Lewerenz et al., 2013). With the rodent model of drug seeking, it
has been demonstrated that repeated cocaine exposure leads to a significant reduction in
basal glutamate and disrupted glutamate transmission in the NAc, resulting from
decreased function of Sxc, which consequently lead to the reinstatement of drug seeking
(Baker et al., 2003; Madayag et al., 2007; Kau et al., 2008; Knackstedt et al., 2010). In
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support, restoration of NAc Sxc activity by ceftriaxone or prodrug N-acetylcysteine
normalizes the basal level of glutamate, and significantly decreases the reinstatement of
cocaine-seeking behavior (Madayag et al., 2007; Kau et al., 2008; Knackstedt et al., 2010;
Trantham-Davidson et al., 2012).
Regulation of Sxc
Regulation of Sxc has been shown at the expression and phosphorylation levels.
Consistent with its role in antioxidant defense, Sxc activity is upregulated in response to
oxidative stress (Kim et al., 2001; Dun et al., 2006; Mysona et al., 2009). This
upregulation is likely mediated by the nuclear factor erythroid 2-related factor 2 (Nrf2),
which could be induced by oxidative insults and increases xCT transcription through
interacting with the Nrf2-antioxidant responsive element (ARE) sequences on the
SLC7A11 promoter (Itoh et al., 1997; Sasaki et al., 2002; Itoh et al., 2004; Shih et al.,
2006). Such a pathway also underlies ceftriaxone-induced upregulation of xCT in
astrocytes (Lewerenz and Maher, 2009). Another transcription factor identified is the
eukaryotic initiation factor-2-activating transcription factor 4 (ATF4). By binding to the
ATF4-amino acid response elements (AAREs) on the SLC7A11 promoter, it increases
the transcription of xCT (Sato et al., 2004; Lewerenz and Maher, 2009; Lewerenz et al.,
2012b). In addition to its involvement in coping with oxidative stress, this pathway
mediates the upregulation of Sxc by insulin-like growth factor-1 (IGF-1), and may be
induced in response to neuronal activity (Lewerenz et al., 2014; Yang and Yee, 2014).
Fibroblast growth factor-2 (FGF-2) has also been implicated in increasing Sxc activity
and xCT expression by recruiting both PI3K/Akt and MEK/ERK cascades (Liu et al.,
2012; Liu et al., 2014a).
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Studies suggest that Sxc activity is also influenced by post-translational
modification, such as phosphorylation. For example, xCT harbors multiple
phosphorylation sites, including those for PKA (Baker et al., 2002; McClatchy et al.,
2016). Besides, the phosphorylation states are subjected to regulation and have been
shown to influence the activity of Sxc (McClatchy et al., 2016). It has also been
demonstrated that inhibiting cAMP and hence PKA activity rapidly decreases Sxc
activity in rat striatal tissue slices (Baker et al., 2002). Interestingly, cAMP mediated
signaling also appears to increase the expression of Sxc (Gochenauer and Robinson,
2001). In spite of the important roles of Sxc in brain functions such as its involvement in
motivated behavior, the endogenous mechanism that mediates the regulation of Sxc is
still not clear.

Neuron-Astrocyte Interactions
As introduced above, both neurons and astrocytes possess glutamate receptors,
release and uptake mechanisms, which form a glutamate network that mediates the
primary excitatory neurotransmission. A large body of studies suggests that these two cell
types must coordinate to reach organized glutamate signaling.
Astrocytes
It has been frequently stated in the literature, especially in glia studies, that glia
far outnumber neurons (commonly used ratio, 10:1) in the human or non-human primate
brains. However, there is no direct evidence that supports such a remark. In fact, the most
compelling study quantifying glia and neurons suggests a 1:1 ratio in the human brain
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(Herculano-Houzel, 2009) and this ratio varies depending on brain regions. Regardless,
glia compose no less than half of the human brain, and the ratio is probably one of the
lesser questions, since prevalence does not equal significance. What is important, is that
there is accumulating evidence suggesting that glial participation is critical for every
major aspect of brain functions, for review see (Barres, 2008; Oliveira et al., 2015).
There are two major classes of glia in the CNS, macroglia (astrocytes and
oligodendrocytes) and microglia. Microglia function as macrophages in the CNS, while
the major role of oligodendrocytes is to provide axonal myelination. In this dissertation, I
will focus on astrocytes.
Astrocytes are the major type of macroglia in the CNS. Anatomically, astrocytes
are grouped into two main groups, protoplasmic astrocytes that are mainly distributed in
the grey matter, and fibrillary astrocytes mainly in the white matter (Molofsky et al.,
2012). These two groups of astrocytes demonstrate different morphologies, antigenic
phenotypes/biochemical markers and likely different functions. Astrocytes are often
times identified with the expression of glial fibrillary acidic protein (GFAP), the reason
for this protein to be routinely used as an astrocyte-specific marker. However, it is
necessary to mention that not every astrocyte expresses GFAP, and GFAP-expressing
cells may be precursors for neurons (Alvarez-Buylla et al., 2001; Bushong et al., 2002).
Neuron-astrocyte interactions
Metabolism and homeostasis
Astrocytes typically harbor numerous membranous processes that give its starlike shape, as implicated in the name. Through these end-feet, astrocytes are in close
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contact with both vasculature and synapses (Grosche et al., 1999; Ventura and Harris,
1999; Abbott et al., 2006). Such anatomical positions contribute to the central role of
astrocytes in regulating brain microcirculation (Anderson and Nedergaard, 2003; Zonta et
al., 2003; Takano et al., 2006). Specifically, astrocytes mediate vasodilation to boost local
blood supply in response to increased synaptic/neural activity of a specific brain area.
The metabolic supporting roles of astrocytes also includes serving as a glycogen reservoir
(Brown et al., 2004; Brown and Ransom, 2007; Vilchez et al., 2007). Glycogen is
converted to lactose and glucose, which are exported to neurons and used as fuel
(Dringen et al., 1993; Ghosh et al., 2005). Interestingly, a recent study shows that instead
of providing glucose to neurons in response to neuronal activity, astrocytes actively
influence neuronal activity by gating the energy source to neurons (Garcia-Caceres et al.,
2016). Astrocytes are also critical in maintaining extracellular ion levels and
neurotransmitter (e.g. glutamate) homeostasis.
Gliotransmission and synaptic transmission
One of the principle differences between neurons and astrocytes is that neurons
possess dendrites and axons and are capable of generating action potentials and long
distance signal transductions (Raps et al., 1989). In contrast, astrocytes are incapable of
AP-mediated signal transmission due to the low density of sodium channels
(Vijayaraghavan, 2009). This somewhat contributes to the long-standing stigma that
astrocytes do not participate in neurotransmission. However, this point of view has been
challenged by a growing body of evidence, which implicates the direct involvement and
critical role of astrocytes in synaptic transmission.
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Similar to neurons, astrocytes express various receptors for neurotransmitters,
including AMPARs (Seifert et al., 1997b; Seifert et al., 1997a), NMDARs (Lalo et al.,
2006; Verkhratsky and Kirchhoff, 2007), mGluRs (Shelton and McCarthy, 1999), and
GABA receptors (Fraser et al., 1994; Fraser et al., 1995). Electron microscopy studies
have indicated that a number of astrocyte receptors are in proximity of neurotransmitter
releasing sites on synapse, suggesting that astrocytes respond to neuronal
neurotransmitters (Aoki, 1992; Douyard et al., 2007). In support, NMDAR-mediated
currents have been demonstrated in astrocytes in response to synaptic neurotransmitter
release (Lalo et al., 2006).
Even though astrocytes are not capable of generating action potentials, they
demonstrate a special form of excitability and signal transduction. It is mediated by
sophisticated calcium transmission that appears in the form of calcium waves and
propagates through the cell volume (Yagodin et al., 1994; Fiacco et al., 2007). The
calcium transients could be induced via activation of G-protein coupled receptors by
various transmitters (e.g. glutamate) that are potentially released by neurons (Agulhon et
al., 2008). For example, activation of mGluRs induces the Gαq mediated cascades and
the production of inositol trisphosphates (IP3). IP3 binds to the IP3 receptors (IP3R) on
the ER, which leads to calcium release from ER stores, and consequently, the
intracellular calcium propagation along clusters of IP3R (Porter and McCarthy, 1996;
Pasti et al., 1997; Perea and Araque, 2005; Fiacco et al., 2007; Weerth et al., 2007).
Astrocytes are capable of releasing several gliotransmitters, including glutamate,
D-serine, adenosine triphosphate (ATP) and its metabolic byproduct adenosine, for
review see (Haydon, 2001; Agulhon et al., 2008; Araque et al., 2014). All of these
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molecules have corresponding receptors on the neurons. To date, it is well-established
that activation of neuronal receptors by gliotransmitters is actively involved in synaptic
transmission, plasticity and neuronal functions. For example, ATP released by astrocytes
modulates synaptic release of neurotransmitters (e.g. glutamate, GABA and dopamine),
as well as postsynaptic responses. D-serine acts as a co-agonist for NMDARs by
interacting with the glycine-binding site of GluN1. Also, astrocyte glutamate, including
that released from Sxc, is involved in various synaptic functions by activating a spectrum
of presynaptic and extrasynaptic glutamate receptors, for review see (Agulhon et al.,
2008; Araque et al., 2014).
To date, the releasing mechanism of these neuroactive substances is still not fully
understood. A large body of evidence obtained from in vitro and in situ studies
implicates that gliotransmitter release is dependent on the calcium transient-mediated
exocytosis that is potentially induced by neuronal activity, for review see (Araque et al.,
2014). Among these, vesicular exocytosis of glutamate has received considerable
attention (Bezzi et al., 2004; Montana et al., 2004; Zhang et al., 2004; Crippa et al.,
2006). However, the existence of this mechanism has been challenged by a study
demonstrating the lack of known machinery that is required for vesicular glutamate
release in mature mouse astrocytes (Barres, 2008; Cahoy et al., 2008). Therefore, whether
or not vesicular glutamate release occurs in vivo remains a topic of debate (Volterra and
Meldolesi, 2005; Barres, 2008; Hamilton and Attwell, 2010; Parpura and Zorec, 2010).
Notably, among the glutamate releasing mechanisms expressed by astrocytes, Sxc is not
frequently considered (Haydon, 2001; Araque et al., 2014).
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Synaptogenesis and synaptic elimination
The impact of neuron-astrocyte interaction is not limited to its influence on
metabolism and synaptic functions. It also appears to be critical for brain development
and functions. For example, synaptogenesis is not simply controlled by pre and
postsynaptic neurons (Christopherson et al., 2005), but is dependent on the facilitation
from astrocytes. In fact, astrocytes are involved in the formation, elimination, maturation
and maintenance of synapses (Slezak and Pfrieger, 2003; Christopherson et al., 2005;
Kucukdereli et al., 2011; Chung et al., 2013; Clarke and Barres, 2013; Chung et al., 2015).
In support, it has been recently postulated that astrocytes are involved in
neurodevelopmental diseases such as autism and schizophrenia, both of which
demonstrate abnormal synaptogenesis or synaptic elimination (Clarke and Barres, 2013;
Sloan and Barres, 2014; Petrelli et al., 2016).
Neuronal regulation of astrocytes
Conversely, neurons appear to be critically involved in the differentiation and
maturation of astrocytes, for review see (Stipursky et al., 2011). For example, cortical
neurons regulate the onset of cortical gliogenesis during early brain development
(Barnabe-Heider et al., 2005). In addition, neurons promote the expression of astrocyte
GFAP in vitro via soluble factors (Gomes et al., 1999; de Sampaio e Spohr et al., 2002).
Interestingly, such a function is influenced by the origin of the astrocytes and also the
developmental stage of the neurons. Similarly, as mentioned earlier, expression of GLT1
in astrocytes is significantly influenced by the presence of neurons or secretory neuronal
factors including PACAP (Gegelashvili et al., 1997; Swanson et al., 1997; Schlag et al.,
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1998; Figiel and Engele, 2000). In addition, neurons influence molecular and functional
phenotypes of local astrocytes in vivo (Farmer et al., 2016). Clearly, neuron-to-astrocyte
communication plays a critical role in astrocyte functions. However, the underlying
mechanisms are not clear and the related studies, especially those investigating the
neuronal regulation of astrocytic machinery that is involved in astrocyte-to-neuron
communication (e.g. Sxc), are still scarce.

PACAP
PACAP (pituitary adenylate cyclase-activating polypeptide) was first discovered
in ovine hypothalamus and named by virtue of its high potency in activating adenylyl
cyclase (AC) in pituitary cells (Miyata et al., 1989; Arimura, 2007). It was subsequently
found that PACAP is widely expressed by both the CNS and peripheral tissues (Vaudry
et al., 2009). PACAP expression has been found in many species, including human,
mouse, rat, fish, sheep, chicken (Vaudry et al., 2009). Moreover, the biologically active
portion of PACAP amino acid sequence is almost completely preserved during evolution,
as its structure is almost identical in species from fish to mammals, suggesting that the
biological functions of PACAP may be essential (Vaudry et al., 2009). There are two
forms of PACAP, the originally discovered PACAP1-38 that contains 38 amino acids,
and PACAP1-27 which is a C-terminally truncated version of PACAP1-38 (Miyata et al.,
1990). PACAP1-27 demonstrates a similarly high potency in stimulating AC compared to
PACAP1-38 (EC50 for both: 0.3nM) (Miyata et al., 1990). In the CNS, the predominant
form is PACAP1-38 (Arimura et al., 1991; Dickson and Finlayson, 2009). It is enriched
in the hypothalamus, yet is expressed in a number of brain regions, including the cerebral
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cortex and the amygdala (Arimura et al., 1991; Ghatei et al., 1993; Masuo et al., 1993;
Fukuhara et al., 1997).
Studies using in vitro neural cell cultures demonstrate that PACAP is expressed
exclusively by neurons (Figiel and Engele, 2000; Jaworski, 2000). Such cell-type specific
expression patterns are likely applicable in vivo, as PACAP mRNA is only detected in
cortical neurons compared to other cell types (Zhang et al., 2014). Interestingly, in the
cortex, PACAP appears to be preferably expressed by glutamatergic and primarily
pyramidal neurons in layer V (Koves et al., 1994; Hannibal et al., 2000; Hannibal, 2002a,
b; Stumm et al., 2007; Engelund et al., 2010; Hu et al., 2011). Co-stores of PACAP and
glutamate in nerve terminals also suggest that PACAP is co-transmitted through
glutamatergic synapses (Hannibal et al., 2000; Hannibal, 2002a; Engelund et al., 2010).
In support, it appears that the localization of PACAP does not parallel with the
distribution of PACAP receptors, implicating that PACAP may function as a
neurotransmitter (Masuo et al., 1992; Masuo et al., 1993; Golombek and Rosenstein,
2010; Purrier et al., 2014).
PACAP receptors
Three receptors, PAC1R, VPAC1R and VPAC2R have been identified to mediate
PACAP signaling. These receptors belong to group B G-protein coupled receptor family
(Harmar et al., 1998; Harmar, 2001). As is a major characteristic of this family, all three
receptor subtypes are positively coupled to Gαs (Harmar et al., 1998; Harmar, 2001).
Therefore, activation of these receptors by PACAP leads to stimulation of AC and
consequently, intracellular accumulation of cAMP (Harmar, 2001). While VPAC
receptors are mainly coupled to Gαs, PAC1R is reportedly paired with more diverse
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transduction systems such as the activation of Gαq and the downstream cascades
including the induction of PKC and the elevation of intracellular calcium (Arimura, 1998;
Vaudry et al., 2000; Zhou et al., 2001; Dickson and Finlayson, 2009; Vaudry et al., 2009).
PAC1R mRNA undergoes extensive splicing, resulting in variances in the
transmembrane domain, N-terminal and intracellular loops, and hence corresponding
splicing variants that possess differential signaling properties, including selectivity in
coupling to downstream pathways, agonist potencies and maximal effects in response to
agonist binding, for review see (Dickson and Finlayson, 2009; Vaudry et al., 2009;
Blechman and Levkowitz, 2013).
PACAP receptors are also targets of vasoactive intestinal peptide (VIP) (Vaudry
et al., 2009). Interestingly, PACAP and VIP have high resemblance in their amino acid
sequences and both belong to the secretin superfamily, a collection of revolutionarily
related peptides that exert a variety of functions through activating G-protein coupled
receptors (Dickson and Finlayson, 2009; Vaudry et al., 2009). Out of the three receptors,
PAC1R exhibits selectivity for its ligand, with a much higher affinity for PACAP (Kd:
0.5 nM) compared to VIP (Kd: 500 nM) (Cauvin et al., 1990; Gottschall et al., 1990;
Lam et al., 1990; Gottschall et al., 1991; Suda et al., 1992). In contrast, VPAC receptors
demonstrate similar affinities (Kd: 1 nM) for both PACAP and VIP (Gottschall et al.,
1990; Lam et al., 1990).
Expression of the three PACAP receptors in the CNS is regionally different and
cell-type specific. For example, PAC1R, as the major binding site for PACAP (Dejda et
al., 2011), is the dominant form of all three subtypes in the cortex, while both VPAC
receptors demonstrate lower levels of mRNA expression (Zhang et al., 2014).
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Interestingly, PAC1R mRNA is primarily expressed by cortical astrocytes compared to
all the other cell types (Zhang et al., 2014), while VPAC2R mRNA is also more abundant
in cortical astrocytes compared to neurons.
PACAP functions
PACAP is a pleiotropic peptide, namely it has many different physiological
functions (Vaudry et al., 2009). In the CNS, PACAP acts as a neurohormone, neurotropic
factor, and also a neurotransmitter, for review see (Vaudry et al., 2009). In this
dissertation, I will focus on the impact of PACAP on astrocyte functions, synaptic
transmission, and the possibility of PACAP as a neuronal factor regulating Sxc.
Regulation of astrocytes
Consistent with the abundant occurrence of PACAP receptors in astrocytes
(Zhang et al., 2014), PACAP exerts a number of actions on these cells, including the
regulation of astrocyte proliferation, differentiation, plasticity and release of neuroactive
substances. For example, PACAP at pico-molar concentrations promotes the proliferation
of cultured astrocytes by recruiting MEK/ERK pathway (Hashimoto et al., 2003).
Similarly, PACAP signaling induces astrocytic differentiation of cortical neural
precursors (Vallejo and Vallejo, 2002; Seo and Lee, 2016), and appears critical in
neocortical astrocytogenesis (Zupan et al., 1998). PACAP incubation increases the
number and length of astrocyte processes in vitro, namely provoking the stellation (Ikeda
et al., 2003; Perez et al., 2005). PACAP promotes the expression and release of
neurotropic factors from astrocytes, including ciliary neurotrophic factor (CNF), activitydependent neurotrophic factor (ADNF), activity-dependent neuroprotective protein
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(ADNP), glial cell derived neurotrophic factor (GDNF), interleukin (IL) 1
and 6, macrophage inflammatory protein (MIP) and neurotrophin-3 (Masmoudi-Kouki et
al., 2007; Vaudry et al., 2009). These factors, in turn, induce neuronal proliferation and/or
differentiation, and promote neuroprotection.
PACAP also regulates gliotransmission. For example, PACAP induces
endozepine release from cultured astrocytes, which, in turn, regulates neuronal activity
through multiple mechanisms, including interaction with GABAA receptors (Bormann,
1991; Masmoudi et al., 2003; Compere et al., 2004, 2005; Masmoudi-Kouki et al., 2006;
Papadopoulos et al., 2006). Interestingly, the precursor for endozepine appears to be
exclusively expressed by astrocytes (Guidotti et al., 1983; Tong et al., 1991; Alho et al.,
1995; Burgi et al., 1999). As such, neurons appear to exert self- or neuron-to-neuron
regulation through the releasable factor, PACAP, which mediates neuron-to-astrocyte
communication for recruiting astrocyte machinery. PACAP also regulates astrocyte
glutamate transporters, which is important in maintaining glutamate homeostasis. For
example, PACAP mediates neuronal regulation of the expression and activity of astrocyte
GLT1 and glutamate aspartate transporter (GLAST) (Figiel and Engele, 2000).
Consistently, activation of VPAC2R rapidly increases GLAST mediated glutamate
uptake (Goursaud et al., 2008).
Regulation of synaptic transmission and plasticity
PACAP also regulates synaptic transmission and plasticity mediated by glutamate
receptors, including NMDARs, AMPARs and mGluRs. Potentiation of NMDARmediated synaptic activity by PACAP has been repeatedly demonstrated (Liu and
Madsen, 1997; Wu and Dun, 1997; Harrington et al., 1999). This function likely involves
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the post-translational modification of NMDARs. For example, PACAP promotes
phosphorylation of GluN2B and enhances NMDAR-mediated currents in hippocampal
neurons (Yaka et al., 2003; Macdonald et al., 2005). Similarly, PACAP-induced
regulation of GluN2B phosphorylation is also demonstrated in the hypothalamic
ventromedial nuclei, and is involved in feeding behavior (Resch et al., 2014a).
PACAP differentially regulates AMPAR-mediated synaptic transmission in a
dose-dependent manner; the amplitude of AMPAR-mediated excitatory postsynaptic
currents (EPSCs) in hippocampal slices increase with a lower concentration of PACAP
(i.e., 0.5 nM), while decreases with a higher concentration (i.e., 10 nM) (Costa et al.,
2009). In contrast, another group showed that a high concentration of PACAP (100 nM)
induces and amplifies AMPAR-mediated intracellular calcium concentrations in rat
suprachiasmatic nucleus (SCN) neurons, while a low concentration (100 pM) fails to do
so (Kopp et al., 2001). Moreover, it has been shown that PACAP alters hippocampal
synaptic strength (Kondo et al., 1997; Roberto and Brunelli, 2000; Roberto et al., 2001;
Ciranna and Cavallaro, 2003) and reduces synaptic expression of GluA1 (Gardoni et al.,
2012). This function is likely mediated by post-translational events. For example,
phosphorylation of T840 on the GluA1 subunits of AMPARs enhances channel
conductance of AMPARs (Jenkins et al., 2014), while PACAP decreases GluA1-T840
phosphorylation (Toda and Huganir, 2015). Interestingly, the dephosphorylation of
GluA1-T840 subunit induced by PACAP appears to be mediated by NMDARs (Toda and
Huganir, 2015). In support, NMDARs have been demonstrated to regulate the
phosphorylation of this site (Delgado et al., 2007; Lee et al., 2007; Gray et al., 2014), and
as introduced above, PACAP regulates the function of NMDARs.
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Though still preliminary, studies indicate that PACAP modulates group I mGluRmediated calcium currents in rat SCN neurons. For example, 100nM PACAP inhibits
intracellular calcium increases mediated by activation of mGluR1/5 (Kopp et al., 2001).
In another study, however, PACAP (200nM) appears to promote mGluR1/5-coupled
calcium currents in SCN and hippocampal neurons (Kammermeier, 2008).
Integrating neuron-astrocyte glutamate transmission through Sxc: a possibility
The broad impact of PACAP on glutamate machinery raises a question of whether
or not PACAP also regulates astrocyte Sxc. In fact, a recent study by (Resch et al., 2014b)
shows that PACAP increases Sxc activity in glial cultures from mouse cortices. Given the
converging actions (or potential actions) of PACAP and Sxc on NMDAR functions and
AMPAR-mediated synaptic transmission, and the potential link between NMDARs and
AMPARs, as discussed above (Figure 1.4), we speculate that PACAP may be a neuronal
factor that regulates Sxc in rat astrocytes, through which to integrate glutamate
transmission across neurons and astrocytes, and therefore to achieve the proper
expression of behaviors.

Summary
Drug addiction is a chronic CNS disorder characterized by persistent relapse
susceptibility, even after years of abstinence. This results at least in part from druginduced aberrant glutamate signaling within the corticostriatal projections of the motive
circuit, the substrate in the brain that mediates motivated behaviors. A challenge in
revealing the glutamatergic basis of CNS pathology is that excitatory neurotransmission
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likely relies on integrated activities between neurons and astrocytes, yet how these cells
interact to form a coordinated glutamate network is largely unknown. Therefore, in these
studies, we aim to investigate whether the neuronal PACAP and the astrocyte Sxc form a
critical link that orchestrates neuron-astrocyte communication to achieve integrated
glutamate transmission that underlies motivated behavior. Specifically, we hypothesize
that PACAP mediates neuronal regulation of Sxc in astrocytes, which, in turn, releases
glutamate to activate extrasynaptic NMDARs, through which to modulate AMPAR
functions (Figure 1.4). Findings from these studies should further our understanding of
the complex excitatory signaling network and how its disruption by drugs of abuse may
contribute to relapse. Beyond this, our findings may have implications for understanding
other CNS conditions, given the fundamental role of glutamate in mediating the
excitatory signaling that contributes numerous brain functions.

Figure 1.4. The hypothetical model. Schematic illustrates the hypothesized mechanistic model
in this dissertation. Pre: presynaptic terminal; Post: postsynaptic terminal; Glu: glutamate; A:
AMPA receptor; N: NMDA receptor; PRs: PACAP receptors; Sxc: system xc-.
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CHAPTER II

PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE
ORCHESTRATES NEURONAL REGULATION OF THE ASTROCYTIC
GLUTAMATE RELEASING MECHANISM SYSTEM XCIntroduction
Glutamate is often described as the primary excitatory neurotransmitter in the
brain, in part because it may be present in up to 80% of all synapses (Curtis and Johnston,
1974; Choi, 1988; Harris and Kater, 1994; Meldrum, 2000; Franks et al., 2002; Javitt et
al., 2011). As such, altered excitatory neurotransmission likely contributes to most CNS
diseases (Carlsson and Carlsson, 1990; Olney, 1990; Brown and Bal-Price, 2003; Hynd et
al., 2004; Maragakis and Rothstein, 2004; Foster and Kemp, 2006; Niswender and Conn,
2010; Rondard and Pin, 2015). While traditional models of glutamate signaling depict
release solely from presynaptic terminals and diffusion throughout the synaptic cleft to
activate pre- and postsynaptic receptors, it is becoming increasingly evident that
excitatory neurotransmission is achieved by an elaborate network expressed across
multiple types of cells that regulate signaling within and outside of the synaptic cleft
(Herrera-Marschitz et al., 1996; Timmerman and Westerink, 1997; Jabaudon et al., 1999;
Danbolt, 2001; Schoepp, 2001; Baker et al., 2002; Baker et al., 2003; Pirttimaki et al.,
2011; Bridges et al., 2012a). In support, astrocytes and neurons express glutamate
receptors, transporters, and release mechanisms, and astrocyte to neuron signaling has
been shown to be a key determinant of synaptic transmission (Porter and McCarthy,
1996; Pasti et al., 1997; Araque et al., 1999; Fellin et al., 2004; Perea and Araque, 2005;
Fellin et al., 2006a; Haydon and Carmignoto, 2006; Panatier et al., 2011; Santello et al.,
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2012; Perez-Alvarez et al., 2014; Gomez-Gonzalo et al., 2015). Therefore, decoding the
complex molecular and cellular regulation of glutamate could lead to novel opportunities
to better understand and treat pathological excitatory signaling.
A critical gap in modeling excitatory signaling is how distinct components of the
glutamate system expressed by neurons and astrocytes are coordinated. In these
experiments, we tested the hypothesis that neurons regulate the activity of glutamaterelated mechanisms expressed by astrocytes. To do this, we examined the neuronal
regulation of system xc- (Sxc), a non-canonical glutamate-release mechanism primarily
expressed by astrocytes (Bannai and Kitamura, 1980, 1981; Sato et al., 1999; Pow, 2001;
Zhang et al., 2014).
Sxc is a key component of glutamate signaling that is implicated in the pathology
or treatment of multiple CNS diseases. It contributes to glutamate signaling by coupling
the release of non-vesicular glutamate to the intracellular transport of cystine (Bannai and
Kitamura, 1980, 1981; Sato et al., 1999). Manipulations that increase Sxc activity have
been shown to a) influence multiple aspects of synaptic transmission and plasticity
(Baker et al., 2002; Xi et al., 2002; Moran et al., 2005; Moussawi et al., 2009; Moussawi
et al., 2011; Kupchik et al., 2012), b) normalize behavior in preclinical disease models
(Baker et al., 2003; Madayag et al., 2007; Baker et al., 2008; Knackstedt et al., 2010;
Alajaji et al., 2013; Lutgen et al., 2013), and c) exert therapeutic effects against multiple
CNS diseases including drug addiction and schizophrenia (Berk et al., 2008; Amen et al.,
2011; Lewerenz et al., 2013; Canavan et al., 2014; Verrico et al., 2014). Unfortunately,
the regulation of Sxc is poorly understood.
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In these studies, our primary objective was to evaluate the possibility that neurons
regulate astrocyte Sxc. In addition, we tested the hypothesis that the pituitary adenylate
cyclase-activating peptide (PACAP) is a neuronal factor capable of regulating astrocyte
Sxc activity. To do this, we verified that PACAP is expressed by rat cortical neurons and
not astrocytes, and that rat cortical astrocytes express PACAP receptors. We then found
that application of PACAP to cortical astrocytes increased Sxc activity. Moreover,
inhibition of PACAP signaling blocked neuron-induced upregulation of Sxc. Collectively,
these data are consistent with the possibility that altered neuronal activity could give rise
to pathological changes in astrocyte functions, including altered Sxc activity which may
be present in numerous CNS disorders ranging from drug addiction to schizophrenia.

Material and Methods
Animals and materials: These experiments utilized cortical tissues obtained
from Sprague Dawley rats (age was gestational day 15-16 or post-natal day 3-4; sex was
undetermined; Envigo, Indianapolis, IN). Experimental procedures were approved by the
Marquette University Institutional Animal Care and Use Committee. The primary
materials included fetal bovine serum and horse serum (Atlanta Biologicals;
Lawrenceville, GA), 14C-cystine (PerkinElmer, Waltham, MA), rabbit anti-PACAP1-38
antiserum (final dilution 1:600; Peninsula Laboratories, San Carlos, CA), PACAP1-38
(California Peptide Research, Napa, CA), and PACAP6-38 (Anaspec, Fremont, CA).
PACAP1-38 (PACAP) is the endogenous full-length peptide whereas PACAP6-38 (P6-38)
is a truncated version of PACAP and inhibits PACAP receptors (Miyata et al., 1989;
Robberecht et al., 1992; Arimura, 2007; Vaudry et al., 2009).
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Cell culture procedures: Purified cortical astrocyte cultures were prepared from
post-natal days 3-4 rat pups. In brief, cortical cells were disassociated and then suspended
in Neurobasal A media (Thermo Fisher Scientific, Waltham, MA) supplemented with
10% fetal bovine serum, and 1% Glutamax (Thermo Fisher Scientific, Waltham, MA).
Cells were initially grown in 25cm2 or 75cm2 cell culture flasks. Once confluent, cells
were then subjected to prolonged, orbital shaking (250 rpm for 18 hours at 37oC) which
has been used to yield purified astrocyte cultures (McCarthy and de Vellis, 1980;
Schildge et al., 2013). Purified astrocytes were then plated on 24-well plates, and
refreshed with 70% new culture media every 2-3 days.
Purified cortical neuronal cultures were prepared from embryonic rat cortical
tissue (gestational day 15 to 16) as previously described (Lobner, 2000). In brief,
dissociated cells were suspended in Eagles’ Minimal Essential Medium (MEM, Earle’s
salts, glutamine-free) supplemented with glutamine (2mM), glucose (21mM), horse
serum (5%), and fetal bovine serum (5%). Cells were seeded on 24-well plates. Forty
eight hours later, cytosine arabinoside (at a final concentration of 10 µM) was added to
the culture media to inhibit glial reproduction (Dugan et al., 1995). Neurons were then
grown for an additional 11-13 days.
Mixed Neuronal and Glial Cultures Procedure for preparing mixed cultures was
identical to that of obtaining neuronal cultures (see above) except that cytosine
arabinoside was not added to the culture media.
Physically Separated Astrocyte and Neuronal Cultures. Because the above mixed
cultures also contained a limited number of non-astrocyte glial cells, and to determine
whether neuron-astrocyte communication involves the release of a neuronal factor, we
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utilized a “non-contact” co-culture system in which purified astrocytes were physically
separated from purified neurons. Note, these cells are referenced in the manuscript as
Astrocytes + NCM (neuronal conditioned media). In these experiments, purified
astrocytes were obtained as described above. When astrocytes reached confluency after
13-16 days in vitro (DIV), neuronal cultures were seeded on removable inserts (Corning,
Corning, NY) that had been placed into the wells containing astrocytes, such that both
cell types were immersed in the media but were not in physical contact. Fourteen days
later, downstream experiments to examine the effects of neurons on astrocytes were
performed upon removal of the neuronal inserts. As a result, the DIV for these cells was
27-30.
All cell-growing surfaces in culture flasks and 24-well plates were pre-coated
with poly-D-lysine (10mg/L) and laminin (0.4mg/L). All cell cultures were maintained in
humidified 5% CO2 incubators at 37oC.
14

C-cystine uptake assay: The assessment of system xc- (Sxc) activity is often

achieved by measuring intracellular uptake of radiolabeled cystine since this is primarily
dependent on Sxc (Liu et al., 2009; Liu et al., 2014a; Resch et al., 2014b; Albano et al.,
2015). Note, we demonstrated that over 85% of 14C-cystine uptake in our cells was
blocked by the Sxc inhibitor sulfasalazine (SSZ; see Figure 2.3B). In contrast,
extracellular glutamate is an insensitive indicator of Sxc since this is a product of
numerous mechanisms (Swanson et al., 1997; Duan et al., 1999; Perego et al., 2000;
Montana et al., 2004; Hires et al., 2008). Radiolabeled cystine uptake assays were
performed as described previously with minor modifications (Liu et al., 2009). In brief,
experiments were conducted in a bead bath at 37oC. Cells were washed 3 times with
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warm HEPES buffered saline solution, after which 14C-cystine was added to the media
for 20 min at a final concentration of 0.3µM. This concentration was used since it is
similar to extracellular cystine concentrations in the brain (Baker et al., 2003). DL-threoβ-Hydroxyaspartic acid (TBOA; 10 µM) was added to the culture media to prevent 14Ccystine uptake by sodium-dependent glutamate transporters. As described below, some of
the experiments also involved the addition of the Sxc inhibitor SSZ (300 µM), PACAP, or
P6-38. After incubating cells with 14C-cystine, cells were washed 3 times with ice-cold
HEPES buffered saline solution, and then solubilized with 1M NaOH solution. One
aliquot of cell lysate was used for protein determination using a BCA protein assay, and
another aliquot was used for scintillation counting to measure the level of 14C-cystine
uptake. 14C-cystine content was normalized to protein concentration. Data are presented
as CPM/µg of protein.
RNA extraction and cDNA construction: Total RNA was isolated from cell
cultures with Trizol Reagent (Invitrogen; Carlsbad, CA) following the manufacture’s
protocol. DNase treatment was applied to all RNA samples to remove potential genomic
DNA contamination with a DNA-free kit (Life Technologies, Carlsbad, CA). Assessment
of RNA purity and quantity was performed on a NanoVue Plus Spectrophotometer (GE
life sciences; Pittsburg, PA). cDNA was constructed from total RNA using the Reverse
Transcription System (Promega, Madison, WI) with oligo(dT) primers following the
manufacture’s protocol.
Real-time quantitative PCR: Quantitative PCR was performed using a StepOne
Real-Time PCR System (Applied Biosystems; Carlsbad, CA) and PerfeCTa SYBR Green
FastMix with ROX (Quanta Biosciences; Gaithersberg, MD). Relative quantification of
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target gene expression was normalized to the housekeeping gene glyceraldehyde-3phosphate dehydrogenase (GAPDH) using the ∆∆Ct method (Schmittgen and Livak,
2008). Primer sequences were as follows. xCT (catalytic subunit of Sxc) forward- 5’
AGG GCA TAC TCC AGA ACA CG 3’; xCT reverse- 5’ ATG CTC GTA CCC AAT
TCA GC 3’; PACAP forward-5’ AAC CCG CTG CAA GAC TTC TA 3’; PACAP
reverse- 5’ CTT TGC GGT AGG CTT CGT TA 3’; PAC1R forward- 5’ TGC CTG TGG
CTA TTG CTA TG 3’; PAC1R reverse- 5’ TTT AGT CCC ATC AGG TCG TTG 3’;
GAPDH forward- 5’ CTC CCA TTC TTC CAC CTT TGA 3’; GAPDH reverse- 5’ ATG
TAG GCC ATG AGG TCC AC 3’. Primers were designed to be intron-spanning using
the online primer design tool Primer3
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi). A single product from
amplification was confirmed by melt curve analysis. Amplification efficiency of all genes
was determined to be approximately 95%.
Statistics: Statistical analyses were performed using SPSS Statistics (Version 19,
IBM; Armonk, New York). Analysis of variance (ANOVA) was used when comparing
data sets that included more than two groups. Bonferroni tests were used for subsequent
post hoc analyses of significant effects involving more than two groups. Student’s t tests
were used when comparing results from only two groups. In all instances, statistical
significance was designated as p < 0.05.
Experiment 1: Neuronal regulation of Sxc. The goal of this experiment was to
test the hypothesis that a releasable neuronal factor regulates Sxc activity in astrocytes.
To do this, we used two distinct approaches to co-express rat cortical neurons and
astrocytes in culture. First, we measured 14C-cystine uptake in rat mixed cortical cultures
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(DIV 13-16). The advantage of this approach is that astrocytes are continuously grown in
the presence of neurons. A disadvantage of this approach is that these cultures contain a
limited number of microglia and oligodendrocytes. In addition, neurons physically
contact astrocytes in these cultures. To address these two points, we also measured 14Ccystine uptake by astrocytes that had been exposed to neuron-conditioned media. To do
this, we first generated purified astrocyte cultures as described above. When astrocytes
reached confluency (typically 13-16 DIV), neuronal cultures were seeded on removable
inserts which were placed into the wells containing astrocytes, such that both cell types
were co-cultured yet with no physical contact. Fourteen days later, the neuronal inserts
were removed, and 14C-cystine uptake was measured as described above. Note the 14-day
period represents the time needed for the neurons to mature. The control cells in this
experiment were purified astrocyte cultures in which the inserts lacked neurons. Tests
using these cells occurred on DIV 27-30.
Experiment 2: Neuronal upregulation of Sxc requires PACAP receptor
signaling. In an effort to begin to unmask the molecular basis of neuron-astrocyte
signaling that regulates Sxc, we examined the impact of disrupting PACAP signaling on
cystine uptake in rat cortical cultures. Our interest in PACAP stems from previous
studies showing that stimulation of PACAP receptors increases the activity of Sxc and
GLT1 (Figiel and Engele, 2000; Resch et al., 2014b), both of which are primarily
expressed by astrocytes (Rothstein et al., 1994; Lehre et al., 1995; Rothstein et al., 1996;
Torp et al., 1997; Pow, 2001; Zhang et al., 2014). To examine the involvement of
PACAP, we modified the neuronal insertion design that was introduced in Experiment 1.
In brief, media from cultured astrocytes only or astrocytes that were cocultured with
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neurons (i.e., neuronal insertion) were applied to astrocytes (13-16 DIV) for 24 hours.
PACAP antiserum was added to the media of some cultures during 24-hour incubation to
neutralize the potential PACAP content (Figiel and Engele, 2000). Alternatively, we
examined the impact of blocking PACAP receptors on cystine uptake. To do this, vehicle
or 10 µM P6-38 (see Figiel and Engele, 2000 for concentration justification) was applied
to rat cortical cultures (DIV 13-16) for 60 min, at which point 14C-cystine uptake was
measured as described above.
Experiment 3: PACAP upregulates Sxc on astrocytes. In this experiment, we
tested the hypothesis that exogenous application of PACAP would significantly
upregulate Sxc activity in purified astrocyte cultures. To test this, PACAP (0-100 nM)
was applied to purified astrocyte cultures (DIV 13-16) for 24 hours. Afterwards, 14Ccystine uptake was measured as described above. This experiment was also conducted in
purified neuronal and mixed cortical cultures although the predicted outcome was less
certain given the likely expression of endogenous PACAP in these cultures.
Experiment 4: Cellular distribution of PACAP and PAC1R in rat cortical
cultures. To further examine the possibility that PACAP is a neuronal factor capable of
regulating astrocytes, we examined the cellular expression patterns of PACAP and its
primary receptor, PAC1R. We were specifically interested in determining whether
PACAP was solely expressed in neurons and PAC1R in purified astrocytes. To do this,
we used RT-qPCR to measure mRNA expression for PACAP and PAC1R in mixed
cultures, purified astrocyte cultures, and purified neuronal cultures (DIV 13-16).
Experiment 5: Regulation of xCT mRNA by neurons and the neuronal factor
PACAP. To better understand the observed upregulation of astrocyte Sxc by neurons or
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PACAP, we measured xCT mRNA in purified astrocytes and mixed cultures, purified
astrocytes ±neuronal-conditioned media, and purified astrocytes ±PACAP.

Results
Experiment 1: Neuronal regulation of Sxc. To determine whether neurons are
capable of regulating astrocyte Sxc activity, we used two approaches to permit neuronastrocyte signaling. First, astrocyte and neurons were co-cultured upon plating (mixed
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Figure 2.1. Neurons upregulate Sxc activity in astrocytes. Data depict the mean ±SEM levels
of 14C-cystine measured in rat cortical cells (N=8-12/condition) that had been cultured for 13-16
or 27-30 days in vitro (DIV). Astro, astrocytes; NCM, neuronal conditioned media. * represents a
significant difference from corresponding purified astrocytes, p < 0.001.

cultures). This approach is designated in Figure 2.1 as DIV 13-16, which refers to the
number of days the cells had been cultured. In addition, confluent, purified astrocyte
cultures were exposed to neuronal conditioned media (NCM) by placing neurons grown
onto an insert into the wells containing the astrocytes for 14 days (as described in the
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methods for experiment 1). This approach is designated in Figure 2.1 as DIV 27-30. A
univariate ANOVA with DIV and culture cellular composition (i.e., astrocytes only or
mixed or astrocyte + NCM) as between subjects factors produced a main effect of cell
composition [Figure 2.1; F(1,36)=77.979, p < 0.001] but not a main effect of DIV or an
interaction between these variables. These findings illustrate that a releasable neuronal
factor significantly upregulates Sxc activity on astrocytes (see Figure 2.1).
Experiment 2: Neuronal upregulation of Sxc requires PACAP receptor
signaling. Previous studies have shown that PACAP increases the activity of Sxc and
GLT1 (Figiel and Engele, 2000; Resch et al., 2014b), both of which are primarily
expressed by astrocytes (Rothstein et al., 1994; Lehre et al., 1995; Rothstein et al., 1996;
Torp et al., 1997; Pow, 2001; Zhang et al., 2014). In an effort to reveal the molecular
basis of neuron-astrocyte signaling that regulates Sxc, we examined the impact of
inhibiting PACAP signaling via neutralizing PACAP on the 14C-cystine uptake in rat
cortical cultures. Twenty-four hours later, Sxc activity was assessed with cystine uptake
assay (Figure 2.2A). A univariate ANOVA with media origin (ACM vs NACM) and
PACAP antiserum treatment (vehicle or 1:600 antiserum) as between-subjects variables
yielded a significant interaction [Figure 2.2A; F(1,30)=10.577, p < 0.01].
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Figure 2.2. PACAP mediates neuronal regulation of Sxc activity. (A) Data depict mean ±
SEM levels of 14C-cystine in rat purified astrocyte cultures after 24 hours treatment with the
media transferred from astrocytes (astrocyte-conditioned media, ACM) or astrocytes cocultured
with neurons (neuron-astrocyte-conditioned media, NACM), with or without the presence of
PACAP antiserum (Ab; N=6-12/condition). * indicates a significant difference relative to ACM
treated cells that were not exposed to PACAP antiserum, T-test p < 0.01. # indicates a significant
difference relative to NACM treated cells that were not exposed to PACAP antiserum, T-test p <
0.01. (B) Data depict the uptake of 14C-cystine in rat cortical cultures in the presence or absence
of the PACAP receptor inhibitor P6-38 (vehicle or 10 µM; N=6-12/condition). * indicates a
significant difference relative to vehicle treated mixed cortical cultures, Bonferroni, p < 0.001.
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As predicted, media from the astrocyte-neuron cocultures (NACM) increased Sxc activity
(T-test, p <0.01), while removing free-PACAP from the NACM with PACAPneutralizing antiserum significantly decreased Sxc activity (T-test, p <0.01). In addition,
we examined the impact of inhibiting PACAP receptors with PACAP6-38 (P6-38) on 14Ccystine uptake in rat mixed, purified astrocyte, and purified neuronal cortical cultures. A
univariate ANOVA with cell composition and P6-38 treatment (0 or 10 µM) as betweensubjects variables yielded a significant interaction [Figure 2.2B; F(2,62)=73.849, p <
0.001]. To deconstruct the interaction, we compared 14C-cystine levels in vehicle-treated
mixed cultures to every other condition. We found that vehicle-treated cultures
containing neurons and astrocytes (i.e., mixed) displayed significantly higher levels of
14

C-cystine, and that this effect was blocked by inhibiting PACAP receptors with

PACAP6-38 (P6-38) (Bonferroni, p < 0.001). Interestingly, P6-38 did not alter 14Ccystine levels in purified astrocyte or in purified neuronal cultures. Together, these data
suggest that PACAP mediates neuronal regulation of Sxc activity on astrocytes through
activating PACAP receptors, and that the endogenous PACAP-induced upregulation of
Sxc activity is only present in mixed cortical cultures (see Figure 2.2).
Experiment 3: PACAP up-regulates Sxc on astrocytes. To confirm that
PACAP promotes Sxc activity in rat cortical astrocytes, we compared 14C-cystine uptake
in mixed cultures, purified astrocyte cultures, and purified neuronal cultures following
PACAP application (24 hours) in the presence or absence of the Sxc inhibitor
sulfasalazine (SSZ). A univariate ANOVA with culture cell composition and PACAP
treatment as between subjects factors produced a significant interaction [Figure 2.3A;
F(4,62)=31.958, p < 0.001]. To further analyze the data, we examined the impact of
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PACAP on 14C-cystine uptake in each type of culture. A significant simple main effect
of PACAP treatment was obtained only in purified astrocyte cultures [F(2,21)=75.904, p
< 0.001]. Subsequent post hoc analyses revealed that PACAP increased uptake at 10 and
100 nM (Bonferroni, p < 0.001).
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Figure 2.3. PACAP upregulates Sxc activity in cortical astrocytes only. (A) Data depict mean
±SEM levels of 14C-cystine in rat cortical cell cultures after 24 hours PACAP treatment (0-100
nM; N=8/condition). * indicates a significant difference relative to vehicle-treated purified
astrocyte cultures, Bonferroni, p < 0.001. (B) Data depict mean ±SEM levels of 14C-cystine in rat
purified astrocyte cultures after 24 hours PACAP (0 or 100 nM) assessed in the presence of an
Sxc inhibitor sulfasalazine (SSZ, 0 or 300 µM; N=4/condition). * indicates a significant
difference relative to PACAP vehicle treated cells that were not exposed to SSZ (-SSZ),
Bonferroni p < 0.001.
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Although Sxc is primarily associated with astrocytes, we verified that PACAPinduced increases in 14C-cystine uptake reflect Sxc activity. To do this, we assessed the
impact of PACAP on 14C-cystine uptake by astrocytes in the presence and absence of the
Sxc inhibitor SSZ. A univariate ANOVA with PACAP and SSZ treatments as betweensubjects factors resulted in a significant interaction [Figure 2.3B; F(1,12)=19.130, p <
0.01]. Post hoc analyses indicated that PACAP increased 14C-cystine uptake in astrocytes
when tested in the absence (Bonferroni, p < 0.001), but not in the presence of SSZ.

Experiment 4: Cellular distribution of PACAP and PAC1R in rat cortical
cultures. To further examine the possibility that PACAP is a neuronal factor capable of
regulating astrocytes, we assessed the cellular expression patterns of PACAP and its
primary receptor, PAC1R (Gottschall et al., 1990; Lam et al., 1990). A one-way
ANOVA with culture cell composition as a between-subjects factor yielded a main effect
on PACAP mRNA levels [Figure 2.4A; F(2,17)=294.774, p < 0.001]. Post hoc analyses
revealed that mixed and purified neuronal cultures expressed the highest levels of
PACAP mRNA (Bonferroni, p < 0.001). In fact, PACAP mRNA was not detectable in
purified astrocyte cultures (Figure 2.4A). A one-way ANOVA comparing the cellular
distribution of PAC1R mRNA yielded a main effect of cell type [Figure 2.4B;
F(2,17)=93.863, p < 0.001]. Post hoc analyses revealed expression of PAC1R in every
cell type, but with the highest levels evident in mixed cortical cultures (Bonferroni, p <
0.001). Collectively, these results demonstrate that in rat cortical cultures, PACAP is
solely expressed in neurons and its primary receptor, PAC1R, is expressed by astrocytes.
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Figure 2.4. The cellular expression patterns of PACAP and its primary receptor, PAC1R,
support the possibility that PACAP is a neuropeptide capable of regulating astrocyte Sxc
activity. (A) Data depict mean ±SEM levels of PACAP mRNA in rat cortical cells cultures (N=
5-8/cell type). * indicates a significant difference relative to mixed cultures, Bonferroni, p <
0.001. # indicates a significant difference relative to purified astrocyte cultures, Bonferroni, p <
0.001. (B) Data depict mean ±SEM levels of PAC1R mRNA in rat purified astrocyte and
neuronal cultures relative to that in cortical mixed cell cultures (N= 5-8/cell type). * indicates a
significant difference relative to mixed cultures, Bonferroni, p < 0.001.

Experiment 5: Neurons and PACAP increase xCT mRNA. To better
understand the observed upregulation of astrocyte Sxc activity by neurons or PACAP, we
measured mRNA levels of xCT, the functional subunit of Sxc (Sato et al., 1999; Sato et
al., 2000; Bridges et al., 2001). Mixed cultures of astrocytes and neurons [t(6)=17.734, p
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< 0.001], as well as purified astrocyte cultures exposed to NCM [t(13)=13.431, p < 0.001]
expressed significantly higher levels of xCT mRNA relative to respective controls
(Figure 2.5). Similarly, PACAP application in purified astrocytes also robustly increased
xCT mRNA [Figure 2.5; t(10)=16.554, p < 0.001]. Together, these results suggest that
the upregulation of astrocyte Sxc by neurons or PACAP may involve increased Sxc
expression.
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Figure 2.5. Exposure to neurons and PACAP increase xCT mRNA in cultured cortical
astrocytes. Data depict mean ±SEM levels of xCT mRNA (normalized to respective controls) in
rat cortical cells cultures (N=4-12/condition). Astro refers to purified astrocyte cultures; mixed
cells refer to cultures comprised of neurons and astrocytes; NCM refers to neuronal conditioned
media achieved by placing neurons grown on inserts into the culture wells containing astrocytes
for 14 days; PACAP treatment was for 24 hours at 10 nM. * indicates a significant difference
relative to the respective control, t-test, p < 0.001.

57

Discussion
Glutamate signaling is achieved by an elaborate network likely requiring
coordinated activity between neurons and astrocytes. In support, both cells express
glutamate receptors, transporters, and release mechanisms (Choi, 1988; Greenamyre et al.,
1988; Coyle and Puttfarcken, 1993; Moghaddam and Adams, 1998; Araque et al., 1999;
Tapia et al., 1999; Marino et al., 2001; Franks et al., 2003; Haydon and Carmignoto, 2006;
Javitt et al., 2011; Santello et al., 2012; Araque et al., 2014; Perez-Alvarez et al., 2014).
The purpose of these experiments was to determine whether, and how, neurons regulate
components of the glutamate system expressed by astrocytes. To do this, we focused on
system xc- (Sxc) since this non-canonical release mechanism has been shown to be
expressed primarily by astrocytes (Bannai and Kitamura, 1980, 1981; Sato et al., 1999;
Pow, 2001; Zhang et al., 2014), significantly contributes to glutamate homeostasis (Baker
et al., 2002; Xi et al., 2002; Melendez et al., 2005), regulates neuronal activity (Xi et al.,
2002; Moran et al., 2005; Moussawi et al., 2009; Moussawi and Kalivas, 2010; Moussawi
et al., 2011; Kupchik et al., 2012), and has been linked to multiple CNS diseases (Bridges
et al., 2012a; Lewerenz et al., 2013; Deepmala et al., 2015). Our major finding is that
Sxc activity is significantly increased when astrocytes are exposed to neurons or to
neuronal factors, including pituitary adenylate cyclase-activating peptide (PACAP).
These findings are significant, in part, because they illustrate a novel form of neuron to
astrocyte communication. Hence, pathological changes involving components of the
glutamate system expressed by astrocytes, such as Sxc, may stem from aberrant activity
of neuronal circuits.
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Neuronal Regulation of Sxc
In these studies, we found that the uptake of 14C-cystine was higher in rat cortical
cultures comprised of neurons and astrocytes relative to purified astrocyte cultures. One
interpretation of these data is that neurons up-regulate Sxc activity in astrocytes. This
conclusion, along with findings that neurons are critical in regulating the expression and
activity of sodium-dependent glutamate transporters (Swanson et al., 1997; Figiel and
Engele, 2000), highlights the need for neurons and astrocytes to display coordinated
activity in order to achieve normal glutamate signaling. Alternative interpretations of our
data include the possibility that neurons indirectly regulate Sxc activity. For example,
neurons may influence the development of astrocytes, which may in turn influence Sxc.
In order to more directly test the hypothesis that a releasable neuronal factor
coordinates Sxc activity on astrocytes, we evaluated the impact of neuronal conditioned
media on 14C-cystine uptake in cortical astrocytes. In this experiment, purified astrocyte
cultures were conditioned to neurons through a non-contact co-culture system, in which
neurons seeded on removable inserts were placed in astrocyte cultures for 14 days.
Afterwards, the neuronal inserts were removed in order to measure 14C-cystine uptake
into astrocytes. Similar to our earlier finding, we found that cortical astrocytes that were
exposed to neuronal conditioned media displayed significantly higher 14C-cystine uptake.
We did not observe any other difference in the astrocyte cultures exposed to neuronal
conditioned media from those lacking neurons. For example, the protein counts (mean ±
SEM: astrocytes, 267.1 ± 6.8 µg/ml; astrocytes exposed to NCM, 254.4 ±6.0 µg/ml) or
cell confluency did not differ. As a result, these findings support the conclusion that
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neurons are capable of regulating components of the glutamate system expressed on
astrocytes.
Regulation of Sxc by the neuropeptide PACAP
In an attempt to identify potential neuronal factors capable of regulating Sxc on
astrocytes, we examined the possible involvement of PACAP since this peptide has been
shown to be expressed by cortical neurons (Koves et al., 1991; Waschek et al., 1998;
Figiel and Engele, 2000) and capable of regulating components of the glutamate system
expressed by astrocytes including GLT1 and GLAST in rat cortical glial cultures and Sxc
in mouse glial cultures (Figiel and Engele, 2000; Resch et al., 2014b). We sought to
extend these studies by examining whether neuron-induced upregulation of 14C-cystine
uptake requires PACAP signaling. To do this, we took two separate approaches to disrupt
signaling of PACAP in astrocytes. First, we sought to use neutralizing antiserum to
remove PACAP from neuronal conditioned media (Figiel and Engele, 2000). In order to
do this, however, we needed to modify the assay such that the compensatory changes
involving PACAP release would not overwhelm PACAP antiserum. Therefore, instead
of co-incubating astrocytes with neurons for 14 days, we applied neuronal conditioned
media for 24 hours. As we predicted, media from neuron-astrocyte cocultures were
capable of significantly increasing Sxc activity in astrocytes in a much shorter time
period (e.g., 24 hours versus 14 days). This is important because it allowed us to examine
the involvement of PACAP by neutralizing the potential PACAP content in the media
with PACAP antiserum. Alternatively, blocking PACAP receptors with antagonists could
also inhibit PACAP signaling. Application of PACAP6-38 (P6-38), a truncated version of
PACAP that inhibits PACAP receptors including PAC1R and VPAC2R, and also CART
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receptor (Robberecht et al., 1992; Gourlet et al., 1995; Laburthe et al., 2007; Hawke et al.,
2009; Mounien et al., 2009; Lin et al., 2011), decreased 14C-cystine uptake in mixed
cortical cultures to the level observed in purified astrocyte cultures. Interestingly, P6-38
did not alter 14C-cystine uptake in purified astrocytes or neurons. The results obtained in
purified neuronal cultures likely reflect the relative lack of Sxc activity in these cells,
although it should be noted that low amounts of 14C-cystine are detected in these cells.
The lack of a P6-38 effect in purified astrocytes indicates the lack of endogenous PACAP
signaling in these cells.
In order to further evaluate the conclusion that PACAP is a neuropeptide capable
of directly regulating astrocytes, we examined the cellular distribution of mRNA for
PACAP and its primary receptor, PAC1R. PACAP mRNA expression in cortical cultures
was restricted to neurons, thereby establishing PACAP as a neuropeptide in these cultures.
In contrast, both cortical neurons and astrocytes express mRNA for PAC1R, which has
been shown to be the most abundant PACAP receptor that is expressed in cortical
astrocytes (Zhang et al., 2014). However, PACAP also stimulates VPAC1 and VPAC2
receptors, which are also expressed by astrocytes (Grimaldi and Cavallaro, 1999). Hence,
there is a need to identify the receptor(s) that contributes to the regulation of Sxc by
PACAP. Interestingly, we found significantly higher levels of PACAP and PAC1R in
mixed cultures comprised of neurons and astrocytes, compared to either cell type cultured
alone, which may suggest that astrocytes influence the neuronal PACAP expression. Yet,
whether the upregulation of PAC1R reflects an increase in astrocytes or neurons is not
clear. Notably, changes in mRNA do not always result in changes in protein expression
and function. While future experiments are needed to further explore the potential for

61

astrocyte-neuron communication to be an important determinant of PACAP signaling,
our extant results are consistent with the possibility that PACAP is a neuropeptide
capable of regulating components of the glutamate system expressed by astrocytes.
Next, we directly tested the hypothesis that PACAP application increases Sxc
activity in astrocytes. We found that PACAP application significantly increased 14Ccystine uptake in rat cortical astrocytes, but not in mixed or purified neuronal cultures.
While we anticipated PACAP-induced increases in 14C-cystine uptake in rat cortical
astrocytes and a lack of an increase in purified neuronal cultures since these cells
generally display little to no Sxc activity, we expected a modest increase in the mixed
cortical cultures, an outcome we previously observed in mouse cultures (Resch et al.,
2014b). Aside from species, the difference between these studies is not clear, but likely
reflects the existence of endogenous PACAP signaling. Collectively, these results are
consistent with PACAP functioning as a neuronal factor controlling glutamate signaling
involving astrocytes.
The nature of PACAP-induced regulation of Sxc in astrocytes is likely complex.
For example, we found evidence that application of PACAP for 24 hours increased
mRNA of xCT, the active subunit for Sxc. While increases in mRNA do not always
result in augmented protein, it is important to note that PACAP also upregulated Sxc
activity. Further, elevated xCT mRNA and increased Sxc activity were also evident in
astrocytes cultured with neurons. Collectively, these data suggest that neurons influence
the expression of Sxc in astrocytes. In addition, however, we found that relatively brief
inhibition of PACAP signaling (i.e., 60 min) produced a significant reduction in Sxc
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activity, which suggests the possibility of post-translational modification. Additional
studies are needed to better understand neuron or PACAP-induced regulation of Sxc.
Altered glutamate signaling likely underlies, at least in part, many disorders of the
brain. Hence, it is critical to better understand how coordinated activity across distinct
cell types involved in the transmission of this amino acid, is achieved. For example, Sxc
has been implicated in several CNS diseases (Baker et al., 2003; Chung et al., 2005;
Madayag et al., 2007; Baker et al., 2008; Knackstedt et al., 2010; Bridges et al., 2012a;
Lewerenz et al., 2013; Lutgen et al., 2013; Albano et al., 2015; Ching et al., 2015;
Deepmala et al., 2015). Similarly, altered activity of GLT1 and other glutamate
transporters expressed by astrocytes has also been implicated in pathological glutamate
transmission (Soni et al., 2014; Jensen et al., 2015; Roberts-Wolfe and Kalivas, 2015). In
each case, however, it is unclear how glutamate signaling involving astrocytes may be
altered. Collectively, these studies indicate that aberrant neural activity may be a novel
factor underlying pathological changes in glutamate stemming from altered regulation of
astrocytes. Moreover, PACAP itself is especially interesting in this regard as it has been
shown to regulate glutamate uptake and release by astrocytes.
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CHAPTER III

PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE-INDUCED
REGULATION OF SYSTEM XC- IN STRIATAL ASTROCYTES
Introduction
The previous chapter revealed that neurons regulate system xc- (Sxc), a cystineglutamate antiporter expressed primarily by astrocytes, through releasable factors.
Moreover, this regulation appears to be mediated by the pituitary adenylate cyclaseactivating polypeptide (PACAP), a neuropeptide expressed exclusively by neurons. This
novel form of neuron-astrocyte interaction likely contributes to coordinated glutamate
transmission in the brain, to which malfunctions have been indicated in numerous CNS
disorders.
The regulation involved 24-hr PACAP application. Thus, it is unclear whether
rapid, phasic changes in PACAP would regulate Sxc. This is important because phasic
regulation is likely necessary for rapid control of synaptic transmission and behavior. At
this point, the impact of PACAP is only observed in cortical astrocytes. Given our
interest in understanding the regulation of NAc astrocytes, there is a need to determine
whether these properties are restricted to the cortex. As such, in this chapter, we seek to
expand our understanding of PACAP-induced regulation of Sxc in the cortex and
striatum.
Three receptors, PAC1R, VPAC1R and VPAC2R, have been identified to
mediate PACAP signaling (Vaudry et al., 2009). They are G-protein coupled receptors
and are positively linked to Gαs (Harmar et al., 1998; Harmar, 2001). Therefore,
activation of these receptors leads to stimulation of adenylyl cyclase (AC) and
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intracellular accumulation of cAMP (Harmar, 2001). In addition, PAC1R is reportedly
paired with more diverse transduction systems, including the activation of a Gαq-PLC
cascade and the elevation of intracellular calcium (Arimura, 1998; Vaudry et al., 2000;
Zhou et al., 2001; Dickson and Finlayson, 2009; Vaudry et al., 2009).
PKA and PKC are the two canonical kinases induced by Gαs and Gαq activations.
Interestingly, sequence analyses of human xCT demonstrate two consensus PKA sites
(Baker et al., 2002), and both PKA and PKC have been shown to influence Sxc activity
(Gochenauer and Robinson, 2001; Baker et al., 2002; Tang and Kalivas, 2003). Taken
together, PKA and PKC are potentially involved in PACAP-induced regulation of Sxc.
Other cascades induced by PACAP include AC-cAMP-Epac, PI3K-AKT, MEK-ERK
and CaMK pathways, some of which have been implicated in the regulation of Sxc
and/or PACAP-induced regulation of astrocyte functions (Moroo et al., 1998; Vallejo and
Vallejo, 2002; Hashimoto et al., 2003; Perez et al., 2005; Liu et al., 2012; Seo and Lee,
2016). Therefore, these pathways also potentially contribute to the actions of PACAP on
Sxc.
In this chapter, we used purified astrocyte cultures derived from striatal tissues to
expand our understanding of PACAP-induced regulation of Sxc. We found that PACAP
upregulates Sxc in a dose- and time- dependent manner in both striatal and cortical
astrocytes. Importantly, phasic PACAP significantly increases Sxc activity. In addition,
we show the expression of all three PACAP receptor subtypes in both cortical and striatal
astrocytes, with PAC1R and VPAC2R more abundantly expressed in astrocytes than in
neurons. Lastly, our data suggest that the actions of PACAP on astrocyte Sxc are
mediated by PKA, Epac and MEK/ERK.
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Material and Methods
Animals and Materials: These experiments utilized cortical tissues obtained
from Sprague Dawley rats (age was gestational day 15-16 or post-natal day 3-4; sex was
undetermined; Envigo, Indianapolis, IN). Experimental procedures were approved by the
Marquette University Institutional Animal Care and Use Committee. The primary
materials included fetal bovine serum and horse serum (Atlanta Biologicals;
Lawrenceville, GA), 14C-cystine (PerkinElmer, Waltham, MA) and PACAP1-38
(PACAP; California Peptide Research, Napa, CA). All kinase activators and inhibitors
were obtained from Sigma-Aldrich (Milwaukee, WI), including H89 (PKA inhibitor),
Go6983 (PKC inhibitor), ESI09 (Epac inhibitor), KN93 (CaMKII inhibitor), LY294002
(PI3K inhibitor), U0126 (MEK inhibitor) and PD98059 (MEK inhibitor). All peptides
were dissolved in saline, while all kinase inhibitors were reconstituted in DMSO.
Cell Culture Procedures: Purified astrocyte cultures were prepared from rat pups
on post-natal day 3-4. In brief, cortical or striatal cells were disassociated and then
suspended in Neurobasal A media (Thermo Fisher Scientific, Waltham, MA),
supplemented with 10% fetal bovine serum, and 1% Glutamax (Thermo Fisher Scientific,
Waltham, MA). Cells were initially grown in 25cm2 or 75cm2 cell culture flasks. Once
confluent, cells were then subjected to prolonged, orbital shaking (250 rpm for 18 hours
at 37oC), which has been used to yield purified astrocyte cultures (McCarthy and de
Vellis, 1980; Schildge et al., 2013). Purified astrocytes were then plated on 24-well
plates, and refreshed with 70% new culture media every 2-3 days. Typically, it required
13-16 days in vitro (DIV13-16) for these cells to reach confluency, after which
experiments were conducted.
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Purified neuronal cultures were prepared from embryonic rat cortical (gestational
day 15 to 16) tissues as previously described (Lobner, 2000), or striatal tissues
(gestational day 17 to 18). In brief, dissociated cells were suspended in Eagles’ Minimal
Essential Medium (MEM, Earle’s salts, glutamine-free), supplemented with glutamine
(2mM), glucose (21mM), horse serum (5%), and fetal bovine serum (5%). Cells were
seeded on 24-well plates. Forty eight hours later, cytosine arabinoside (at a final
concentration of 10 µM) was added to the culture media to inhibit glial reproduction
(Dugan et al., 1995). Neurons were then grown for an additional 11-13 days.
All cell-growing surfaces in culture flasks and 24-well plates were pre-coated
with poly-D-lysine (10mg/L) and laminin (0.4mg/L). All cell cultures were maintained in
humidified 5% CO2 incubators at 37oC.
14

C-cystine Uptake Assay: The assessment of system xc- (Sxc) activity is often

achieved by measuring intracellular uptake of radiolabeled cystine, since this is primarily
dependent on Sxc (Liu et al., 2009; Liu et al., 2014a; Resch et al., 2014b; Albano et al.,
2015). As demonstrated previously, over 85% of 14C-cystine uptake in our cells was
blocked by the Sxc inhibitor sulfasalazine (SSZ; Chapter II, Figure 2.3B). Radiolabeled
cystine uptake assays were performed as described previously with minor modifications
(Liu et al., 2009). In brief, experiments were conducted in a bead bath at 37oC. Cells were
washed 3 times with warm HEPES buffered saline solution, after which 14C-cystine was
added to the media for 20 min at a final concentration of 0.3µM. This concentration was
used since it is similar to extracellular cystine concentrations in the brain (Baker et al.,
2003). DL-threo-β-hydroxyaspartic acid (TBOA; 10 µM) was added to the culture media
to prevent 14C-cystine uptake by sodium-dependent glutamate transporters. After
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incubating cells with 14C-cystine, cells were washed 3 times with ice-cold HEPES
buffered saline solution, and then solubilized with 1M NaOH solution. One aliquot of cell
lysate was used for protein determination using the bicinchoninic acid (BCA) assay, and
another aliquot was used for scintillation counting to measure the level of 14C-cystine
uptake. 14C-cystine content was normalized to protein concentration. Data are presented
as CPM/µg of protein or normalized to respective controls.
RNA extraction and cDNA construction: Total RNA was isolated from cell
cultures with Trizol Reagent (Invitrogen; Carlsbad, CA) following the manufacture’s
protocol. DNase treatment was applied to all RNA samples to remove potential genomic
DNA contamination with a DNA-free kit (Life Technologies, Carlsbad, CA). Assessment
of RNA purity and quantity was performed on a NanoVue Plus Spectrophotometer (GE
life sciences; Pittsburg, PA). cDNA was constructed from total RNA using the Reverse
Transcription System (Promega, Madison, WI) with oligo(dT) primers following the
manufacturer’s protocol.
Polymerase Chain Reaction (PCR) and Gel Electrophoresis: PCR were
performed with GoTaq Green Master Mix (Promega, Madison, WI) on a thermocycler
with the following parameters: initial denaturation (3min at 95°C), amplification (35
cycles of the following: 95°C for 30s, 60°C for 45s, 72°C for 45s), and extension (72°C
for 10min). PCR products were then examined with electrophoresis on an agarose gel
(1.8%) along with a 100bp DNA Ladder (Promega, Madison, WI) to locate target PCR
products.
Real-time quantitative PCR: Quantitative PCR was performed using a StepOne
Real-Time PCR System (Applied Biosystems; Carlsbad, CA) and PerfeCTa SYBR Green
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FastMix with ROX (Quanta Biosciences; Gaithersberg, MD). Relative quantification of
target gene expression was normalized to the housekeeping gene glyceraldehyde-3phosphate dehydrogenase (GAPDH) using the ∆∆Ct method (Schmittgen and Livak,
2008). Primer sequences were as follows. xCT (catalytic subunit of Sxc) forward- 5’
AGG GCA TAC TCC AGA ACA CG 3’; xCT reverse- 5’ ATG CTC GTA CCC AAT
TCA GC 3’; PAC1R forward- 5’ TGC CTG TGG CTA TTG CTA TG 3’; PAC1R
reverse- 5’ TTT AGT CCC ATC AGG TCG TTG 3’; VPAC1R forward-5’ TGA GAT
ACA GCG TCA GCA GTG 3’; VPAC1R reverse- 5’ GCA AAC AGC TGA AAG ATG
AGG 3’; VPAC2R forward-5’ TGG CAA TGA CCA GTC ACA GT 3’; VPAC2R
reverse- 5’ CCT GGA AGG AAC CAA CAC AT 3’; GAPDH forward- 5’ CTC CCA
TTC TTC CAC CTT TGA 3’; GAPDH reverse- 5’ ATG TAG GCC ATG AGG TCC AC
3’. Primers were designed to be intron-spanning using the online primer design tool
Primer3 (http://biotools.umassmed.edu/bioapps/primer3_www.cgi). A single amplified
product was confirmed by melt curve analysis. Amplification efficiency of all genes was
determined to be approximately 95%.
Statistics: Statistical analyses were performed using SPSS Statistics (Version 24,
IBM; Armonk, New York). Analysis of variance (ANOVA) was used when comparing
data sets that included more than two groups. Tukey HSD tests were used for subsequent
post hoc analyses of significant effects involving more than two groups. Student’s t-tests
were used when comparing results from only two groups. In all instances, statistical
significance was designated as p < 0.05.
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Results
Experiment 1: PAC1R and VPAC2R are enriched in cultured astrocytes
obtained from striatal tissues. Since Sxc in the nucleus accumbens (NAc, ventral
striatum) is critical for motivated behavior (Baker et al., 2003; Kau et al., 2008; Berglind
et al., 2009; Kalivas, 2009; Knackstedt et al., 2009; Kupchik et al., 2012), we were
interested in examining whether PACAP would regulate Sxc in striatal astrocytes. To do
this, we first sought to determine which PACAP receptors these cells express. To date,
three PACAP receptors, including PAC1R, VPAC1, and VPAC2R, have been identified.
Therefore, we investigated the expression of these receptors in cortical and striatal
astrocytes; cortical astrocytes were used as positive controls as they have been shown to
express all these receptors (Zhang et al., 2014). Using PCR, we detected mRNAs of all
three receptors in both cortical and striatal astrocytes. With a more stringent quantitative
method, RT-qPCR, we investigated the relative levels of PAC1R and VPAC2R in striatal
cell cultures (Figure 3.1B, C). These two PACAP receptors are selected because they
have been shown to be significantly more abundant than VPAC1R in astrocytes, with
FPKM (fragments per kilobase of transcript per million mapped reads) values to be > 150
(PAC1R), < 0.2 (VPAC1R) and ≈ 2 (VPAC2R) (Zhang et al., 2014). Moreover, both
PAC1R and VPAC2R appear to be more enriched in astrocytes than in neurons, with
ratios at 10:1 (PAC1R) and 5:1 (VPAC2R), while VPAC1R is more enriched in neurons,
with a 5:1 ratio compared to astrocytes (Zhang et al., 2014). Consistently, we found that
striatal astrocytes express significantly higher levels of mRNA for both PAC1R [Figure
3.1B; t(6)=5.618, p < 0.01] and VPAC2R [Figure 3.1C; t(6)=11.082, p < 0.001],
compared to neurons of the same origin.
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Figure 3.1. PAC1R and VPAC2R are enriched in cultured astrocytes obtained from striatal
tissues. (A) Pictures illustrate the PCR products on agarose gels (1.8%) after electrophoresis.
cDNA was synthesized through reverse transcription with mRNA extracted from cortical or
striatal astrocyte cultures: CTA, cortical astrocytes; STA, striatal astrocytes. PCR was conducted
with cDNA templates and primers specific to rat PAC1R, VPAC1R and VPAC2R. Presence of
bands at expected sizes indicates the expression of the target genes. (B, C) Data depict mean ±
SEM levels of PAC1R (B) or VPAC2R (C) mRNA in rat striatal cell cultures (N= 4/cell type).
STN, striatal neurons. * indicates a significant difference relative to STA cultures, T-test, p <
0.01.

Experiment 2: Twenty-four hour PACAP incubation increases Sxc activity in
striatal astrocytes. Having observed the expression of PACAP receptors in striatal
astrocytes, we next examined the impact of PACAP on Sxc. In Chapter II, we
demonstrated that 24-hr PACAP treatment significantly increased Sxc activity in cortical
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astrocytes. Therefore, we investigated whether the same treatment would also impact
striatal astrocytes (Figure 3.2). One-way ANOVAs revealed a main effect of PACAP
concentration on the uptake levels in either cortical [Figure 3.2A; F(4,43)=82.563, p <
0.001] or striatal [Figure 3.2B; F(4,47)=18.04, p < 0.001] astrocytes, suggesting that
PACAP dose-dependently increases astrocyte Sxc activity, independent of cell origins.
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Figure 3.2. Twenty-four hour PACAP incubation increases Sxc activity in striatal astrocytes.
Data depict mean ±SEM levels of 14C-cystine in purified rat cortical (A) or striatal (B) astrocyte
cultures (14-15 days in vitro) after incubation with PACAP for 24 hours (0-100 nM; N=816/condition). * indicates a significant difference relative to vehicle-treated group, Tukey HSD, p
< 0.01.

Experiment 3: Inhibition of PKA or Epac attenuates the upregulation of Sxc
activity by 24-hr PACAP treatment in striatal astrocytes. Each of the PACAP
receptors is coupled to Gαs and/or Gαq. As such, PKA and PKC have been primarily
implicated in the intracellular actions of PACAP (Miyata et al., 1989; Lazarovici et al.,
1998; Figiel and Engele, 2000; Zhou et al., 2001). However, PACAP has also been
shown to signal through AC-cAMP-Epac, PI3K-AKT, MEK-ERK or CaMK pathways
(Moroo et al., 1998; Vallejo and Vallejo, 2002; Hashimoto et al., 2003; Perez et al., 2005;
Blechman and Levkowitz, 2013). To determine the involvement of these potential
signaling cascades in PACAP-induced regulation of Sxc, we examined the impact of
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inhibiting respective kinases. Specifically, we pre-incubated striatal astrocytes for one
hour with the following kinase inhibitors: H89 (PKA inhibitor), Go6983 (PKC inhibitor),
ESI09 (Epac inhibitor), KN93 (CaMKII inhibitor), LY294002 (PI3K inhibitor) or U0126
(MEK inhibitor). Vehicle or PACAP (10nM) was then added to the cultures for an
additional 24 hours (Figure 3.3). A one-way ANOVA comparing the 14C-cystine uptake
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Figure 3.3. Inhibition of PKA or Epac attenuates the upregulation of astrocyte Sxc by 24-hr
PACAP treatment. Data depict mean ±SEM levels of 14C-cystine in purified rat striatal
astrocyte cultures after 24-hr treatment with vehicle or PACAP 10nM (designated as P1-38), with
or without the presence of H89 (10 µM, PKA inhibitor), ESI09 (5 µM, Epac inhibitor), Go6983
(1 µM, PKC inhibitor), KN93 (5 µM, CaMKII inhibitor), LY294002 (designated as LY, 45 µM,
PI3K inhibitor), U0126 (25 µM, MEK inhibitor) (N=4-14/condition). Note that the kinase
inhibitors were added one hour prior to PACAP application (A). * indicates a significant
difference relative to vehicle-treated purified astrocyte cultures, Tukey HSD, p < 0.001; #
indicates a significant difference relative to PACAP treated purified astrocyte cultures, Tukey
HSD, p < 0.001.
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levels yielded a main effect of treatment [Figure 3.3A; F(7,36)=61.130, p < 0.001]. Post
hoc analyses indicate that presence of H89 and ESI09 significantly reduced PACAPinduced Sxc activity (Tukey HSD, p < 0.001), suggesting that the effect of 24-hr PACAP
is mediated by Gαs-AC-cAMP-PKA/Epac. Note, we observed that applying the kinase
inhibitors alone to astrocyte cultures did not alter cystine uptake compared to the vehicle
group (Figure 3.3B).
Experiment 4: Phasic PACAP upregulates Sxc activity in a time- and dosedependent manner in striatal astrocytes. In these studies, we were interested in
investigating whether short-term application of PACAP would regulate Sxc, given that
phasic regulation is likely involved in the rapid control of synaptic transmission and
behavior. To examine this, we applied 10 nM PACAP to cortical or striatal astrocytes
cultures (DIV 14-15) for 6 or 20 min, prior to 14C-cystine uptake assays (Figure 3.4A).
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Figure 3.4. Time- and dose-dependent regulation of Sxc activity by short-term application
of PACAP in striatal astrocytes. (A) Data depict mean ±SEM levels of 14C-cystine in rat
cortical or striatal astrocyte cultures after 6 or 20 min treatment with vehicle (designated as 0 min
group) or PACAP (10 nM; N=4-38/condition). , * indicates a significant difference relative to the
vehicle group of striatal cultures, Tukey HSD, p < 0.05; # indicates a significant difference
relative to the vehicle-treated cortical cultures, Tukey HSD, p < 0.01; + indicates a significant
difference relative to 20 min PACAP-treated cortical cultures, T-test, p < 0.01. (B) Data depict
mean ±SEM levels of 14C-cystine in striatal astrocyte cultures after incubation with PACAP for
20 min (0-100 nM; N=8/condition). * indicates a significant difference relative to vehicle-treated
group, Tukey HSD, p < 0.05.
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This concentration was selected because of its effectiveness in inducing an Sxc increase
(see Figure 3.2). A univariate ANOVA with cell origin and incubation time as betweensubjects factors produced a significant interaction between these variables. Further
analyses revealed that PACAP time-dependently increased Sxc activity in both cortical
[One-way ANOVA; F(2,55)=8.862, p < 0.01] and striatal astrocytes [One-way ANOVA;
F(2,33)=18.405, p < 0.001]. Notably, twenty minute incubation yielded a higher level of
Sxc activity in striatal astrocytes compared to cortical cultures [t(10)=4.397, p < 0.01].
Next, we investigated the dose-dependent effect of phasic PACAP. We chose 20
min as incubation time as it yields a more robust Sxc activity increase than 6 min, as well
as a higher level than the cortical group, and also fits the behavior time frame (two hours)
that we often use to measure drug seeking behaviors. One-way ANOVAs revealed an
effect of PACAP concentration on cystine uptake [Figure 3.4B; F(4,35)=8.015, p <
0.001], indicating that 20-min PACAP incubation dose-dependently increases Sxc
activity in striatal astrocytes. These results indicate that phasic PACAP augments Sxc
activity in a time- and dose-dependent manner in striatal astrocytes, suggesting the
occurrence of this regulation in the NAc.
Experiment 5: The impact of PACAP on Sxc is reversed by inhibiting PKA,
Epac and MEK pathways. Next, we sought to explore the involvement of potential
signaling cascades, as introduced above, in the rapid regulation of Sxc. To do this, we
first applied PACAP to striatal astrocytes for 72 hr followed by the addition of the kinase
inhibitors during the last hour of the PACAP treatment period. A one-way ANOVA
comparing the 14C-cystine uptake levels yielded a main effect of treatment [Figure 3.5;
F(7,36)=74.607, p < 0.001]. Post hoc analyses revealed that H89 and ESI09 significantly
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reduced the upregulation of Sxc activity induced by PACAP (Tukey HSD, p < 0.001).
Interestingly, blocking the MEK/ERK pathway with PD98059 also attenuated PACAPinduced upregulation of Sxc activity, suggesting a differential role of this pathway in
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Figure 3.5. PKA, Epac and MEK pathways are involved in the rapid regulation of Sxc
activity by PACAP. Data depict mean ±SEM levels of 14C-cystine in purified rat striatal
astrocyte cultures. Prior to 14C-cystine uptake assay, cells were incubated with vehicle or 10nM
PACAP (designated as P1-38) for 72 hours. Kinase inhibitors, H89 (10 µM), ESI09 (5 µM),
Go6983 (1 µM), KN93 (5 µM), LY294002 (designated as LY, 45 µM), or PD98059 (50 µM,
MEK inhibitor) was applied and present only for the last hour during PACAP incubation (N=412/condition). * indicates a significant difference relative to vehicle-treated purified astrocyte
cultures, Tukey HSD, p < 0.05. # indicates a significant difference relative to PACAP treated
purified astrocyte cultures, Tukey HSD, p < 0.001.

Discussion
The primary goal for these studies was to determine whether Sxc is modulated by
PACAP in regions other than the cortex and to better understand the nature of this novel
form of neuron-astrocyte communication. The major findings in these data are that both
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prolonged and phasic PACAP upregulate Sxc in astrocytes obtained from either rat cortex
or striatum. We also found that two major subtypes of PACAP receptors, PAC1R and
VPAC2R, are enriched in astrocytes compared to neurons. Consistent with the evidence
that these receptors are commonly coupled to Gαs (Harmar, 2001; Vaudry et al., 2009),
our data suggest that two major Gαs-induced kinases, PKA and Epac, mediate the actions
of PACAP.
To date, PACAP-induced regulation of Sxc has only been detected in cortical
cells (Resch et al., 2014b; Kong et al., 2016). However, we are interested in
understanding the molecular regulation of Sxc in astrocytes obtained from the striatum.
This brain region is of particular interest because Sxc function in the nucleus accumbens
(NAc, ventral striatum) is critical for the proper expression of motivated behaviors,
whereas malfunction of this transporter contributes significantly to the development or
maintenance of substance abuse (Baker et al., 2003; Kau et al., 2008; Berglind et al.,
2009; Kalivas, 2009; Knackstedt et al., 2009; Kupchik et al., 2012). To examine this, we
first compared the impact of 24-hour PACAP treatment on cystine uptake, in part so that
we could compare our results with prior observations from cortical astrocytes. We found
that PACAP yielded similar effects on striatal astrocytes to those from the cortex,
suggesting that PACAP-induced regulation of Sxc is also present in the striatum. This
raises the prospect that PACAP-induced regulation of astrocyte Sxc may be a common
feature in the brain. This is important, since Sxc is an important component of glutamate
signaling, and has been found to regulate synaptic transmission (Manzoni et al., 1997;
Baker et al., 2002; Moran et al., 2005; Augustin et al., 2007; Moussawi and Kalivas, 2010;
De Bundel et al., 2011; Massie et al., 2011; Williams and Featherstone, 2014). Moreover,
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Sxc is expressed in various regions of the CNS, including the amygdala, hippocampus
and spinal cord (Roberto and Brunelli, 2000; De Bundel et al., 2011; Albano et al., 2013;
Aal-Aaboda et al., 2015), where PACAP signaling has been implicated (Moller et al.,
1993; Zhang et al., 1995; Roberto and Brunelli, 2000; Cho et al., 2012). As such, this
evidence creates a need to better understand the contribution of this novel form of
neuron-astrocyte communication to the excitatory signaling in these brain regions and
related CNS functions, including memory, emotion and motor generation.
Next, we determined whether PACAP could produce rapid regulation of Sxc in a
manner that would be consistent with the regulation by phasic changes in PACAP. This
is important because phasic regulation is likely necessary for rapid control of synaptic
transmission and behavior. We found that PACAP application for as short as 6 min
induced a significant upregulation of Sxc activity in striatal astrocytes. Given that
neuropeptides (e.g. PACAP) are often released in a phasic manner (Nusbaum et al., 2001;
van den Pol, 2012), this finding implicates that activity-dependent phasic release of
PACAP in the striatum is capable of increasing Sxc, through which to regulate synaptic
transmission and motivated behavior.
In these studies, we found that cortical and striatal astrocytes express all three
receptor subtypes that mediate PACAP signaling, PAC1R, VPAC1R and VPAC2R
(Harmar, 2001; Vaudry et al., 2009), consistent with earlier reports (Ashur-Fabian et al.,
1997; Magistretti et al., 1998; Grimaldi and Cavallaro, 1999; Joo et al., 2004; MasmoudiKouki et al., 2007; Nishimoto et al., 2007; Nishimoto et al., 2011; Zhang et al., 2014).
These receptors bind to PACAP with similarly high affinities and are reportedly
expressed at differently levels in the CNS. For example, PAC1R, the major binding site
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for PACAP (Dejda et al., 2011), appears to be the most abundant subtype in the cortex,
while the VPAC1R appears to be the least expressed subtype (Zhang et al., 2014). For
example, the FPKM (fragments per kilobase of transcript per million mapped reads)
values of these three receptors in astrocytes are > 150 (PAC1R), < 0.2 (VPAC1R) and ≈
2 (VPAC2R) (Zhang et al., 2014). Moreover, both PAC1R and VPAC2R appear to be
more enriched in astrocytes than in neurons, with ratios at 10:1 (PAC1R) and 5:1
(VPAC2R), while VPAC1R is more enriched in neurons, with a 5:1 ratio compared to
astrocytes (Zhang et al., 2014). Interestingly, we also show that both PAC1R and
VPAC2R, the more abundant subtypes, are more enriched in striatal astrocytes compared
to neurons. Together with our previous observation that PACAP6-38 (antagonist for both
PAC1R and VPAC2R) in mixed rat cortical cultures significantly decreased Sxc activity
(Chapter II, Figure 2.2), this evidence suggests that PAC1R and VPAC2R may be major
receptors mediating the PACAP effects on astrocyte Sxc.
Activation of PAC1R and VPAC2R induces Gαs and Gαq, and subsequently a
number of interconnected signaling cascades (Dickson and Finlayson, 2009; Vaudry et al.,
2009; Blechman and Levkowitz, 2013). To tease out those that were most likely involved
in the current studies, we chose the major pathways that were reported to mediate
PACAP-induced regulation of astrocytes, including those that are involved in regulating
Sxc (Moroo et al., 1998; Vallejo and Vallejo, 2002; Hashimoto et al., 2003; Perez et al.,
2005; Seo and Lee, 2016). With this strategy, we first examined the involvement of PKA,
PKC, Epac, CaMKII, PI3K/Akt and MEK/ERK in the action of 24-hr PACAP, as this
time point yields the most robust effect on Sxc activity. Our data show that inhibiting
cAMP-responding kinases, either PKA or Epac, significantly attenuated the effect of
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PACAP in striatal astrocytes. In contrast, inhibition of two major kinases induced by Gαq,
PKC and CaMKII, had no impact on PACAP effect (Figure 3.3). Thus, our results
suggest that the Gαs- but not the Gαq- induced cascades mediate the actions of PACAP
on astrocyte Sxc. This is consistent with a number of studies showing that Gαs-ACcAMP-PKA/Epac pathway mediates PACAP-induced regulation of astrocyte functions
(Figiel and Engele, 2000; Masmoudi et al., 2003; Seo and Lee, 2016).
In these studies, we also examined the impact of acutely inhibiting the potentially
involved kinases (Figure 3.5). To our surprise, we found that inhibiting either PKA or
Epac for one hour significantly attenuated the effect of PACAP (by approximately 75%
and 100% respectively). In this experiment, striatal astrocytes were incubated with
PACAP for 72 hours, for the purpose of maximizing the activity of Sxc. This treatment
likely induces increased xCT and subsequently Sxc expression. In support, we showed
that 24-hr PACAP incubation robustly upregulates xCT transcripts (Kong et al., 2016).
However, the increased Sxc activity induced by 72-hr PACAP is probably not a mere
reflection of increased Sxc expression. This is because that inhibiting the involved kinase
Epac for only one hour, which unlikely induces a complete turnover of the increased Sxc
expression, completely abolished the effect of PACAP. A feasible explanation is that, for
the newly synthesized Sxc to gain function, they must undergo certain rapid molecular
processes (e.g. post-translational modifications), which are also regulated by PACAP,
and that the prolonged PACAP (i.e. 72 hr)-induced upregulation of Sxc activity results
from both increased Sxc expression and augmented molecular processes that render Sxc
function. Based on this presumption, our data suggest that cAMP-induced cascades (i.e.
PKA and Epac) are also important for mediating the rapid effect of PACAP on Sxc.
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Interestingly, PI3K/Akt and MEK/ERK, which were shown to mediate Sxc expression
(Liu et al., 2012), did not demonstrate their involvement in the actions of 24-hr PACAP
(Figure 3.3); yet inhibiting MEK/ERK for one hour after 72-hr PACAP incubation
significantly decreased Sxc activity. These results suggest that the MEK/ERK pathway is
only involved in mediating the rapid impact of PACAP on Sxc.
Although H89 is commonly used as a PKA inhibitor, it has been shown to inhibit
other kinases, including MSK (Lochner and Moolman, 2006). It is intriguing to note that
MSK is a downstream kinase of both PKA and Epac (Delghandi et al., 2005; Shi et al.,
2012), and sequence analyses reveal that xCT harbors phosphorylation sites for MSK,
including amino acid serine 26 (S26). This is important, because it has been recently
demonstrated that mutagenesis of S26 on xCT and consequently altering phosphorylation
state of the protein lead to changes of Sxc (McClatchy et al., 2016). Such evidence
implicates MSK as a potential kinase that could mediate the effect of PKA and Epac on
Sxc phosphorylation. Alternatively, PKA itself may also influence Sxc activity through
direct phosphorylation of xCT, given that this catalytic subunit also harbors
phosphorylation sites for PKA (Baker et al., 2002).
To summarize, we expanded our previous findings by showing that PACAP
regulates Sxc in striatal astrocytes, implicating the occurrence of this mechanism in the
NAc. Moreover, we observed a rapid upregulation of Sxc activity induced by phasic
PACAP. Lastly, we found that two cAMP-regulated signaling pathways, PKA and Epac,
may underlie PACAP-induced increases in Sxc activity. These findings indicate that
PACAP potentially regulates glutamate transmission in the NAc via its actions on Sxc,
and consequently influences motivated behaviors.
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CHAPTER IV

PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE PROMOTES
GLUTAMATE RELEASE FROM ASTROCYTE SYSTEM XC- TO GATE SYNAPTIC
OUTPUT FROM THE NUCLEUS ACCUMBENS
Introduction
Drug addiction is a complex, multi-faceted disorder characterized by compulsive
drug seeking even when such behavior results in profound negative consequences to the
individual. The chronic aspect of the disease involves episodes of heightened relapse
vulnerability even following long periods of abstinence (Jaffe et al., 1989; Withers et al.,
1995). Studies suggest that relapse originates from the persistent neuroadaptations at the
molecular and cellular levels in the related brain circuit (Kalivas and Volkow, 2005;
Nestler, 2005; Hyman et al., 2006; Koob and Volkow, 2010). Among these
neuroadaptations, drug-induced changes in synaptic transmission due to aberrant
glutamate signaling in the nucleus accumbens (NAc) and related circuitry have been
linked to behavior in virtually every preclinical model of drug seeking and have been
found to correlate with the severity of drug craving in human substance abusers (Pierce et
al., 1996; Breiter et al., 1997; Volkow et al., 1999; Park et al., 2002; Baker et al., 2003;
McFarland et al., 2003; McFarland et al., 2004; Schmidt et al., 2005; Madayag et al.,
2007; Kau et al., 2008; Ary et al., 2013). However, a challenge in revealing the molecular
or cellular basis of drug-induced plasticity is that excitatory neurotransmission is
achieved by an elaborate network of glutamate-related proteins expressed across multiple
cell types, including neurons and astrocytes (Herrera-Marschitz et al., 1996; Timmerman
and Westerink, 1997; Danbolt, 2001; Schoepp, 2001; Baker et al., 2002; Baker et al.,
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2003; Pirttimaki et al., 2011; Bridges et al., 2012a), and that this signaling occurs in and
outside of the synaptic cleft. Hence, it has been difficult to develop a comprehensive
model that mechanistically integrates disparate forms of plasticity spanning multiple cell
types. Of particular importance, it would be very useful to decode the molecular basis for
integrating glutamate-related processes across cell types.
Here, we pursue the idea that the molecular integration of the cellular network
underlying glutamate signaling in the NAc is achieved by the neuropeptide pituitary
adenylate cyclase-activating polypeptide (PACAP). Our interest in PACAP stems from
emerging results establishing this peptide as a powerful regulator of excitatory signaling
capable of regulating neuronal and astrocytic glutamate-related mechanisms. In support,
published reports demonstrate that PACAP signaling in hippocampal and SCN
(suprachiasmatic nucleus) neurons regulates AMPAR-mediated EPSCs (Kopp et al.,
2001; Costa et al., 2009), an effect that may be dependent on the activation of highaffinity extrasynaptic receptors (Toda and Huganir, 2015). Moreover, we and others
have discovered that PACAP can upregulate the activity of Sxc (Resch et al., 2014b;
Kong et al., 2016), even when briefly applied (Chapter III). Collectively, these studies
provide support for the proposed hypothesis that PACAP integrates astrocytes and
neurons in a manner that regulates synaptic transmission and behavior.
To test our hypothesis, we first had to determine whether in vivo PACAP
signaling exists in the adult NAc. It is important to determine whether PACAP and
PACAP receptors are expressed in the adult NAc since many glutamate related proteins
show drastic development-induced changes (Sun et al., 2013). To do this, we determined
whether PACAP mRNA is present in excitatory projections to the NAc and if astrocytes

83

in this region express mRNA for PACAP receptors. Having found PACAP mRNA in
NAc afferents and PACAP receptor mRNA in NAc astrocytes, we then investigated
whether PACAP application alters AMPAR-mediated EPSCs in NAc efferents, similar to
what has been observed in other brain regions (Kopp et al., 2001; Costa et al., 2009;
Gardoni et al., 2012; Toda and Huganir, 2015). Having found that PACAP depresses
AMPAR-EPSCs in NAc efferents projecting to the substantia nigra, we determined
whether this effect requires Sxc regulation. In support of this idea, PACAP did not alter
synaptic transmission in NAc slices obtained from loss of Sxc-function transgenic rats
(MSxc rats). Lastly, we examined the relevance of these findings to addiction by
assessing the impact of PACAP microinjection into the NAc on cocaine-primed
reinstatement. Intra-NAc PACAP blocked cocaine reinstatement in wild-type but not
MSxc rats. Collectively, these data are the first to establish that PACAP signaling is a
key component of excitatory signaling in the NAc.

Material and Methods
Animals and Materials: These experiments utilized Sprague Dawley rats
purchased from Envigo (Indianapolis, IN) and Sprague Dawley wild-type (WT) and
transgenic mutants obtained from internal colonies, including Sxc loss of function
mutants (MSxc) and eGFP knock-in (GFAP-lck-eGFP) rats. Experimental procedures
were approved by the Marquette University Institutional Animal Care and Use
Committee. The primary materials included fetal bovine serum and horse serum (Atlanta
Biologicals, Lawrenceville, GA), 14C-cystine (PerkinElmer, Waltham, MA), PACAP1-38
(California Peptide Research, Napa, CA), and PACAP6-38 (Anaspec, Fremont, CA).
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PACAP1-38 (PACAP) is the endogenous full-length peptide whereas PACAP6-38 is a
truncated version of PACAP and inhibits PACAP receptors (Miyata et al., 1989;
Robberecht et al., 1992; Arimura, 2007; Vaudry et al., 2009). Picrotoxin and all other
common chemicals were obtained from Sigma-Aldrich (St Louis, MO). Tetrodotoxin
(TTX) was obtained from Tocris Bioscience (Ellisville, MO).
Creation of GFAP-lck-eGFP Rats: GFAP-lck-eGFP rats were generated using
Sleeping Beauty (SB) transpositional transgenesis (Katter et al., 2013; Ivics et al., 2014).
Briefly, a plasmid harboring a SB transposon transgene consisting of the GFAP promoter
(Glial Fibrillary Acidic Protein), Lck-eGFP cDNA, and rabbit beta globin
polyadenylation signal, was injected into fertilized embryos with an in vitro transcribed
source of the SB100X transposase. A transgenic animal was identified harboring a single
copy of the transgene inserted on chromosome 13, near 97.97Mb (sequence tag: TAC
CTC TGT GAA GAC CCT CAG AGA GCT GTA ATT GTT CAT CCA AAT TTG
AAG ACT TTG). A colony was established by back crossing to the parental Crl:SD
strain and a fixed transgenic line was established by intercrossing. Genomic PCR
primers GFAP04_forward 5’ –TTT TCC TGA ATT TAT GTT TGT GCA G -3’,
GFAP04_reverse 5’- TCA TTC TTA GCT GTT TGA CAT CTG TCC -3’, and a
transposon specific primer 5’-GAC TTG TGT CAT GCA CAA AGT AGA TGT CC - 3’
were used to determine zygosity.
Surgeries: All surgeries were conducted with rats under ketamine HCl (100
mg/kg, i.p.; Henry Schein, Dublin, OH) and xylazine (2 mg/kg, i.p.; Lloyd Laboratories,
Shenandoah, IA) induced anesthesia.
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Microinjection of Retrograde Tracers: In order to label NAc afferents, red beads
(fluorescent latex microspheres that contain rhodamine; Lumafluor Inc., Durham, NC;
used for FACS) or Cholera Toxin Subunit B (CTB; Thermo Fisher Scientific, Waltham,
MA; used for immunostaining and in situ hybridization) were injected into the NAc. In
order to label NAc efferents, red beads were injected into either the ventral pallidum (VP)
or substantia nigra (SN) to label NAc-VP or NAc-SN medium spiny neurons (MSNs),
respectively. In each case, guide cannula (C315G, 26GA, 11mm; Plastic One) were
surgically implanted 2mm above the target structure with the coordinates (skull leveled,
with Bregma as reference) derived from Paxinos and Watson (2007): Substantia Nigra
(SN), AP -5.0, ML +3.0mm, DV -6.1mm, 6o angle from midline; Ventral Pallidum (VP),
AP -0.2mm, ML +3.2mm, DV -5.8mm, 6o angle from midline; Nucleus Accumbens
(NAc) core, AP +1.7mm, ML +2.4mm, DV -5.3 mm, 6o angle from midline.
Microinjectors (C315I-SPC, 33GA, with 2mm projection; Plastic One) were inserted in
the cannula. Tracer was then microinjected with 2µL Hamilton syringes at a rate of
50nL/min, to reach a target volume of 300 nL/hemisphere for SN and VP, and 500
nL/hemisphere for the NAc. For the purpose of a thorough perfusion of the beads,
microinjectors remained unremoved after microinjection for 10min and were then slowly
pulled out together with cannula. Openings on the skull for guide cannula were then
sealed with bone wax before scalp being sutured.
Implantation of jugular catheters: Rats included in self-administration studies
were implanted with indwelling catheters. In brief, a custom polyurethane catheter
(Access Technologies, Skokie, IL) was implanted such that it entered the superior vena
cava and terminated at the right atrium. The catheter was sutured to the vein at the entry
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point. The distal aspect of the catheter, which consisted of a 22-gauge guide cannula
(Plastics One, Roanoke, VA) attached with dental acrylic to a piece of polypropylene
monofilament mesh, exited 2 cm posterior to the scapulae. Throughout the experiment,
catheters were filled daily with a heparin solution (83 i.u./ml; Elkins-Sinn, Cherry Hill,
NJ) and capped when disconnected from the leash/delivery line assembly.
Implantation of Intracranial Guide Cannula: Some rats received indwelling
bilateral guide cannulas (26 gauge, 14 mm; Plastics One) targeting the NAc core using
the following coordinates derived from Paxinos and Watson (2007): AP +1.7mm, ML
+2.4mm, DV -5.3mm, 6o angle from vertical (skull leveled, with Bregma as reference).
Dummy internals were inserted in the cannula to prevent blocking. After surgeries, rats
were given at least 7 days to recover before testing. During this time, rats were provided
chewable Rimadyl tablets (first three days, Bio-Serv, Flemington, NJ) and injected daily
with sterile cefazolin antibiotic solution (15 mg, i.v.; Sagent Pharmaceuticals,
Schaumburg, IL).
Cell Dissociation: The NAc or prefrontal cortex (PFC) tissues were freshly
dissected from male GFAP-lck-eGFP or WT Sprague Dawley rats and placed
immediately into ice-cold Hanks´Balanced Salt Solution (HBSS) without Ca2+ and Mg2+
(Sigma-Aldrich, St Louis, MO). Tissues were further minced before enzymatic digestion
to obtain single cell suspension with Neural Tissue Dissociation Kit - P (Miltenyi Biotec,
San Diego, CA), following manufacturer’s protocol. 1% BSA, 1mM EDTA and 12.5
U/ml DNase DNase I (Sigma, Cat. DN25) were added to single cell suspension to reduce
cell clustering. Cells were incubated with 3µM Calcein Violet 450 AM Viability Dye
(eBioscience, San Diego, CA) on ice for 10min to stain live cells.

87

Fluorescence-Activated Cell Sorting (FACS): FACS analyses were performed
using FACSDiva software, 6.1.3, (BD Biosciences). Fluorescence Minus One (FMO)
control samples derived from store-bought Sprague Dawley rats were first analyzed to set
primary gates to exclude double cells, dead cells and debris. An aliquot of cell suspension
was extracted as unsorted total population prior to cell sorting. Target cells were collected
from a population with high levels of calcein violet staining, indicating live cells. GFP+
and GFP- (see Figure 4.1), or rhodamine + and rhodamine - (see Figure 4.8) cell
populations were isolated through FACS based on the intensity of the respective
fluorophore (e.g. GFP, rhodamine). Flow rate was carefully adjusted to increase purity.
RNA Extraction and cDNA Construction: Total RNA from sorted cells was
isolated with PicoPure RNA Isolation Kit (Thermo Fisher Scientific, Waltham, MA),
following the manufacturer’s protocol. On column DNase treatment was applied to all
samples to remove potential genomic DNA contamination with the RNase-Free DNase
Set (Qiagen; Germantown, MD). RNA quantity and quality were assessed on an Agilent
2100 Bioanalyzer using Agilent RNA 6000 Pico Chips. Only those samples with higher
quality (e.g RIN > 7.0) were used for downstream procedures.
Total RNA from brain tissues or cell cultures was isolated with Trizol Reagent
(Invitrogen, Carlsbad, CA) following the manufacturer’s protocol. DNase treatment was
applied to all RNA samples to remove potential genomic DNA contamination with a
DNA-free kit (Life Technologies, Carlsbad, CA). Assessment of RNA purity and
quantity was performed on a NanoVue Plus Spectrophotometer (GE life sciences,
Pittsburg, PA).
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cDNA was constructed from total RNA using the Reverse Transcription System
(Promega, Madison, WI) with oligo(dT) primers following the manufacturer’s protocol.
Real-Time Quantitative Polymerase Chain Reaction (qPCR): qPCR was
performed using a StepOne Real-Time PCR System (Applied Biosystems; Carlsbad, CA)
and PerfeCTa SYBR Green FastMix with ROX (Quanta Biosciences; Gaithersberg, MD).
Relative quantification of target gene expression was normalized to the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the ∆∆Ct method
(Schmittgen and Livak, 2008). Primer sequences were as follows: xCT (catalytic subunit
of Sxc) forward - 5’ AGG GCA TAC TCC AGA ACA CG 3’; xCT reverse - 5’ ATG
CTC GTA CCC AAT TCA GC 3’; PAC1R forward - 5’ TGC CTG TGG CTA TTG CTA
TG 3’; PAC1R reverse - 5’ TTT AGT CCC ATC AGG TCG TTG 3’; GFAP forward - 5’
GCA GGT GAG GAA GAA ATG GA 3’; GFAP reverse - 5’ TAC GAT GTC CTG
GGA AAA GG 3’; NeuN forward - 5’ ATC ATA CCA TCG GCC CCA CA 3’; NeuN
reverse - 5’ GTG AAG CGG CTG TAC CCT CC 3’. GAPDH forward - 5’ CTC CCA
TTC TTC CAC CTT TGA 3’; GAPDH reverse - 5’ ATG TAG GCC ATG AGG TCC
AC 3’. Primers were designed using the online primer design tool Primer3
(http://biotools.umassmed.edu/bioapps/ primer3_www.cgi). Another online software
Primer-Blast (https://www.ncbi.nlm.nih. gov/tools/primer-blast/) was used to confirm the
target-specificity of the primers. A single product from amplification was confirmed by
melt curve analysis. Amplification efficiency of all genes was determined to be
approximately 95%.
Creation of Sxc loss of function mutants (MSxc): Zing-finger nucleases (ZFNs)
were procured from Sigma Aldrich to target xCT-encoding gene SLC7A11. ZFNs were
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introduced to SD rat embryos at the one-cell stage by pronuclear microinjection of in
vitro-transcribed ZFN mRNAs, to create whole animal disruption of SLC7A11 in a single
step. An xCT mutant was identified with a 39-bp deletion in exon 2 of SLC7A11 gene,
which predictably leads to the missing of 13 amino acids (see Figure 4.3A) that
correspond to the majority of the 3rd transmembrane domain of the xCT protein.
Polymerase Chain Reaction (PCR) and Gel Electrophoresis: PCR was
performed with GoTaq Green Master Mix (Promega, Madison, WI) on a thermocycler
with parameters as follows. Initial denaturation (3min at 95°C), Amplification (35 cycles
of the following: 95°C for 30s, 60°C for 45s, 72°C for 45s), and Extension (72°C for
10min). PCR products were then examined with electrophoresis on an agarose gel (1.8%).
Sequences of primers used to target the mutation sites in xCT KO rats were as follows,
xCT M forward - 5’ TTT GGA GCC CTG TCT TAT GC 3’; xCT M reverse - 5’ ACC
CAG ACT CGA ACA AAA GC 3’. Other primers used for PCR included GFAP forward
- 5’ GCA GGT GAG GAA GAA ATG GA 3’; GFAP reverse - 5’ TAC GAT GTC CTG
GGA AAA GG 3’; NeuN forward - 5’ ATC ATA CCA TCG GCC CCA CA

3’;

NeuN reverse - 5’ GTG AAG CGG CTG TAC CCT CC 3’; PACAP forward-5’ AAC
CCG CTG CAA GAC TTC TA 3’; PACAP reverse- 5’ CTT TGC GGT AGG CTT CGT
TA. 100bp DNA Ladder (Promega, Madison, WI) was used to locate target PCR
products.
Western Blotting: NAc tissues of WT or MSxc rats were mechanically
homogenized in buffer containing 320mM sucrose and 10mM Tris-HCl, supplemented
with protease and phosphatase inhibitors (Thermo Fisher Scientific, Waltham, MA). 10
µg of total protein was resolved in a 7.5% polyacrylamide SDS-PAGE gel followed by
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wet transfer to a polyvinylidene fluoride (PVDF) membrane. The membrane was blocked
with Odyssey Blocking Buffer (PBS) (LI-COR, Lincoln, NE) for one hour prior to an
overnight treatment with a mouse anti-GluA1 antibody (1:1000, Millipore), a rabbit antipT840 antibody (1:3333, Abcam), a chicken anti-GAPDH antibody (1:10000, Millipore),
or a custom rabbit anti-xCT antibody that was generously donated to us by Dr. Jeffrey
Rothstein at John Hopkins School of Medicine. Next, membranes were rinsed and
incubated with IRDye 680 goat anti-rabbit (1:15000, LI-COR) or IRDye 800 donkey
anti-chicken (1:20000, LI-COR) secondary antibodies for one hour. Membranes were
rinsed again prior to imaging on an Odyssey Fc Imaging System (LI-COR).
Ex vivo 14C-cystine Uptake Assays: The assessment of system xc- (Sxc) activity
is often achieved by measuring intracellular uptake of radiolabeled cystine, since this is
primarily dependent on Sxc (Liu et al., 2009; Liu et al., 2014a; Resch et al., 2014b;
Albano et al., 2015). The NAc tissue punches (1mm thick and 1mm in diameter) were
freshly dissected and placed immediately into artificial cerebrospinal fluid that was
constantly infused with 95% O2:5% CO2. Following a 20-minute equilibration period
during which the buffer was warmed to 37oC, 14C-cystine and DL-threo-βhydroxyaspartic acid (TBOA) were added to the media to reach a final concentration of
1µM and 10 µM, respectively. This concentration of cystine was used since it is similar
to extracellular cystine concentrations in the brain (Baker et al., 2003). TBOA was added
to the culture media to prevent 14C-cystine uptake by sodium-dependent glutamate
transporters. Some conditions also involved the addition of the Sxc inhibitor sulfasalazine
(SSZ, 300 µM) to block Sxc-mediated cystine uptake. Immediately following 20-min
exposure to14C-cystine, tissues were washed three times with ice-cold 1xPBS and then
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solubilized with 1N NaOH. One aliquot of tissue lysate was used to determine protein
concentration with BCA protein assay and another aliquot was used for 14C-cystine
uptake determination. 14C-cystine uptake was normalized to protein concentration and
data were presented as CPM/µg of protein.
Cell Culture Procedures: Purified striatal astrocyte cultures were prepared from
post-natal days 3-4 rat pups. In brief, striatal cells were dissociated and then suspended in
Neurobasal A media (Thermo Fisher Scientific, Waltham, MA) supplemented with 10%
fetal bovine serum, and 1% Glutamax (Thermo Fisher Scientific, Waltham, MA). Cells
were initially grown in 25cm2 or 75cm2 cell culture flasks that were pre-coated with polyD-lysine (10mg/L) and laminin (0.4mg/L). Once confluent, cells were then subjected to
prolonged, orbital shaking (250 rpm for 16-18 hours at 37oC), which has been used to
yield purified astrocyte cultures (McCarthy and de Vellis, 1980; Schildge et al., 2013).
Purified astrocytes were then plated on 24-well plates, and refreshed with 70% new
culture media every 2-3 days prior to experiments. All cell cultures were maintained in
humidified 5% CO2 incubators at 37oC.
Glutamate Release Assay and Glutamate HPLC: Purified striatal astrocytes
(DIV14) were incubated with PACAP at designated concentrations for 30 minutes at
37oC in a Na+ free buffer containing 116mM Choline Chloride, 13.4 mM MgSO4, 1.68
mM KH2PO4, 2.34 mM CaCl2, 5.49 mM Dextrose, 11.9 mM HEPES, 10 μM cystine and
0.2% Choline bicarbonate. Buffer pH was titrated to 7.4 with NaOH. After incubation,
100 μL media was extracted for HPLC analysis. Cells were solubilized in 0.5% sodium
dodecyl sulfate (SDS). One aliquot of cell lysate was used for protein quantification using
the bicinchoninic acid (BCA) assay.
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Media collected in glutamate release assays were analyzed for glutamate content
via fluorescence detection on an isocratic Shimadzu HPLC system. A 10μL sample
underwent pre-column derivatization with ortho-phthalaldehyde (OPA) in the presence of
2-mercaptoethanol. Samples were resolved with a Kinetex XB C-18 (50x4.6mm, 2.6μm;
Phenomenex, Torrence, CA) and 100mM Na2HPO4, 0.1mM Ethylenediaminetetraacetic
acid (EDTA), 10% Acetonitrile, pH 6.04 mobile phase. Peak areas were quantitated in
Shimadzu VP client software compared to known standards. Glutamate content for each
sample was normalized to protein concentration.
Brain slice preparation: Rats were anesthetized by isoflurane inhalation and
perfused through the aorta with a cold sucrose-based solution (4–6 °C) containing 78 mM
NaCl, 68 mM sucrose, 26 mM NaHCO3, 2.5 mM KCl, 1.25 mM NaH2PO4, 2 mM CaCl2,
2 mM MgCl2 and 25 mM glucose. The rat brain was trimmed and embedded in lowmelting-point agarose, and coronal striatal slices (200-250 μm thick) were cut in the
sucrose-based solution (4-6 °C) using a vibrating slicer (Leica VT1200s, Nussloch,
Germany). The slices were incubated in the sucrose-based solution at room temperature
for 30-40 min. Then, the slices were transferred and allowed to recover for at least 1 hour
in the artificial cerebrospinal fluid (ACSF) containing 119 mM NaCl, 2.5 mM KCl, 2.5
mM CaCl2, 1 mM MgCl2, 1.25 mM NaH2PO4, 26 mM NaHCO3, and 10 mM glucose. All
solutions were saturated with 95% O2 and 5% CO2.
Electrophysiology: AMPAR-mediated EPSC Male Sprague Dawley rats (300350g) received a bilateral microinjection of red beads into SN or VP. After 3-5 days of
recovery, rats were anesthetized with isoflurane and decapitated. Striatal slices were
prepared as previously described (Liu et al., 2014b). Whole-cell voltage-clamp
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recordings were made from medium spiny neurons (MSNs) in the core of the NAc.
MSNs that were retrogradely labeled with red beads were selected for recording.
AMPAR-EPSCs were evoked by a bipolar tungsten stimulation electrode that was placed
~300 μm away from the recording pipette. The MSNs were voltage-clamped at -80 mV,
close to the resting membrane potential of these neurons. PACAP or PACAP6-38 was
administered through bath application.
Cocaine Self-Administration Training: Self-administration occurred in operant
chambers (ENV-008CT; MEDAssociates, St. Albans, VT) housed in sound-attenuating
cubicles (ENV- 016M; MED-Associates) and equipped with two retractable levers, two
stimulus lights, and a water bottle. At least 7 d after surgery, rats were food restricted for
18 h with water available ad libitum. Rats were then placed into the operant chambers
overnight and responses on the lever designated as active resulted in the delivery of food
pellets under a fixed ratio 1 schedule of reinforcement. Daily food training continued
until subjects received at least 100 food rewards in a session, which typically occurred
after the first session. During the acquisition phase of the experiment, all rats underwent
drug self-administration training during daily 2 h sessions in which operant responses on
the active lever were reinforced with an infusion of saline or cocaine (0.5 mg/kg/200µL,
i.v.; National Institute on Drug Abuse, Bethesda, MD) under a fixed ratio 1 schedule of
reinforcement. Each reinforced lever response resulted in the illumination of the stimulus
light located above the active lever and was followed by a 25 s time-out period.
Responding on a second, inactive lever located on the back wall was recorded but had no
programmed consequences. Acquisition of cocaine self-administration was operationally
defined as < 10% variation in daily responding over at least three consecutive sessions.
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Once rats met the acquisition criteria, they were advanced to maintenance sessions in
which saline or cocaine was self-administered under long-access conditions (1.0
mg/kg/200µL, i.v.; 6 h/d for 12 d).
Extinction Training: After completing maintenance self-administration sessions,
rats remained in their home cages for 7 d before extinction training. A seven-day delay
was used to ensure an adequate drug-free period before reinstatement, even in rats that
quickly extinguished responding. Extinction training involved placing rats into the
operant chambers for 2 h/d as described above in the self-administration section except
each active lever press now resulted in an infusion of saline. This continued until the
mean number of lever presses was no more than 15 responses across two sessions, at
which point rats were tested for cocaine-primed reinstatement.
Microinjection and Reinstatement Testing: Once rats reached extinction
criteria, mock microinjections were conducted to familiarize rats with the procedure
approximately two days prior to reinstatement test day. The reinstatement test was
identical to each extinction session except rats were injected with cocaine (10 mg/kg, IP).
Prior to the cocaine injection, microinjectors were inserted into indwelling guide cannula,
and rats received infusion of vehicle [0.9% NaCl], PACAP [100μM] or [200μM], or
PACAP6-38 [1000μM] at a rate of 0.125 μL/min for four minutes. Six minutes after
microinjection, rats were given an injection of cocaine (10 mg/kg, IP), and then
immediately placed in the self-administration chamber for reinstatement test, behavior
was recorded for 120 min.
Histology: Rats that received implantation of indwelling guide cannula were
anesthetized with CO2, and the brains removed and imbedded in OCT compound.
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Coronal sections (30 μm) were cut on a cryostat and stained with cresyl violet to verify
probe placements.
CTB Immunostaining and PACAP In Situ Hybridization: One week after
microinjecting CTB into the NAc, brains were collected via rapid decapitation and flash
frozen in OCT with a dry ice/ethanol bath. Brains were kept at -80oC before being cut on
a cryostat into coronal sections (12 µm thick) which were thaw-mounted onto
electrostatically clean slides. The brain sections were stored at -80°C until in
situ hybridization. Prior to overnight hybridization, the brain sections were post-fixed in 4%
PFA, rinsed in 0.1 M PBS (pH 7.4), equilibrated in 0.1 M triethanolamine (pH 8.0) and
acetylated in triethanolamine containing 0.25% acetic anhydride. Sense and antisense
digoxigenin conjugated riboprobes specific for PACAP were diluted (1:100) in a
hybridization solution (Amersco; Solon, OH) containing 1/4th riboprobe volume of tRNA
(4µl riboprobe/1µl tRNA). The probe cocktail was incubated for 10 minutes at 65 °C and
then applied to the sections (100µl/slide). Once the probe was applied, the slides were
coverslipped and hybridized overnight at 60 °C. Approximately 14-16 hours later, the
slides were treated with an RNase A solution, stringently washed in 0.1x SSC at 65 °C
and then incubated overnight at 4 °C with an antibody against DIG conjugated to a
horseradish peroxidase (HRP; Roche; Indianapolis, IN). The DIG conjugated PACAP
riboprobes were visualized using a TSA-plus fluorophore system with fluorescein (Perkin
Elmer; Waltham, MA). Following the in situ hybridization procedure, slides were then
incubated overnight in an antibody against CTB (Goat anti-CTB; List Biological
Laboratories Inc.; Campbell, CA). This primary antibody was then visualized using a
donkey anti-goat AlexaFluor 594 conjugated secondary antibody (Life Technologies;
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Grand Island, NY). Images were then captured using fluorescent microscopy (Axioskop2, Zeiss; Thornwood, NY) and Axiovision image analysis software (Zeiss; Thornwood,
NY).
Statistics: Data are presented as the mean ±SEM. The data of mEPSCs were
analyzed using Mini-analysis (Synaptosft, Decatur, GA). The frequency and amplitude of
mEPSCs were calculated for 3-5 min of recordings. The analysis of mEPSCs was
performed with cumulative probability plots (Van der Kloot, 1991). All other statistical
analyses were performed using SPSS Statistics (Version 24, IBM; Armonk, New York).
Analysis of variance (ANOVA) was used when comparing data sets that included more
than two groups. Bonferroni tests were used for subsequent post hoc analyses of
significant effects involving more than two groups. Student’s t tests were used when
comparing results from only two groups. In all instances, statistical significance was
designated as p < 0.05.

Results
Experiment 1: xCT and PAC1R mRNAs are enriched in adult NAc
astrocytes. The purpose of this experiment was to determine whether PACAP receptors
are expressed in NAc astrocytes isolated from adult tissues. In order to do this, we first
characterized astrocyte labelling in GFAP:Lck-eGFP rats. To verify this, eGFP
expression produced by the transgene was compared with GFAP-IHC
(immunohistochemistry) in the same tissue. Figure 4.1B-D illustrates that eGFP provides
a more complete labelling of astrocytic processes in GFAP+ cells. To further verify that
the eGFP+ cells were astrocytes, we used FACS (fluorescence-activated cell sorting) to
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isolate these cells from NAc tissue punches obtained from adult (i.e., aged 3-4 months)
GFAP:Lck-eGFP transgenic rats (Figure 4.1E-J).

Figure 4.1. Isolation of adult NAc astrocytes from GFAP:Lck-eGFP transgenic rats with
fluorescence-activated cell sorting. (A) Schematic diagram of the plasmid harboring a Sleeping
Beauty transposon transgene consisting of the glial fibrillary acidic protein (GFAP) promoter,
cDNA for a membrane-targeted form of enhanced green fluorescent protein (Lck-eGFP)
(Benediktsson et al., 2005), and rabbit beta globin polyadenylation signal (pA). (B-D) Visualizing
eGFP in GFAP:Lck-eGFP transgenic rat permits a more complete labelling of astrocytes (B)
relative to GFAP immunoreactivity of the same tissue (C), see merged images (D). (E-J) The
gating parameters of the flow cytometer were utilized to identify/isolate cellular debris (E;
forward scatter area (FCS-A)/side scatter area (SSC-A), cell doublets (F: side scatter height (SSCH)/side scatter area (SSC-A) and G: forward-scatter height/forward scatter width), viable cells (H;
calcein violet/SSC-A), background green fluorescent protein in negative control tissue (I; tissue
obtained from WT rats), and transgene-induced fluorescence above background (J: tissue
obtained from GFAP:Lck-eGFP transgenic rats).
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Next, we used PCR to compare the mRNA expression of astrocyte-enriched genes
(i.e., GFAP, xCT) and neuron-enriched genes (NeuN). When including the three sample
types (total or unsorted, GFP+, and GFP-), one-way ANOVAs revealed significant main
effects of sample type for the expression of NeuN [Figure 4.2A; F(2,9)=27.798, p <
0.001], GFAP [Figure 4.2B; F(2,9)=16.829, p = 0.001], and xCT [Figure 4.2C;
F(2,9)=11.209, p < 0.01]. Post hoc tests revealed that GPF+ cells contained significantly
higher mRNA levels of the positive control genes GFAP and xCT (Tukey HSD, p < 0.05)
and did not express the negative control gene NeuN (Figure 4.2C), indicating that this
astrocyte-enriched sample did not contain neurons.
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Figure 4.2. xCT and PAC1R mRNAs are highly expressed in rat NAc astrocytes. Data depict
Mean ±standard error of means (SEM) mRNA levels of NeuN (A), GFAP (B), xCT (C), and
PAC1R (D) in unsorted (total) cell populations, GPF+, and GFP- isolates (N= 4/gene/population)
from NAc tissues. * indicates a significant difference relative to unsorted total population, Tukey
HSD, p < 0.05.
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Next, we examined mRNA expression of the test gene PAC1R in the three tissue
samples (total or unsorted, GFP+, and GFP-). A one-way ANOVA yielded a main effect
of sample type on the PAC1R mRNA expression [Figure 4.2D, F(2,9)=14.993, p = 0.001]
with post hoc analyses revealing enrichment in the GFP+ cells (Tukey HSD, p < 0.05).
Experiment 2: PACAP regulates Sxc mediated glutamate release. Given that NAc
astrocytes express the receptor needed to encode PACAP signaling, we then examined
whether this neuropeptide can regulate glutamate release by Sxc. Note, in Chapter III, our
measure of interest was primarily cystine uptake. Thus, we sought to confirm that
PACAP would promote glutamate release from striatal astrocytes. To do this, we used
loss of function Sxc mutant (MSxc) rats. Zinc-finger nucleases were used to mutate the
gene (Slc7A11) that encodes the protein (xCT) containing the binding sites for the
transported substrates (i.e., cystine, glutamate). The mutation was identified as a 39-bp
deletion in exon 2 of SLC7A11, which predictably leads to the loss of 13 amino acids
(Figure 4.3A) that corresponds to the majority of the 3rd transmembrane domain of the
xCT protein. For further validation of MSxc rats, we examined the expression of xCT
mRNA and protein, and Sxc function in striatal tissues (Figure 4.3B-D). Using primers
that partially corresponded to the mutation region, we confirmed the absence of intact
xCT mRNA in the mutants (Figure 4.3B). Consistent with this observation, MSxc rats
did not display xCT protein as assessed using western blotting (Figure 4.3C). To evaluate
the functional consequence of the mutation, we compared 14C-cystine uptake in NAc
tissue punches in the presence or absence of an Sxc inhibitor sulfasalazine (SSZ). A
univariate ANOVA with genotype and SSZ concentration as between-subjects factors
produced a significant interaction [Figure 4.3D; F(1,15)=13.098, p < 0.01]. Further
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analyses of the data revealed that SSZ significantly reduced uptake levels in WT (T-test,
p < 0.01) but not in MSxc tissues, suggesting a lack of Sxc activity in the mutants.
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Figure 4.3. PACAP regulates Sxc mediated glutamate release. (A) Amino acid sequence
(101-150) of xCT in MSxc and WT rats. Zinc-finger nucleases (ZFNs) specific for exon 2 of the
rat SLC7A11 gene (encoding xCT, the catalytic subunit of Sxc) were used to create Sxc mutants;
the sequence eliminated by the mutation is denoted by the dotted lines. (B) Gel electrophoresis
results showing the lack of intact xCT mRNA in MSxc striatum. Reverse transcription and PCR
were used to validate the elimination of xCT mRNA sequence corresponding to AAs 116-128 as
depicted in panel A. (C) Western blot analysis was used to confirm a lack of xCT protein in
MSxc NAc tissue punches. (D) Data depict the mean ±SEM levels of total (i.e., in the presence
of vehicle) or non-Sxc-mediated (i.e. in the presence of the Sxc inhibitor sulfasalazine, SSZ; 300
µM) 14C-cystine uptake in WT or MSxc striatal tissue punches (N=3-6/condition/genotype). *
indicates a significant difference relative to WT tissues treated with vehicle, T-test, p < 0.01. (E)
Data depict the mean ±SEM levels of extracellular glutamate levels in purified striatal astrocytes
obtained from WT or MSxc rats after PACAP treatment (30 min at 0-100 nM; N=6/condition). *
indicates a significant difference relative to WT with the corresponding PACAP treatment, T-test,
p < 0.001; # indicates a significant difference relative to WT astrocytes treated with vehicle,
Tukey HSD, p < 0.05.
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Next we examined the impact of PACAP on Sxc-mediated glutamate release in
WT or MSxc striatal astrocytes following PACAP application (30 min). A univariate
ANOVA with genotype and PACAP concentration as between subjects factors produced
a significant interaction [Figure 4.3E; F(3,40)=4.058, p <0.05]. Further analyses revealed
significantly lower levels of glutamate in MSxc astrocytes compared to WT at each of the
PACAP concentrations (T-test, p <0.001), consistent with the lack of Sxc activity in the
mutants. A one-way ANOVA with PACAP concentration as a between-subjects factor
revealed a PACAP dose-dependent increase of glutamate in WT [F(3,20)=4.564, p <0.05]
but not in MSxc astrocytes, suggesting that PACAP potentially increases astrocyte Sxcmediated glutamate release in rat striatum.
Experiment 3: PACAP attenuates AMPAR-mediated EPSCs in SNprojecting MSNs in the NAc. Having established that PACAP regulates astrocyte
glutamate release mediated by Sxc, we then determined whether this neuropeptide
regulates synaptic transmission in a manner that could contribute to behavior linked to
this structure. To do this, we examined the impact of PACAP application on the activity
of the two primary NAc efferents, NAc-SN and NAc-VP MSNs, each of which are linked
to goal-directed behaviors (Kravitz and Kreitzer, 2012). We found that bath application
of PACAP at 100 nM induced significant depression of AMPAR-EPSCs [t(12) = 2.10, p
< 0.05] but failed to do so at 1 nM (Figure 4.4A) in SN-projecting NAc MSNs. In
contrast, PACAP at 100 nM or 0.1 nM did not alter AMPAR-EPSCs (Figure 4.4B) in
VP-projecting NAc MSNs.
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Figure 4.4. PACAP attenuates AMPAR-mediated EPSCs in SN-projecting NAc MSNs. (A)
Data depict AMPAR-mediated EPSCs in retrogradely labeled NAc MSNs that project to the SN
when incubated with PACAP at 1 nM (n = 7) or 100 nM (n = 8). 100 nM PACAP depressed
AMPAR-mediated EPSCs. (B) Data depict AMPAR- mediated EPSCs in VP-projecting MSNs in
the NAc when incubated with PACAP at 0.1 nM (n = 15) or 100 nM (n = 8).

Experiment 4: Characterization of PACAP-induced regulation of AMPARmediated EPSCs. To investigate the mechanisms mediating the actions of PACAP (100
nM), we first examined the involvement of PACAP receptors in PACAP-induced
regulation of synaptic transmission in NAc tissue slices. When co-applied with the
PACAP receptor inhibitor PACAP6-38, PACAP-induced depression of AMPAR-EPSCs
in NAc-SN MSNs was abolished [Figure 4.5A; t(13) = 3.19, p < 0.01].
Next, we sought to test the hypothesis that PACAP regulates synaptic
transmission via an Sxc-dependent mechanism. Support for this key hypothesis would
provide a clear demonstration that PACAP functions as a molecular bridge linking
astrocytes and neurons in the regulation of excitatory signaling-induced synaptic
transmission in the NAc. We found that PACAP altered AMPAR-EPSCs in NAc tissue
slices obtained from WT but failed to do so in MSxc rats [Figure 4.5B; t(12) = 3.09, p <
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0.01]. This finding is consistent with the hypothesis that the neuropeptide PACAP
integrates glutamate release from astrocytes to regulate synaptic transmission in the NAc.
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Figure 4.5. PACAP-induced regulation of AMPAR-mediated EPSCs in SN-projecting
MSNs involves PACAP receptors, Sxc, NMDARs and possibly phosphorylation of
GluA1-T840. (A-C) Data depict the effects of PACAP (100 nM) on AMPAR-mediated EPSCs in
SN-projecting MSNs in the NAc, with or without the presence of PACAP receptor antagonist
PACAP 6-38 (A; N= 7-8/treatment), in WT or MSxc rats (B; N=7/genotype), or with or without
the presence of GluN2B-selective NMDAR antagonist Ro 25-6981 (C; 1µM, N= 6-7/treatment),
(D) Data depicts the effect of PACAP microinjection (100 pmol; N=7-8/group) into the NAc on
the phosphorylation of GluA1-T840. Upper panel: representative western blotting results; lower
panel: data depicts the phosphorylation levels (mean+ SEM) of GluA1-T840 in vehicle and
PACAP groups (normalized to vehicle group; N=7-8/group). V, vehicle; P, PACAP; pT840,
phosphorylated T840. * indicates a significant difference relative to vehicle group, T-test, p <
0.05.
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Prior work has implicated GluN2B-containing NMDARs, which are high-affinity
glutamate receptors that can be tonically activated by astrocytes and expressed extrasynaptically (Barria and Malinow, 2002; Yoshii et al., 2003; van Zundert et al., 2004;
Herman and Jahr, 2007; Le Meur et al., 2007; Hamilton and Attwell, 2010; Petralia et al.,
2010; Gladding and Raymond, 2011; Paoletti, 2011; Povysheva and Johnson, 2012;
Paoletti et al., 2013), in PACAP-induced regulation of synaptic transmission in
hippocampal neurons (Toda and Huganir, 2015). Hence, we sought to determine if these
receptors also contribute to PACAP-induced regulation of synaptic transmission in the
NAc. Interestingly, we found that co-application of the GluN2B-selective NMDAR
antagonist Ro 25-6981 blocked PACAP-induced depression of AMPAR-EPSCs [Figure
4.5C; t(11) = 2.97, p < 0.05].
The negative regulation of AMPARs by extrasynaptic NMDARs is thought to
involve dephosphorylation of the key subunit GluA1 at T840 (Delgado et al., 2007; Lee
et al., 2007; Gray et al., 2014; Toda and Huganir, 2015). To assess if this may contribute
to our above observations, we examined whether PACAP dephosphorylates NAc
AMPARs at GluA1-T840. We found that one hour after PACAP microinjection (100
pmol/side) in the NAc, the phosphorylation of GluA1-T840 was significantly decreased
[Figure 4.5D; t(13) = 2.178, p < 0.01].
Experiment 5: Increasing PACAP signaling in the NAc attenuates cocaineinduced reinstatement via the regulation of Sxc. Since either decreased activity of Sxc
or activation of SN-projecting MSNs in the NAc are linked to the expression of drugseeking behaviors (Baker et al., 2003; Madayag et al., 2007; Rogers et al., 2008;
Moussawi et al., 2009; Amen et al., 2011; Moussawi et al., 2011; Kravitz et al., 2012;
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Schmaal et al., 2012; Bossert et al., 2013; Macpherson et al., 2014), we predicted that
increasing PACAP signaling in the NAc, which potentially restores Sxc function and
suppresses the SN-projecting neurons, would reduce cocaine seeking. To test this, we
first examined the impact of microinjecting PACAP in the NAc on cocaine-induced
reinstatement in rats (Figure 4.6A). A one-way ANOVA with PACAP concentration as a
between-subjects factor yielded a main effect on reinstatement responses [Figure 4.6A;
F(2,26)=8.814, p = 0.001]. We then examined the impact of PACAP in WT and MSxc
rats. Repeated measures with genotype as a between-subjects factor and microinjection
treatment as a within-subjects factor revealed a main interaction [Figure 4.6B;
F(1,7)=6.945, p < 0.05]. PACAP microinjection in the NAc decreased reinstatement
levels in WT rats [t(8) = 5.999, p < 0.001) but failed to do so in MSxc subjects. Therefore,
these data suggest that increasing PACAP signaling in the NAc decreased compulsive
cocaine seeking by upregulating Sxc activity.
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Figure 4.6. Increasing PACAP signaling in the NAc attenuates cocaine-induced
reinstatement via the regulation of Sxc. Data depict lever responding during a two-hour session
following intra-NAc PACAP microinjections (0-100 pmol) and a systemic injection of cocaine
(10 mg/kg, i.p.) in commercially purchased WT rats (A; Envigo, Indianapolis, IN; N=613/condition) and in internally-generated WT and MSxc rats (B; N=4-5/condition). * indicates a
significant difference relative to the vehicle group of WT rats, T-test, p < 0.001.
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Experiment 6: PACAP is expressed in corticostriatal afferents to the NAc.
Having observed the importance of PACAP signaling in the NAc to synaptic
transmission and motivated behavior, we were interested in investigating the sources of
endogenous PACAP in this brain region. A number of studies implicate that PACAP is
primarily, if not exclusively, expressed by glutamatergic neurons, and is co-transmitted
with glutamate as a neurotransmitter (Masuo et al., 1992; Masuo et al., 1993; Koves et al.,
1994; Hannibal et al., 2000; Hannibal, 2002a, b; Stumm et al., 2007; Engelund et al.,
2010; Golombek and Rosenstein, 2010; Hu et al., 2011; Purrier et al., 2014). Given the
importance of glutamatergic corticostriatal projections to the NAc to cocaine seeking, we
hypothesized that these NAc afferents would express PACAP. To test this, we used two
complementary approaches to determine if these cells express PACAP mRNA. In the
first approach, we combined retrograde circuit tracing with in situ hybridization.
Specifically, we microinjected retrograde tracer cholera toxin subunit B (CTB) in rat
NAc (Figure 4.7A). In situ hybridization (ISH) shows expression of PACAP mRNA in
the prelimbic PFC, particularly cortical layer V (Figure 4.7B), which has been suggested
to possess a major neuronal population projecting to the NAc (Ding et al., 2001). Colocalization of the CTB and PACAP mRNA indicates that the majority of PFC neurons
projecting to the NAc express PACAP (Figure 4.7C-E).
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Figure 4.7. PACAP is expressed in NAc-projecting PFC neurons. (A) The retrograde tracer
cholera toxin subunit B (CTB) was delivered to the NAc core. This was confirmed by visualizing
cannula tracts (top right insert) and comparing the spread of CTB (bottom right insert) with the
defined boundaries of the NAc core (left); LV, lateral ventricle. Aca, anterior part of anterior
commissure. (B) A 10X photomicrograph illustrating PACAP mRNA in the prefrontal cortex as
detected using in situ hybridization (ISH). The boxed area is further magnified to 20X in panel CE. The vertical dotted lines define areas approximating layer V of the prelimbic cortex. (C-E)
20X photomicrographs illustrating PFC cells that express PACAP mRNA (C, ISH) and project to
the NAc (D, CTB IHC). White arrows represent PFC-NAc projections that express PACAP.

The expression of PACAP in the PFC-to-NAc projecting neurons was confirmed
using a second approach, in which we labelled corticostriatal projections by
microinjecting a fluorescent retrograde tracer (rhodamine-containing micro-beads) into
the NAc. The labeled cells were then isolated from the PFC using FACS (Figure 4.8A, B).
Due to the limited efficiency of the experimental procedures and our aim for high circuit
specificity, each sample/subject yielded a limited target population (several hundreds to
several thousand positive events), yet, we were able to obtain high-quality RNA from
such small samples, demonstrated by high RNA integrity numbers (RINs: 7-8.5 on a 1-10
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scale; Figure 4.8C). Using PCR combined with gel electrophoresis, we observed the
presence of PACAP mRNA in isolated PFC neurons projecting to the NAc (Figure 4.8D).
Using this approach, we also detected PACAP mRNA in the basolateral amygdala (BLA)
neurons projecting to the NAc. Collectively, these data provide the first demonstration
that PACAP is expressed in the corticostriatal glutamatergic projections to the NAc.
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Figure 4.8. PACAP is expressed in PFC- and BLA-NAc projections. (A, B) Representative
gating parameters of the FACS for identifying and isolating viable projecting neurons to the NAc
in rats that received retro-tracer microinjections (A) or in controls (B). Pacific Blue-A represents
the intensity of cell-viability dye, calcein violet; PE-A (phycoerythrin-area) represent the intensity
of rhodamine dye contained in the retro-tracer. As such, Hi (high) population represent highly
viable projection neurons, while Int (intermediate) are sub-viable or dying cells. (C)
Representative RNA electrophoresis diagram showing high quality of RNA with a RNA integrity
number (RIN) 8.4 (1-10 scale) extracted from a sorted PFC sample that contained 1376 events.
18s, 28s represent 18s, 28s ribosome RNAs. (D) Picture illustrates the PCR products on agarose
gels (1.8%) after electrophoresis. cDNA were synthesized through RNA/cDNA amplification
with mRNA extracted from sorted PFC or BLA neurons projecting to the NAc.
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Experiment 7: Inhibiting endogenous PACAP signaling in the NAc increases
cocaine-induced reinstatement. The above data raise the intriguing prospect that
PACAP is a novel contributor to excitatory signaling in the NAc. To determine whether
PACAP is an endogenous protective factor capable of limiting drug-seeking behavior, we
examined whether a PACAP receptor inhibitor microinjected into the NAc would
promote cocaine-seeking behavior. To do this, we modified the reinstatement paradigm
to avoid potential ceiling effects of cocaine IP on reinstatement. Particularly, after the
initial extinction training, rats received three cocaine reinstatement tests on separate days
(Tests 1-3) so that behavior would approach extinction levels, thereby permitting
sensitivity within the assay to detect increases in behavior. Next, PACAP6-38 was
microinjected into the NAc and behavior was measured. PACAP6-38 microinjection in
the NAc during Test 4 significantly increased cocaine-induced reinstatement compared to
subjects receiving saline [Figure 4.9; t(5) = 3.109, p < 0.05), suggesting that endogenous
PACAP in the NAc is an unrecognized factor influencing relapse vulnerability.
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Figure 4.9. Inhibiting endogenous PACAP signaling in the NAc increases cocaine-induced
reinstatement. Data depict lever responding during a two-hour session following intra-NAc
microinjections of vehicle (saline) or PACAP6-38 (500 pmol) and a systemic injection of cocaine
(10 mg/kg, i.p.) in rats (N=3-4/condition). * indicates a significant difference relative to vehicle
group, T-test, p < 0.05.
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Discussion
In this chapter, we found that PACAP depresses AMPAR-mediated EPSCs in the
nucleus accumbens (NAc) medium spiny neurons (MSNs) projecting to the substantia
nigra (SN). Moreover, this effect involves PACAP-induced upregulation of Sxc. This is
the first finding that PACAP signaling regulates synaptic transmission in the NAc. The
significance of this was evident by our finding that increasing PACAP signaling in the
NAc significantly decreased cocaine-induced reinstatement of drug seeking. This effect
of PACAP is abolished in Sxc loss-of-function mutants, suggesting the involvement of
Sxc. In contrast, inhibiting PACAP receptors in the NAc exaggerated cocaine-seeking
behavior, suggesting that endogenous PACAP in the NAc is a novel factor influencing
relapse vulnerability. Next, we found that PACAP is expressed in NAc-projecting
neurons in the prefrontal cortex (PFC) and basolateral amygdala (BLA). These are the
first data demonstrating the existence of this peptide in corticostriatal projections to the
NAc. Together, our data support the hypothesis that in the NAc, PACAP influences
AMPAR-mediated synaptic transmission and plasticity through regulating Sxc. Such a
function likely contributes to the coordinated glutamate network in the NAc and the
proper expression of motivated behaviors.
The current study demonstrates that xCT and the primary PACAP receptor,
PAC1R, are enriched in NAc astrocytes. These findings are consistent with a recent
study conducted with mice cortical tissues (Zhang et al., 2014), suggesting that the
enrichment of PAC1R and Sxc in in vivo astrocytes may be a general pattern in the CNS.
The expression of PACAP signaling machinery in the NAc is consistent with the
abundant immunoreactivity of this peptide in this brain region (Ghatei et al., 1993). To
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investigate the cell-type specific expression of target genes, we used FACS with a newly
developed transgenic rat model, which expresses membrane-targeted eGFP under GFAP
control in order to better label astrocytes. The successful labeling of astrocytes is
demonstrated by the lack of NeuN and abundant expression of GFAP mRNA in the
GFP+ populations (Figure 4.1). Note that, even though the GFP- population is enriched
in NeuN (e.g., relative to the total sample), it likely contains other cell populations,
including astrocytes, microglia and oligodendrocytes. As these glia subtypes also express
small amounts of Sxc (Zhang et al., 2014), this may explain the low level of xCT mRNA
in GFP- samples.
Using two different approaches including FACS and combined
immunohistochemistry and in situ hybridization, we found PACAP mRNA in the NAc
afferents from the PFC and BLA. These findings support prior observations that PACAP
is expressed primarily in glutamatergic neurons. In support, PACAP is co-expressed with
vGluT2, and may be co-released with glutamate (Hannibal et al., 2000; Hannibal, 2002a;
Engelund et al., 2010). This represents an important finding since neither this nor any
other peptide has been implicated in the activity of NAc excitatory afferents. While it is
unclear whether PACAP expression is exclusive to or ubiquitously expressed by all NAc
excitatory afferents, our finding may have important implications for the cellular basis of
cocaine-induced changes in the NAc. For example, cocaine-induced disruptions in
glutamate homeostasis may be linked to cocaine-induced reductions in the activity of
corticostriatal inputs to the NAc. This outcome may explain an interesting finding
whereby manipulations in the cortex appear to be capable of normalizing astrocytic
activity in the NAc (Berglind et al., 2009).
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PACAP signaling in the NAc was found to depress AMPAR-mediated synaptic
transmission. Interestingly, this function of PACAP appears to be circuit specific, as
PACAP attenuates the AMPAR-EPSCs in SN-projecting MSNs, but not in VP-projecting
MSNs. Moreover, this action of PACAP appears to be mediated by Sxc, since it is not
observed in NAc tissues obtained from Sxc loss of function rats. This parallels prior
observations in which astrocyte subpopulations in the striatum differentially regulate –SN
and –VP projecting MSNs (Martin et al., 2015). Therefore, selective coupling to specific
astrocyte subpopulations may add a layer of regulation for the MSNs which lead to the
pathway-specific effects of PACAP.
Alternatively, efferent-specific gene expression may prime NAc-SN to undergo
PACAP-induced regulation of synaptic transmission. In support, the MSNs involved in
NAc-SN and NAc-VP pathways express heterogeneous biochemical profiles. For
example, these pathways display differential expression of D1- and D2-like receptors (Lu
et al., 1998; Gerfen and Surmeier, 2011). Interestingly, dopamine receptor activation may
oppose PACAP-induced regulation of GluA1, which may provide a molecular basis for
PACAP-induced signaling in one pathway but not the other. In addition, there may be
other biochemical differences in neurons that account for this effect. For example,
PAC1R is expressed in the SN-projecting neurons, while it is absent in the VP-projecting
neurons (see Figure 5.2). In any of the above scenarios, the regulation of synaptic
transmission in the NAc efferents likely results from the collective actions of PACAP on
both astrocytes and neurons.
Consistent with others’ findings that Sxc facilitates postsynaptic removal of
AMPAR, resulting in the attenuation of synaptic strength (Williams and Featherstone,
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2014), we found that application of PACAP to the NAc, which potentially increases Sxc
activity, suppresses AMPAR-mediated synaptic transmission and reduces the
phosphorylation of T840-GluA1, which is positively linked to AMPAR trafficking and
channel conductance (Delgado et al., 2007; Jenkins et al., 2014). Given that the T840 site
is a substrate for NMDAR-mediated signaling (Delgado et al., 2007; Lee et al., 2007;
Gray et al., 2014), it is possible that glutamate from Sxc activates the extrasynaptic
NMDARs which in turn reduce the phosphorylation of GluA1-T840. In support of these
links, we found that PACAP-induced depression of AMPAR-EPSCs is abolished by Ro
25-6981, a selective antagonist for GluN2B-containing NMDARs, which are highaffinity glutamate receptors that can be tonically activated by astrocytes and expressed
extrasynaptically (Barria and Malinow, 2002; Yoshii et al., 2003; van Zundert et al., 2004;
Herman and Jahr, 2007; Le Meur et al., 2007; Hamilton and Attwell, 2010; Petralia et al.,
2010; Gladding and Raymond, 2011; Paoletti, 2011; Povysheva and Johnson, 2012;
Paoletti et al., 2013).
Interestingly, Ro 25-6981blocked PACAP-induced depression of AMPAR-EPSCs
even though the MSNs were voltage-clamped at -80 mV, which is near their resting
membrane potential. We used these parameters because it was found that astrocyteinduced regulation of GluN2B-NMDARs is voltage- and Mg2+--independent (Hahn et al.,
2015). Hence these data support the possibility that PACAP promotes astrocyte-neuron
signaling (and/or signaling between extrasynaptic-synaptic microdomains) under resting
conditions. This supports the possibility that signaling between astrocytes and neurons (or
between extrasynaptic and synaptic domains) influences synaptic transmission even in
cells or synapses that have not received recent synaptic inputs, which is important since
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astrocytes have been implicated in regulating the firing of distal synapses or even entire
networks of neurons (Fellin et al., 2004; Pascual et al., 2005; Fellin et al., 2006a). While
beyond the scope of this study, this could be due to several possibilities. First, the voltage
response in dendrites to the evoked synaptic inputs may have enabled the removal of the
Mg2+ block of proximal NMDARs (Palmer and Stuart, 2009; Williams and Wozny, 2011;
Acker et al., 2016). While this could contribute to our observations, it would not account
for the observations of Hahn et al. (2015) since neurons in their study did not received
synaptic (i.e., evoked) inputs. Second, astrocytes (and PACAP) may promote the activity
of NMDARs that are incompletely blocked by Mg2+. This could be due to fluctuations in
local Mg2+ concentrations, which seems more likely in extrasynaptic microdomains since
astrocytes are thought to regulate extracellular ion concentrations. Unfortunately, the
biology of Mg2+ transporters is poorly understood (Ferre et al., 2011). It is shown that
these transporters are enriched in astrocytes (Zhang et al., 2014), yet it is unclear if they
are restricted to mitochondria in these cells. Alternatively, our finding could involve
NMDARs that are partially resistant to Mg2+ blockade (e.g., triheteromeric GluN1GluN2B-GluN2D-NMDARs) (Huang and Gibb, 2014). Lastly, this could indicate that
the action of neuronal PACAP receptor signaling may include the removal of Mg2+ from
NMDARs. In support of this compelling possibility, several studies have shown that
PKC, which can be driven by PACAP receptors, is capable of removing Mg2+ blockade
of NMDARs (Chen and Huang, 1992; Tyszkiewicz et al., 2004; Moriguchi et al., 2007).
Regardless, these findings illustrate the potential complexity that exists in the striatum,
and suggest that PACAP regulates synaptic transmission through upregulating Sxc
activity and ensuring glutamate release from astrocytes, which activates extrasynaptic
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NMDARs and subsequently inhibits AMPAR function. This multi-cellular mechanism
may also underlie a number of findings in different brain regions where PACAP regulates
phosphorylation of GluA1 and synaptic strength (Kondo et al., 1997; Roberto and
Brunelli, 2000; Roberto et al., 2001; Ciranna and Cavallaro, 2003; Costa et al., 2009;
Gardoni et al., 2012; Toda and Huganir, 2015). However, further studies are needed to
validate these links.
Consistent with the behavioral outcome that would be predicted when suppressing
the activity of NAc-SN MSNs (Rogers et al., 2008; Kravitz et al., 2012; Bossert et al.,
2013; Macpherson et al., 2014), we found that PACAP microinjected into the NAc
significantly attenuates cocaine-primed reinstatement. Consistent with our above findings,
PACAP-induced regulation of behavior is likely mediated by Sxc since it is not evident in
MSxc rats. Collectively, these data may establish PACAP signaling in the NAc as a
critical protective factor capable of limiting drug-induced relapse. In support, we found
that inhibiting endogenous PACAP signaling in the NAc following micro-injection of the
PACAP receptor inhibitor PACAP6-38 augmented cocaine-induced reinstatement.
Hence, these data indicate that heightened drug seeking may result from impaired
PACAP signaling, which needs to be examined in future studies.
In conclusion, our data establish PACAP signaling in the NAc as a novel, key
component of excitatory signaling cocaine seeking behavior. Moreover, PACAP is
present in corticostriatal neurons, which are NAc afferents that are known to display
persistent hypofunction following long-term cocaine administration (Jentsch and Taylor,
1999; Naqvi and Bechara, 2010; Goldstein and Volkow, 2011). These collective results
may yield novel opportunities to understand the biological basis of addiction. In support,
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human cocaine abusers exposed to craving-inducing stimuli exhibit increased activation
of excitatory circuits originating in cortical regions, including orbital and prefrontal
cortex, and projecting to the ventral striatum (Breiter et al., 1997; Volkow et al., 2005).
Preclinical data also indicate the existence of drug-induced plasticity leading to activation
of corticostriatal pathways. Activation of these circuits results in heightened extracellular
glutamate in the NAc (Pierce et al., 1996; Reid and Berger, 1996) and stimulation of
ionotropic glutamate receptors, both of which are necessary for cocaine primed
reinstatement (Cornish and Kalivas, 2000; McFarland et al., 2003). Thus, these data raise
the provocative possibility that PACAP signaling may be altered by cocaine. If so, this
could have tremendous implications in understanding the pathological basis of cocaine
addiction, since PACAP signaling regulates Sxc activity, NMDAR and AMPAR
signaling, dendritic spine morphology (Gardoni et al., 2012), and LTP & LTD (Roberto
and Brunelli, 2000) – all of which are altered in the NAc by cocaine.
Beyond cocaine addiction, our findings may have implications for understanding
other CNS conditions given the role of glutamate as the primary excitatory signal in the
brain. Moreover, our findings are consistent with the emerging viewpoint that normal
excitatory signaling involves the highly integrated activity of multiple cell types in the
brain, including astrocytes and neurons. These findings parallel compelling studies
demonstrating that astrocyte-neuron communication may underlie the activity patterns of
entire neural networks (Caudle, 2006; Volman et al., 2007; Pereira and Furlan, 2010;
Amiri et al., 2013; Dallerac and Rouach, 2016). In fact, a recent report found that
astrocytes contribute to gamma oscillations and recognition memory (Lee et al., 2014). It
has been suggested that astrocytes may enable a high-degree of coordination over entire
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populations of neurons due to several key morphological and structural features including
the non-overlapping domains of these cells and the high number of synapses that can be
contacted by an individual astrocytes (which may number in the millions in the human
cortex) (Bushong et al., 2002; Halassa et al., 2007; Robertson, 2013, 2014). While
astrocytes release a number of neuro-active substances that may underlie this important
activity (Araque et al., 1999; Haydon, 2001; Perea and Araque, 2005; Fellin et al., 2006a;
Haydon and Carmignoto, 2006; Araque et al., 2014; Perez-Alvarez et al., 2014),
glutamate is clearly involved in this process. Hence, it is possible that the unique form of
neuron-astrocyte signaling identified in these studies may contribute to the activity of
entire neural networks, and changes in PACAP signaling may contribute to pathological
states in a variety of CNS conditions.
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CHAPTER V

DISCUSSION
General Discussion
Drug addiction is a chronic central nervous system (CNS) disorder characterized
by persistent relapse susceptibility, even after years of abstinence (Jaffe et al., 1989;
Withers et al., 1995). This results at least in part from drug-induced changes in glutamate
signaling, especially within the corticostriatal projections to the nucleus accumbens (NAc)
(Pierce et al., 1996; Reid and Berger, 1996; Breiter et al., 1997; Volkow et al., 1999;
Cornish and Kalivas, 2000; Park et al., 2002; Baker et al., 2003; McFarland et al., 2003;
McFarland et al., 2004; Kalivas and Volkow, 2005; Schmidt et al., 2005; Volkow et al.,
2005; Madayag et al., 2007; Kau et al., 2008; Kalivas, 2009; Ary et al., 2013). While it is
reasonable to predict that these discoveries could be leveraged to develop novel
approaches to treat drug addiction, a challenge in revealing the molecular or cellular basis
of pathological glutamate transmission in addiction (or any other CNS disorder) is that
excitatory neurotransmission is comprised of a complex network of glutamate
transporters, receptors, and release mechanisms expressed by multiple cell types,
including neurons and astrocytes (Herrera-Marschitz et al., 1996; Timmerman and
Westerink, 1997; Danbolt, 2001; Schoepp, 2001; Baker et al., 2002; Baker et al., 2003;
Pirttimaki et al., 2011; Bridges et al., 2012a). Moreover, while it is highly likely that
glutamatergic signaling across distinct cell types is highly coordinated, little is known
about the molecular basis of integrated astrocyte-neuron signaling.
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These studies investigated the molecular basis of orchestrated neuron-astrocyte
communication within the context of glutamate transmission in the NAc. To do this, I
primarily focused on the regulation of an astrocytic glutamate release mechanism, system
xc- (Sxc) by neurons and a neuropeptide, pituitary adenylate cyclase-activating
polypeptide (PACAP). Sxc was chosen, since this non-canonical glutamate transporter is
strongly linked to glutamate signaling in the NAc, and because cocaine-induced changes
in Sxc are implicated in pathological changes in neuronal synaptic transmission (Baker et
al., 2003; Madayag et al., 2007; Moussawi et al., 2009; Amen et al., 2011; Moussawi et
al., 2011; Schmaal et al., 2012). As such, we were confident that glutamate released by
Sxc contributes to astrocytic regulation of neuronal glutamate signaling. In turn, we
examined the capacity for PACAP to sub-serve neuronal regulation of astrocytes, since
this peptide is exclusively expressed by neurons in the CNS and has been demonstrated to
regulate glutamate release and clearance by astrocytes (Figiel and Engele, 2000;
Goursaud et al., 2008; Resch et al., 2014b; Zhang et al., 2014). Therefore, the
intersection of PACAP and Sxc on the regulation of astrocytic and neuronal glutamate
systems presents itself as a unique opportunity to understand the importance of neuronastrocyte communication to synaptic transmission and behavior.
The studies in this dissertation demonstrate that glutamate release from astrocytes
via Sxc is regulated by neuronal soluble factors (Chapter II), which likely involves the
neuropeptide PACAP. In support, inhibiting PACAP signaling reversed the neuronal
upregulation of Sxc activity in astrocytes, while PACAP application mimicked the
actions of neuronal supplementation of astrocyte cultures. Interestingly, PACAP-induced
regulation of Sxc was observed in both cortical and striatal astrocytes (Chapters II and
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III), which supports the hypothesis that this unique form of neuron-astrocyte
communication may be of relevance to excitatory signaling in each of these brain regions.
Having found that PACAP is expressed in corticostriatal inputs to the NAc, we then
sought to determine whether this neuropeptide is a novel component of excitatory
signaling in this structure (Chapter IV). We found that PACAP application to NAc slices
depressed synaptic transmission in neurons projecting to the substantia nigra (SN), an
important efferent that is thought to encode positive reinforcement or motivated
behaviors (Rogers et al., 2008; Kravitz et al., 2012; Bossert et al., 2013; Macpherson et
al., 2014). Interestingly, PACAP-induced control over synaptic transmission required
upregulation of Sxc activity. To demonstrate the in vivo relevance of each of these
findings, we then found that microinfusion of PACAP into the NAc attenuated cocaineprimed reinstatement of extinguished drug seeking in rats (Chapter IV). Collectively, this
dissertation reveals that a novel form of neuron-astrocyte communication, namely
PACAP-induced regulation of Sxc, is a critical link integrating the glutamate network to
permit coordinated excitatory transmission that underlies motivated behaviors and likely
many other CNS functions.

Making the Human Brain Great Again: Critical Roles for Neurons and Astrocytes
In considering the importance of the above findings, it is interesting to examine
our results through the contemporary perspective that the profound capabilities of the
human brain stem from its extraordinary computational capacity as opposed to the size or
other potentially unique features that have been historically used to explain why the
human brain is so special (Roth and Dicke, 2005; Pereira and Furlan, 2010; Robertson,

121

2013, 2014; Dicke and Roth, 2016). In the study of the computational capacity of the
brain (McCulloch and Pitts, 1990; Quian Quiroga and Panzeri, 2009), mathematical
models demonstrate that even simplified neuron-neuron signaling that sum binary inputs
to yield binary outputs is capable of performing logical tasks that are needed for
information processing. This simplistic depiction does not fully account for synaptic
integration, the computational process by which an individual neuron processes its
synaptic inputs and converts them into an output signal. The reason for this is that the
inputs and outputs of neurons are not necessarily binary. Towards this, the complexity of
human neurons (e.g., extensive dendritic fields enabling important increases in the
number of synaptic inputs per cell) has been suggested to account for the extraordinary
computational capabilities of the human brain (Roth and Dicke, 2005; Dicke and Roth,
2016). In addition, local processing at axonal terminals (i.e., at the level of the
presynaptic neuron) can also confer a degree of additional informational processing.
Despite these additional forms of neuronal synaptic integration, it is doubtful that the
profound capabilities of the human brain solely stem from neuron-neuron signaling.
In more recent efforts, attempts to model the extraordinary capabilities of the
human brain have done so by incorporating astrocytes. By some estimates, astrocytes are
the most abundant cell type in the brain (Barres, 2008). While classically depicted as
metabolic support cells, work over the past few decades has definitively established
astrocytes as key components of synaptic transmission and regulators of neural networks
in the brain (Araque et al., 1999; Haydon, 2001; Perea and Araque, 2005; Fellin et al.,
2006a; Haydon and Carmignoto, 2006; Araque et al., 2014; Perez-Alvarez et al., 2014).
Within the context of computational capacity, it is important to note that astrocytes are
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receptive to virtually every known neurotransmitter (NT), may contact millions of
synapses, and are capable of releasing numerous neuro-active molecules, including
glutamate (Bushong et al., 2002; Fellin et al., 2006a; Haydon and Carmignoto, 2006;
Halassa et al., 2007; Verkhratsky, 2009; Robertson, 2013; Araque et al., 2014; PerezAlvarez et al., 2014; Robertson, 2014).
Perhaps due to these attributes, mathematical models that incorporate neuronalastrocyte communications portray an important role for astrocytes as reservoirs or storage
banks of information flowing through neuronal networks (Caudle, 2006; Volman et al.,
2007; Amiri et al., 2013; Dallerac and Rouach, 2016). This and other properties may be
due to unique astrocyte features such as non-overlapping spatial domains and relatively
slow intra-cellular signaling (at least as compared to neurons) (Bushong et al., 2002;
Halassa et al., 2007; Robertson, 2013, 2014). Thus, at a minimum, the incorporation of
astrocytes enables the expansion of temporal and spatial limitations of signal computation
or integration (Caudle, 2006; Volman et al., 2007; Pereira and Furlan, 2010; Amiri et al.,
2013; Dallerac and Rouach, 2016). Therefore, the inclusion of these cells is required to
maximize the computational capacity of the human (or any other) brain. In other words,
the study of these cells within the context of neuron-astrocyte and astrocyte-neuron
communications (Figure 5.1A) will be essential for understanding the local information
processing that underlies the output of a given brain region or related circuits.
The above concepts are useful in considering behavioral control by the NAc. To
the extent that optimized patterns of behavior promote survival through interactions with
the environment in a manner that increases biological fitness, then behavioral control by
the NAc should require the integration of a great number of factors. Indeed, the NAc
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receives diverse input signals originating from many cortical areas, as well as from the
hippocampus, amygdala, midbrain dopamine nuclei and hypothalamus (Salgado and
Kaplitt, 2015). Each of these inputs encodes key behavioral antecedents, such as decision
making (executive function), memory, emotion, environmental salience, internal states
and more. As such, our findings may be framed as demonstrating that presynaptic
neurons recruit astrocytes into the local integration of incoming information through the
release of PACAP (Figure 5.1B). Moreover, astrocytes then can shape the output from
the NAc in part through the release of glutamate from Sxc. Hence, our work may have
identified an important loop of communication between neurons and astrocytes in a
manner that promotes the integrative capacity of local signaling in the NAc for the
purpose of behavioral control. These key points will be discussed within a functional unit

Figure 5.1. A typical neurotransmission unit. (A) Conceptual illustration of an information
processing unit that incorporates an astrocyte. N: neuron; A: astrocyte. (B) Illustration of the
major findings of this dissertation in a tripartite synapse in the NAc. Pre: presynaptic terminal;
Post: postsynaptic terminal; Glu: glutamate; PRs: PACAP receptors; Sxc: system xc-.

of neurotransmission/information processing, namely, a tripartite synapse in the NAc that
is formed by a presynaptic neuron from the prefrontal cortex (PFC), a postsynaptic
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medium spiny neuron (MSN) projecting to the SN, and the adjacent astrocyte process
(Figure 5.1B). As such, the remaining discussion is organized by factors related to a)
presynaptic neuronal regulation or signaling to astrocytes and b) astrocytic regulation or
signaling to postsynaptic neurons.

Presynaptic Neuronal Recruitment of Astrocytes
In these studies, we observed the expression of PACAP mRNA in cortical
neurons both in vitro (Chapter II) and in vivo (Chapter IV), and this represents the first
demonstration that corticostriatal projections to the NAc contain PACAP (Chapter IV). In
addition, we observed PACAP mRNA in glutamatergic projections to the NAc from the
basolateral amygdala. Lastly, we detected extracellular PACAP in the NAc using peptide
microdialysis (data not shown). Collectively, these findings are consistent with other
reports suggesting that PACAP is often, if not exclusively, expressed in glutamatergic
neurons and is released as a neurotransmitter through the same nerve terminals as
glutamate (Koves et al., 1994; Hannibal et al., 2000; Hannibal, 2002b, a; Stumm et al.,
2007; Engelund et al., 2010; Hu et al., 2011;Masuo et al., 1992; Masuo et al., 1993;
Golombek and Rosenstein, 2010; Purrier et al., 2014).
Co-transmission increases computational capabilities of the neural network
The release of PACAP and glutamate from the same neurons represents a
phenomenon that is increasingly recognized to occur throughout the CNS, and this
diversifies the manner in which inputs can alter activity within target regions or circuits
(Seal and Edwards, 2006; Broussard, 2012; Hnasko and Edwards, 2012). On one hand,
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this diversification can involve spatial parameters. For example, the cellular targets of
glutamate and PACAP may be at least partially distinct. It is widely thought that the
primary target of synaptically released glutamate is the postsynaptic neuron and that there
are numerous mechanisms in place to limit spillover (Logan and Snyder, 1971; Balcar
and Johnston, 1972; Danbolt, 2001; Bridges et al., 2012a). Hence, glutamate may be
especially important for neuron-neuron signaling. Alternatively, the primary PACAP
receptor, PAC1R is mainly expressed by astrocytes (Chapter IV). While we have
observed its presence in SN-projecting MSNs (Figure 5.2), I found that the total

Figure 5.2. PAC1R is expressed in NAc neurons projecting to the substantia nigra, but not
to the ventral pallidum. Picture illustrates PCR products on an agarose gel (1.8%) after
electrophoresis. cDNA was synthesized through RNA amplification and reverse transcription
with mRNA extracted from circuit-specific neurons in the NAc that were obtained via
fluorescence-activated cell sorting (FACS). PCR was conducted with cDNA templates and
primers specific to rat GAPDH and PAC1R. Presence of bands at expected sizes indicates the
expression of the target genes. SN: substantia nigra; VP: ventral pallidum.

proportion of PAC1R present in astrocytes from NAc tissues exceeds 95% (Chapter IV).
This is a level of cell-specific expression that is rarely observed for a neurotransmitter
receptor, especially in adult, fully-developed cells. Therefore, glutamate and PACAP
released from corticostriatal inputs to the NAc may differentially target postsynaptic and
astrocytic signaling, with glutamate favoring the postsynaptic terminal, while PACAP
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favoring the astrocyte process. In support, a loss of Sxc function completely eliminated
the capacity of this neuropeptide to regulate glutamate release from striatal astrocytes,
synaptic transmission in the NAc and cocaine reinstatement (Chapter IV). In addition,
PACAP may also increase the temporal aspects of information encoded by incoming
corticostriatal (or other) inputs, given that neuropeptide transmission often permits
increased temporal domains (Nusbaum et al., 2001; van den Pol, 2012). As such, the cotransmission of transmitters (e.g. glutamate and PACAP) provides strong support for the
idea that this novel form of neuron-astrocyte signaling has the benefit of enhancing the
information processing capabilities within local NAc circuits.
Co-transmission in the motive circuit
Interestingly, co-transmission has been demonstrated in other parts of the motive
circuit. For example, it is shown that VTA (ventral tegmental area) dopaminergic
afferents to the striatum co-release (i.e., transmitted through the same vesicles) GABA
(Tritsch et al., 2012). Similarly, it has been demonstrated that VTA neurons projecting to
the NAc express both tyrosine hydroxylase and vesicular glutamate transporter 2
(vGluT2), suggesting the co-transmission of dopamine and glutamate (Chuhma et al.,
2009; Stuber et al., 2010; Tecuapetla et al., 2010). Alternatively, substance P and
enkephalin that are preferably expressed in, respectively, D1- and D2-like receptorexpressing MSNs in the striatum (Lu et al., 1998; Steiner and Gerfen, 1998) co-transmit
with GABA, and have been shown in modulating GABAergic transmission (Maneuf et
al., 1994; Tan and Bullock, 2008; Govindaiah et al., 2010; Tritsch et al., 2016). In
contrast to these, our findings may be the first implicating the co-transmission of a
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neuropeptide with the primary excitatory neurotransmitter glutamate in corticostriatal
(and other excitatory) projections of the motive circuit.
PACAP receptors: the gate to astrocyte information storage.
In these studies, PACAP signaling in astrocytes is considered to be an important
form of astrocytic regulation of incoming information. As such, we sought to identify the
precise PACAP receptor(s) involved in this phenomenon. PACAP binds to three PACAP
receptors (PAC1R, VPAC1R and VPAC2R) with similarly high affinities (Harmar et al.,
1998; Harmar, 2001; Vaudry et al., 2009). In an initial attempt to identify the relevant
receptor(s), we first examined which receptors are expressed by cortical and striatal
astrocytes. Having detected all three PACAP receptors in cortical and striatal astrocytes
(Chapters II and III), a finding that is consistent with others (Ashur-Fabian et al., 1997;
Magistretti et al., 1998; Grimaldi and Cavallaro, 1999; Joo et al., 2004; Masmoudi-Kouki
et al., 2007; Nishimoto et al., 2007; Nishimoto et al., 2011; Zhang et al., 2014), we then
examined expression patterns in adult NAc astrocytes. We found that both PAC1R
(Chapter IV) and VPAC2R are present in NAc astrocytes (Figure 5.3), indicating that the

GAPDH

PAC1R

VPAC1R

VPAC2R

Figure 5.3. PAC1R and VPAC2R are expressed in adult NAc astrocytes. Picture illustrates
PCR products on an agarose gel (1.8%) after electrophoresis. cDNA was synthesized through
reverse transcription with mRNA extracted from adult NAc astrocytes obtained via FACS. PCR
was conducted with cDNA templates and primers specific to rat PAC1R, VPAC1R and VPAC2R.
Presence of bands at expected sizes indicates the expression of the target genes.
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expression of PAC1R and VPAC2R persists beyond any potential developmental changes.
While VPAC1R appears to be undetectable in NAc astrocytes (Figure 5.3), it may be a
false negative result caused by its low abundance, especially in astrocytes, and the
limitation of the detecting method (i.e. PCR). In support, it has been shown that PAC1R
transcripts are much more abundant than either VPAC1R or VPAC2R, especially in
astrocytes, with the respective FPKM (fragments per kilobase of transcript per million
mapped reads) values to be > 150, < 0.2 and ≈ 2 (Zhang et al., 2014). Moreover, both
PAC1R and VPAC2R appear to be more enriched in astrocytes than in neurons, with
ratios at 10:1 (PAC1R) and 5:1 (VPAC2R), while VPAC1R is more enriched in neurons,
with a 5:1 ratio compared to astrocytes (Zhang et al., 2014). Because of this and related
observations, we hypothesized that PAC1R may be the primary mediator for PACAPinduced regulation of astrocyte Sxc. In support, brief application of the PAC1R inhibitor
PACAP6-38 reversed the capacity for neurons to promote Sxc activity in astrocytes
(Chapter II).
However, we are confident that activation of VPAC receptors (VPACRs) is also
sufficient to upregulate astrocytic Sxc. In support, we observed that vasoactive intestinal
peptide (VIP), which activates both VPAC1R and VPAC2R (Dickson and Finlayson,
2009), significantly upregulates Sxc activity in cortical astrocytes (Figure 5.4A),
suggesting that VPACRs are potentially involved, consistent with others’ finding (Resch
et al., 2014b).
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Figure 5.4. PACAP-induced regulation of Sxc activity is likely mediated by PAC1R and
VPAC receptors. Data depict mean ±SEM levels of 14C-cystine in purified rat cortical (A, B, C)
or striatal (D) cultures after 24 hours treatment with vehicle, or ligands including VIP (10 nM),
PACAP1-38 (designated as P1-38, 10 nM), VIP6-28 (designated as V6-28, 1 µM; VPAC1R and
VPAC2R non-selective antagonist) and M65 (1 µM; PAC1R antagonist), or ligand mixtures
including PACAP1-38 10 nM & VIP6-28 1 µM (designated as P1-38&V6-28), VIP 10 nM &
VIP6-28 1 µM (designated as VIP&V6-28) and PACAP1-38 10 nM & VIP6-28 1 µM
(designated as P1-38&V6-28) (N=6-12/condition). (A-D) * indicates a significant difference
relative to vehicle-treated purified astrocyte cultures, Tukey HSD, p < 0.01. (C) # indicates a
significant difference relative to VIP-treated purified astrocyte cultures, Tukey HSD, p < 0.05.

Surprisingly, a non-selective VPACR antagonist VIP6-28 failed to attenuate the
augment of Sxc activity induced by PACAP (Figure 5.4B). One interpretation is that
VIP6-28 lost its potency in blocking VPACRs. This possibility is unlikely, as we found
that VIP6-28 significantly decreased VIP-induced upregulation of Sxc activity (Figure
5.4C). Alternatively, it is possible that both PAC1R and VPACRs are capable of
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mediating PACAP-induced regulation of Sxc in cultured astrocytes, and their functions in
this regard are redundant. Consistent with this idea, application of selective PAC1R
antagonist M65 to striatal astrocytes was not able to attenuate the impact of PACAP.
Although PAC1R and VPACRs all appear to be sufficient in mediating PACAPinduced regulation of Sxc in cultured astrocytes, whether or not they are accountable for
in vivo actions of endogenous PACAP is not clear. This is because that PACAP applied
to cultured cells is likely capable of reaching to all different receptors through diffusion
in the media; while in vivo PACAP may be only released through the presynaptic
terminals, diffuse within a confined compartment and target astrocyte processes that
express a defined population of PACAP receptors, e.g. PAC1R. Alternatively, PAC1R
may be the only receptors expressed in the astrocyte domains facing PACAP releasing
sites of corticostriatal terminals, while VPACRs are compartmentalized to be only
activated by VIP from other inputs.
VIP-induced regulation of Sxc and its potential role in GABA transmission in the NAc
The above discussion supports an idea that VIP may be another critical
endogenous regulator of Sxc, through which this peptide regulates synaptic transmission
in the NAc. This is because, in addition to its capability of increasing Sxc activity in
astrocytes (Figure 5.4A), VIP is highly expressed in the terminal field within the NAc
(Sims et al., 1980). Moreover, we observed the expression of both VPAC1R and
VPAC2R in cultured striatal astrocytes (Chapter III); VPAC2R has also been detected in
adult NAc astrocytes (Figure 5.2).
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In contrast to PACAP, which is located in glutamatergic neurons and is involved
in regulating glutamate transmission (see the above discussion), VIP has been repeatedly
linked to GABAergic neurons and shown to modify GABA signaling. For example, VIP
is co-expressed with GABA in a major population of the suprachiasmatic nucleus (SCN)
of the hypothalamus (Moore et al., 2002). Similarly, VIP in the hippocampus is
expressed exclusively by GABAergic interneurons (Acsady et al., 1996), and influences
GABA release. Moreover, VIP concerts pre and postsynaptic GABAergic transmission in
the hippocampus, which leads to the disinhibition of pyramidal cell dendrites and causes
an enhancement of synaptic transmission (Cunha-Reis et al., 2004). These observations
implicate that VIP signaling in the NAc may regulate GABA transmission, possibly
through a similar mechanism to PACAP, namely, by inducing astrocyte Sxc. This could
be an interesting and important direction for future studies.
However, the origin of the endogenous VIP in the NAc still needs to be determined.
While some studies implicate that the majority of VIP in the NAc originates from its
projections that are embedded in the medial forebrain bundle (Marley et al., 1981), others
show that VIP is expressed in aspiny interneurons in rat striatum (Theriault and Landis,
1987). In contrast, I have observed abundant VIP mRNA in mixed striatal cultures
containing neurons and astrocytes, and a lack of VIP in striatal astrocyte cultures (Figure
5.5). Therefore, similar to PACAP, VIP also appears to be expressed exclusively by
neurons, consistent with others’ finding (Zhang et al., 2014). In a similar manner to our
results suggesting that neuronal PACAP increases xCT expression (Chapter II), neuronderived VIP may contribute to the higher level of xCT mRNA that was observed in the
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mixed striatal cultures compared to striatal astrocytes (Figure 5.6).Yet, whether VIP in
striatal cultures originates from the interneurons or GABAergic MSNs is uncertain.

Figure 5.5. VIP is expressed in cultured striatal neurons but not astrocytes. Picture illustrates
PCR products on an agarose gel (1.8%) after electrophoresis. cDNA was synthesized through
reverse transcription with mRNA extracted from striatal cell cultures: STM, mixed striatal
cultures; STN, striatal neurons; STA, striatal astrocytes. PCR was conducted with cDNA
templates and a primer set specific to rat VIP. Presence of bands at the expected size indicates the
expression of the target gene.
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Figure 5.6. Striatal neurons increase xCT expression in striatal astrocytes. Data depict mean
±SEM levels of xCT mRNA in rat striatal cell cultures (N= 4/cell type). * indicates a significant
difference relative to mixed cultures, Tukey HSD, p < 0.001; # indicates a significant difference
relative to astrocyte cultures, Tukey HSD, p < 0.01.
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Regardless of the uncertainty of the endogenous origin, the abundance of VIP
signaling in the NAc appears consistent across different studies (Sims et al., 1980;
Marley et al., 1981). These evidences discussed above and our observations implicate
that VIP may regulate transmission in the NAc through its actions on astrocyte functions
(e.g. Sxc).
The nature of PACAP-induced regulation of Sxc
In order to understand the potential contributions of phasic PACAP release to
signal integration in the NAc, we became interested in the nature of PACAP-induced
regulation of Sxc. Specifically, we were interested in learning whether brief PACAP
application would be capable of rapidly (i.e., on a scale of minutes, see text box)
Time is often used a key variable in predicting whether changes in protein function reflect
post-translational modification or changes involving gene expression. Thus, when altered
protein function is observed in a manner of minutes, such as 6-min application of PACAP
altering Sxc activity, we often exclude the possibility that changes in gene expression are
involved. Is this a safe assumption? To examine this, we obtained published estimates of the
key phenomena involved in protein expression.
--------------------------------------------------------------------------------------------------------------Transcription - in eukaryotes, transcription has been reported to occur at a rate of 50-100
nucleotides per second (nt/s) (Dundr et al., 2002; Darzacq et al., 2007; Singh and Padgett,
2009), but this may be interspersed with pauses, which leads to a much slower rate at 6 nt/s
(Darzacq et al., 2007).
--------------------------------------------------------------------------------------------------------------Splicing of mRNA - the estimates of splicing are less detailed, but studies provide a
timeframe of 5-10 minutes to excise introns from transcripts (Singh and Padgett, 2009).
--------------------------------------------------------------------------------------------------------------Translation in eukaryotes requires an estimate of one second per 6 amino acids (Ingolia et
al., 2011).
--------------------------------------------------------------------------------------------------------------When applying the above estimates to the gene SLC7A11 that encodes xCT, it is apparent
that it would take at least 75 seconds for transcription (74706 bp) (Gibbs et al., 2004), 5
minutes for splicing, and 85 sec for the translation (502 amino acids) (Alhaddad et al.,
2014). This totals to 7-8 minutes, but it does not include the time needed for protein folding,
trafficking, and insertion. Hence, it is unlikely that transcription is involved in PACAPinduced regulation of Sxc when applied for 30 min or less, especially since time is required
to enable exogenous PACAP to diffuse to its receptor and alter intracellular physiology
needed to regulate Sxc.

134

upregulating Sxc. We found that PACAP applied for as few as 6-30 min (Chapters III and
IV) produced a significant increase in Sxc activity. This timescale likely reflects posttranslational modification of xCT. However, the regulation of Sxc through posttranslational modification is still poorly understood. While the xCT protein has been
reported to contain consensus phosphorylation sites for various kinases (Baker et al.,
2002), there has been only a single study clearly linking Sxc activity with
phosphorylation (McClatchy et al., 2016). In this study, the mutagenesis of S26 on xCT,
which corresponds to a phosphorylation sequence for mitogen and stress activated protein
kinase (MKS), resulted in impaired Sxc activity. Our data are consistent with this
observation in that MSK and its upstream activators PKA, ERK, and Epac are required
for PACAP-induced regulation of Sxc (Chapter III). This is important, in part, since
these signaling pathways have been implicated in cocaine addiction (Nestler, 2004;
Kalivas and O'Brien, 2008; Besnard et al., 2011; Cahill et al., 2014; Liu et al., 2016),
although these changes are often presumed to occur in neurons.
In addition to the rapid regulation, the magnitude of PACAP-induced increases in
Sxc was significantly greater following long-term application, which also leads to
increased xCT mRNA (Chapters II and III). This is of potential interest, given prior
suggestions that astrocytes enrich local synaptic integration, in part by increasing the
temporal dimension or persistence of incoming signals. Hence, it is possible that
PACAP-induced Sxc regulation may occur along multiple timescales that reflect this
important contribution of neuron-astrocyte communication. In support, we detected basal
(i.e., unstimulated) PACAP levels in NAc microdialysis samples at a concentration of at
least 83-267 pM. Note, these values were not corrected by our probe recovery rates,
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which are likely less than 5%. Thus, basal PACAP levels may exist at a concentration as
high as 5 nM. This is interesting, since it is in range of the nanomolar affinity of PACAP
for PACAP receptors (Cauvin et al., 1990; Gottschall et al., 1990; Lam et al., 1990;
Gottschall et al., 1991; Suda et al., 1992). Further, we observed PACAP-induced
regulation of Sxc in striatal astrocytes at concentrations as low as 1 nM (Chapter III).
Both PKA and Epac are also likely involved in PACAP-induced mRNA upregulation of
xCT, given that they are capable of activating transcriptional factors (Mayr and
Montminy, 2001; Schmidt et al., 2013). In addition, inhibition of PKA or Epac
significantly attenuated 24-hr PACAP-induced increase of Sxc activity (Chapter III).
However, more work is needed to understand the direct impact of PKA and Epac on xCT
expression, and to what extent the increased expression of xCT versus post-translational
modification contribute to increased Sxc activity observed following long-term PACAP
treatment (e.g. 24 and 72 hr).
An important assumption in our interpretations up to this point is that Sxc activity
in vivo is primarily if not exclusively astrocytic. This has been widely reported in the
literature by measuring Sxc activity and/or cellular expression of xCT (Pow, 2001; Zhang
et al., 2014). However, other authors suggest that neuronal cell lines and cultures may
also display Sxc (Lewerenz et al., 2012a). To examine this, we determined the
percentage of xCT mRNA obtained from adult rats that was contained in astrocytes
versus every other type of cells. We observed that at least 90% of the total amount of
xCT mRNA was present in our GFP+ samples following fluorescence-activated cell
sorting (Chapter IV). Note, the remaining 10% reflects potential xCT mRNA expression
in astrocytes not sorted into the GFP+ fraction (GFAP is detected in the GFP- fraction
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since it is impossible to sort every astrocyte while excluding neurons in the GFP+
fraction), other glial cells, epithelial cells, and neurons. Importantly, we found that
PACAP did not alter cystine uptake in neuronal cultures (Chapter II). As a result, our
data strongly implicate astrocytic Sxc in our studies. Thus, we are confident that
PACAP-induced regulation of Sxc in the NAc reflects neuron-astrocyte signaling. To
determine whether these findings demonstrate that PACAP-induced regulation of Sxc in
astrocytes is relevant to local synaptic integration, it then became necessary to
demonstrate that PACAP-induced regulation of Sxc alters the output from the NAc and
behavior.

Astrocyte-Neuron Regulation
In Chapter IV, we showed that PACAP depresses AMPAR-mediated EPSCs in
NAc MSNs projecting to the SN. This is the first demonstration that PACAP signaling
regulates synaptic transmission in the NAc, while similar effects have been shown in
other brain regions, such as hippocampus and the suprachiasmatic nucleus (SCN) (Kondo
et al., 1997; Roberto and Brunelli, 2000; Kopp et al., 2001; Roberto et al., 2001; Ciranna
and Cavallaro, 2003; Costa et al., 2009; Gardoni et al., 2012; Toda and Huganir, 2015).
Therefore, there was a need to establish the cellular basis for PACAP-induced regulation
of synaptic transmission. While PACAP-induced regulation of synaptic transmission is
often presumed to involve neuronal PACAP signaling, our data provide strong support
for the involvement of astrocytes. In support, PACAP-induced regulation of AMPARmediated synaptic transmission in the NAc is not present in Sxc loss-of-function mutants,
nor is the impact of PACAP on cocaine-induced reinstatement. Interestingly, our group
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has begun collecting data demonstrating that re-introducing xCT cDNA into the NAc of
these mutant rats rescues PACAP-induced blockade of cocaine reinstatement. Moreover,
we and others have found that the elimination of Sxc in rats and/or mice produces deficits
at the molecular, cellular, and behavioral levels that are opposite to what we have
observed with PACAP and have attributed to increased Sxc. This includes the
attenuation of synaptic strength involving AMPARs, reduced levels of basal glutamate,
heightened phosphorylation of GluA1-T840, and augmented cocaine reinstatement
(Baker data not shown; Williams and Featherstone, 2014; De Bundel et al., 2011; Li et al.,
2012).
Encoding astrocyte-neuron signaling: A possible role for extrasynaptic NMDARs
Having established that PACAP-induced increases in Sxc contribute to the actions
of PACAP in the NAc, we next examined the glutamate receptor that may encode this
unique form of neuron-astrocyte signaling. Outside the NAc, PACAP-induced regulation
of AMPAR signaling appears to be NMDAR-dependent. In support, potentiation of
NMDAR-mediated synaptic activity by PACAP has been repeatedly demonstrated (Liu
and Madsen, 1997; Wu and Dun, 1997; Harrington et al., 1999). This effect likely
involves GluN2B-containing NMDARs. For example, PACAP promotes the
phosphorylation of GluN2B, and in doing so enhances NMDAR-mediated currents,
(Yaka et al., 2003; Macdonald et al., 2005; Resch et al., 2014a). Moreover, PACAPinduced dephosphorylation of GluA1-T840 in the hippocampus is mediated by NMDARs
(Toda and Huganir, 2015). This effect is consistent with several studies implicating that
NMDARs promote the dephosphorylation of GluA1-T840 of AMPARs, possibly through
induction of protein phosphatase 1- and/or 2A (Delgado et al., 2007; Lee et al., 2007;
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Gray et al., 2014). Similar to work in the hippocampus (Toda and Huganir, 2015), we
also found that PACAP-induced regulation of synaptic transmission in the NAc requires
activation of GluN2B-containing NMDARs, as co-application of a GluN2B-selective
NMDAR antagonist Ro 25-6981 blocked PACAP-induced depression of AMPARmediated EPSCs (Chapter IV).
Given the above findings, we are confident that PACAP-induced regulation of
astrocytic Sxc regulates synaptic transmission in NAc efferents by supplying glutamate
capable of activating neuronal GluN2B-containing NMDARs. Moreover, we believe that
the NMDARs encoding PACAP signaling through astrocytes are located
extrasynaptically (Figure 5.1B). First, extrasynaptic NMDARs are often thought or have
been shown to be GluN2B containing (Papouin et al., 2012). In support, GluN2B
preferably associates with scaffolding proteins SAP102 (Yoshii et al., 2003; van Zundert
et al., 2004), which is primarily located outside of synaptic domains (Barria and Malinow,
2002; van Zundert et al., 2004; Petralia et al., 2010; Gladding and Raymond, 2011).
Further, extrasynaptic but not synaptic NMDARs are thought to inhibit AMPARmediated EPSCs (Papouin and Oliet, 2014). Lastly, several studies have implicated
extrasynaptic but not synaptic NMDARs in tonic regulation by either non-vesicular
and/or astrocytic glutamate release (Jabaudon et al., 1999; Warr et al., 1999; Angulo et al.,
2004; Fellin et al., 2004; Shigetomi et al., 2008; Bardoni et al., 2010; Nie et al., 2010).
Consistent with this, extrasynaptic but not synaptic NMDARs are often found to be
clustered at sites proximal to astrocytic processes (Petralia et al., 2010). Given that nonvesicular release from Sxc has been implicated as the major source of extrasynaptic
glutamate in brain regions including the NAc (Baker et al., 2002; De Bundel et al., 2011;

139

Massie et al., 2011), it is possible that this form of neuron-astrocyte-neuron signaling
may be present in the NAc and other structures.
A possible role in astrocyte-mediated neuronal synchronization
We speculate that the PACAP-induced regulation of Sxc and extrasynaptic
NMDARs may not be limited to the synapse where PACAP is released, but underlie the
expanded spatial and temporal influence of an astrocyte on multiple local neurons, for
example, in inducing neuronal synchronization. This is because that glutamate released
from astrocytes has been shown to activate extrasynaptic NMDARs on the postsynaptic
terminals and induce characteristic slow inward currents (SICs) that are synchronized in
local neurons (Parri et al., 2001; Angulo et al., 2004; Fellin et al., 2004; Fellin et al.,
2006b; D'Ascenzo et al., 2007). Notably, in these studies, glutamate release results from
spontaneous or evoked calcium oscillations in astrocytes. Yet, whether or not a calciumindependent astrocyte glutamate release mechanism, such as Sxc, is capable of inducing
SICs has not been investigated. Moreover, it is shown that SICs and neuronal
synchronization could be induced by stimulating the afferents (Pirttimaki et al., 2011),
suggesting that the astrocyte glutamate release mechanism that is involved in SIC
generation and synchronization is regulated by neuronal activity. Along with the above
discussion, these evidences implicate that neuronal PACAP-induced glutamate release
through astrocyte Sxc and subsequent extrasynaptic NMDAR activation may also be
capable of influencing local neuronal network (e.g. synchronizing a number of local
neurons). This could be achieved by different mechanisms, for example, PACAP-induced
signaling cascades from one astrocyte process spread within the astrocyte and regulate
Sxc on other processes that encapsulate neighboring synapses and neurons. Alternatively,
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the increased spatial domains of neuropeptide transmission may allow PACAP to target
Sxc on multiple astrocyte terminals and thus to influence multiple tripartite synapses
simultaneously.
Interestingly, synchronization of SICs induced by stimulating afferents could
sustain an extended time, for example, from minutes to one hour after the initial stimulus
(D'Ascenzo et al., 2007; Pirttimaki et al., 2011). Given the expanded temporal domain of
neuropeptide mediated regulation, it is possible that phasic PACAP release in response to
neuronal activity is capable of inducing sustained Sxc upregulation, which contributes to
the prolonged impact of astrocytes on neuronal SICs. Yet, these ideas are highly
speculative and further investigation is needed to determine whether rapid effect of
PACAP on Sxc activity is long-lasting.

Impaired Neuron-Astrocyte-Neuron Communication: Implications for CNS
Pathology
Drug addiction is a complex, multi-faceted disorder characterized by compulsive
drug seeking even when such behavior results in profound negative consequences to the
individual. The chronic aspect of the disease involves episodes of heightened relapse
vulnerability even following long periods of abstinence, which stem from persistent
cocaine-induced neuroadaptations that disrupt glutamate transmission (Jaffe et al., 1989;
Withers et al., 1995; Baker et al., 2003; Kalivas and Volkow, 2005; Nestler, 2005;
Hyman et al., 2006; Koob and Volkow, 2010). Of particular importance, hypofrontality
(e.g., reduced basal activity) in the PFC and other NAc-related maladaptation have been
linked to behavior in virtually every preclinical model of drug seeking and has been
found to correlate with the severity of drug craving in human substance abusers (Pierce et
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al., 1996; Breiter et al., 1997; Jentsch and Taylor, 1999; Volkow et al., 1999; Park et al.,
2002; Baker et al., 2003; McFarland et al., 2003; McFarland et al., 2004; Schmidt et al.,
2005; Madayag et al., 2007; Kau et al., 2008; Naqvi and Bechara, 2010; Goldstein and
Volkow, 2011; Ary et al., 2013).
To the extent that corticostriatal inputs are an important source of NAc PACAP,
then cocaine-induced hypofrontality may indicate the existence of cocaine-induced
disruptions in PACAP signaling. Interestingly, hypofrontality is also observed in rats
using the cocaine reinstatement model (Chen et al., 2013). Altered firing rates may
particularly impact neuropeptide release, which often requires higher level of neuronal
activity (Nusbaum et al., 2001; van den Pol, 2012). Interestingly, enhancing or
stimulating the rodent PFC suppresses cocaine-seeking behavior (Chen et al., 2013), and
this effect may be due to normalizing astrocytic-maintained glutamate homeostasis (e.g.,
release and clearance) in the NAc (Berglind et al., 2009). In this latter study, intra-PFC
microinjection of BDNF reversed cocaine-induced decreases in NAc extracellular
glutamate levels, which have been largely attributed to Sxc activity. Hence, while it is
known that cocaine-induced plasticity altering excitatory signaling involves changes in
astrocytes and neurons in these regions, these collective findings support the possibility
that cell-specific plasticity in the NAc may be causally related (e.g., due to a loss of
PACAP). The potential for altered PACAP to contribute to cocaine-induced pathology is
evident by our and others’ studies showing that PACAP can regulate Sxc activity (Resch
et al., 2014b; Kong et al., 2016), NMDAR and AMPAR signaling (Costa et al., 2009;
Toda and Huganir, 2015), dendritic spine morphology (Gardoni et al., 2012), and LTP &
LTD (Roberto and Brunelli, 2000) – all of which are altered in the NAc by cocaine.
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Conclusion
Models indicate that incorporating neuronal-astrocyte communication increases
the computational capacity of a neural network. Thus, the study of these forms of intercellular communication will be essential to our understanding of the local signal
processing underlying normal and diseased brain functioning. Towards this, our work
supports the idea that in the NAc, the presynaptic neuronal factor PACAP enables direct
encoding of afferent information to astrocytes. This in turn promotes the activity of Sxc, a
glutamate release mechanism that we found regulates AMPAR-mediated EPSCs in NAc
efferents. Moreover, this integrated network is likely critical to the integration of the
many inputs that are normally used to regulate adaptive behavioral responses. An
interesting question is the degree to which this complex network resembles similar forms
of integrated inter-cellular signaling in other systems or other regions of the brain. For
example, it is shown that endocannabinoid neuromodulators activate CB1 receptors on
hippocampal astrocytes (Navarrete and Araque, 2008). This leads to an increase in
astrocytic glutamate release (presumed but not demonstrated to be a non-Sxc mechanism),
which results in the activation of NMDARs on adjacent neurons (Navarrete and Araque,
2008). While there are interesting parallels to our own findings, this study highlights the
potential for molecular integration through the release of postsynaptic factors (e.g.
endocannabinoid). Hence, it is interesting to speculate that local processing may be
dependent on incorporating the computational capacity of each cell in a given region, and
this can be achieved by inter-cellular signaling originating from any of the participating
cells. To the extent that this is the case, the key to developing a meaningful understanding
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of CNS function in normal and disease states will require identifying the molecular basis
for signal integration.
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